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Abstract 
As the mainstay and principal form of traditional Chinese medicine (TCM), Chinese 
herbal medicine (CHM) has been the subject of growing interest and popular use 
worldwide. However, its unique philosophy, diagnosis and prescription are 
completely different from Western Medicine (WM), which has brought great 
challenges for the quality standardisation, safety control, and efficacy evaluation 
confronting its development in a modernised scientific manner. 
 
This PhD project aims to address challenges that revolve around the efficacy 
research of CHM. Based on CHM theory, the key mechanism of the efficacy of 
CHM is the synergistic interactions among multiple herbal ingredients in a formula 
to reach an optimised therapeutic effect, multi-target mode of actions and reduced 
potential side effects. Several rigorous analytical methods such as combination index 
(CI), isobolographic analysis and systems biology are designed for the quantitative 
evaluations of synergistic effects in pharmaceutical combination therapy, and have 
also been utilised for the study of CHM. Among them, CI and isobologram models 
are applied for studying the interactions of a small number of active components or 
herbal extracts on the same target or receptor in which their chemical and 
pharmacological properties are well defined. A systems biology model may also be 
used to analyse multi-component, multi-target actions in combinational therapy. 
However, following a systematic review, it is apparent that the current literature on 
synergistic study of CHM is still at an early stage. Based on previous studies, we 
hypothesised that a platform to systematically analyse synergistic interactions of 
herbal compounds can be established by modern bioassays and scientific models 
(e.g., CI and isobologram approaches).  
Herb-pairs are the basic unit for the Chinese herbal formulae. Salvia Miltiorrhiza 
Radix et Rhizoma and Notoginseng Radix et Rhizome (known as Danshen [DS] and 
Sanqi [SQ] in TCM) has been one of the most frequently prescribed herb pairs in 
TCM clinics for cardiovascular disease management for over 30 years in Asian 
countries. However, very limited mechanistic studies on the combinational benefits 
on the complex pathological mechanisms of vascular diseases are available, despite 
the fact that the bioactivities for a single extract have been well studied. Therefore, 
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the DS-SQ herb-pair was selected as a case study to address the issue of synergistic 
activities in CHM. 
 
Before the commencement of bioactivity testing, chemical analysis was conducted 
for the DS extract, SQ extract and Danshen-Sanqi combination extract (DS-SQ) for 
quality control. Thin-layer chromatography (TLC) and ultra (high)-performance 
liquid chromatography (UPLC) were used to qualitatively and quantitatively 
determine the major chemical compounds, including Danshensu (DSS), salvianolic 
acid A (SA), salvianolic acid B (SB), tanshinone I (T1), dihydrotanshinone I (DT), 
cryptotanshinone (CT), tanshinone IIA (TIIA), notoginsenoside R1 (NR1), 
ginsenoside Rg1 (Rg1), ginsenoside Rb1 (Rb1), ginsenoside Rg2 (Rg2) and 
ginsenoside Rd (Rd).  
In vitro studies can provide useful mechanistic information and bioactivity for 
medicinal plants. In this study, DS, SQ and DS-SQ (in nine different ratios: 1:9, 2:8 
….9:1) were examined for three bioassays related to vascular diseases: anti-
inflammation, angiogenesis and cell survival. The synergistic/antagonistic 
interactions between DS and SQ in the combination extracts on aforementioned 
bioassays were analysed by the CI and isobologram model for 
synergistic/antagonistic determination, respectively. Fourteen selected chemical 
compounds from both DS and SQ were screened in the same bioassays to investigate 
their mode of actions. The most potent compound from each herb was combined, and 
the possible interactions in the compound combination were also examined by CI 
and isobologram model. 
 
The results of the chemical analyses suggested that one DS and four SQ samples out 
of twelve collected raw samples have met the quality standard of the Pharmacopoeia 
of the People's Republic of China (PPRC) (2010), respectively. A novel UPLC 
method has been established to analyse the chemical composition of DS-SQ extracts 
in various ratios. Five chemical compounds were routinely captured in the DS-SQ 
extracts and were quantified. By comparing the chemical fingerprint of the 
combination extract with the single extract, it was observed that no new chemical 
 
xxviii | P a g e  
compounds in the mixed preparation were formed, although altered proportion of the 
original chemical compounds were noticed. 
 
Bioassay results on anti-inflammation demonstrated that DS-SQ at the ratio of 8:2 
exerted greater effects than the individual extracts, or other ratios in inhibiting 
excessively expressed inflammation mediators (nitric oxide [NO], tumour necrosis 
factor [TNF] and monocyte chemoattractant protein-1 [MCP-1]) on 
lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. CI and isobologram analysis 
suggested that this enhanced effects in inhibiting these three mediators for DS-SQ 
8:2 reached a synergy.  
On in vitro angiogenesis assays, DS-SQ, with the ratio at 3:7 and 2:8, showed 
significant effect in promoting suppressed endothelial cell growth, scratch wound 
closure and tube formation against the damage from homocysteine (Hcy) and 
adenosine (Ado) (P<0.05). This significant effect was synergistically enhanced in 
comparison to the individual effects from DS and SQ alone, or other ratios, as 
analysed by CI and isobologram. Moreover, the signalling pathways of the action of 
DS-SQ 2:8 was likely to be associated with the activation of mitogen-activared 
protein kinase (MEK), extracellular signal regulated kinase (ERK) and 
phosphatidylinositol 3-kinase (PI3K).  
For protecting endothelial cell survival from Hcy-Ado-TNF, DS-SQ at 6:4 ratio 
exerted the most prominent effects, which were found to be stronger than the single 
extracts as well as other DS-SQ combinations. Synergistic cytoprotective effects 
against Hcy-Ado-TNF were observed from DS-SQ extracts at 6:4 ratio analysed by 
CI. This synergistic interaction observed for DS-SQ 6:4 was also observed in 
reducing lactate dehydrogenase (LDH) leakage and Caspase-3 expressions in relation 
to anti-apoptosis. Additionally, DS-SQ 6:4 was found to synergistically protect 
endothelial cells from impaired cellular injury induced by oxidative damage (H2O2). 
DS-SQ 6:4 also restored the reduced cell viability and inhibited excessive expression 
of reactive oxygen species (ROS). 
 
Importantly, multi-target modes of action were observed from the chemical 
compounds in DS and SQ, which contributed to the anti-inflammation, angiogenesis 
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and anti-apoptotic activity for the combinational extracts. The relatively lipid-soluble 
compounds in DS and SQ were found to be the key contributors to anti-inflammatory 
activities. DT and Rd, two lipid-soluble components from DS and SQ, respectively, 
were found to be the most potent bioactive compound in inhibiting the excessive 
expressions of NO, TNF and MCP-1. NR1 from SQ significantly promoted Hcy-
impaired angiogenesis, whereas other individual compounds showed no significant 
effect. SA and Rb1 were the key components restoring impaired cell viability against 
Hcy-Ado-TNF, respectively. To combine the most prominent compounds, it was 
found that DT-Rd at 7:3 showed general antagonist effects in inhibiting LPS-induced 
NO, TNF and MCP-1 release (CI>1). SA-Rb1 4:6 showed synergistic effects in 
preventing cytotoxicity effects caused by Hcy-Ado-TNF (CI<1). This simplified 
combination was further tested on H2O2-induced oxidative damage on EAhy 926 
cells, and also demonstrated prominent effects. 
 
The results of this thesis collectively demonstrated the synergistic benefits of DS-SQ 
on vascular disease through two aspects: enhanced bioactivity on the same target, 
and multi-component, multi-target actions. The bioactivities of DS-SQ were 
synergistically enhanced in comparison to that of individual extract in inhibiting 
LPS-induced excessively expressed pro-inflammatory mediators on RAW 264.7 cells, 
restoring Hcy-Ado impaired angiogenesis, and protecting cell survival against Hcy–
Ado-TNF and oxidative stress on EAhy 926 cells, respectively. The observed 
combination effects of DS-SQ were greatly influenced by their relative proportions 
in combination. Moreover, multiple bioactive compounds from DS and SQ were 
found to act on different biological targets (DT, Rd for anti-inflammation, NR1 for 
angiogenesis and SA and Rb1 for endothelial cells survival), which contributed to the 
overall multi-target therapeutic activity of the combination extracts.  
To our knowledge, this is the first study that systematically evaluates the synergistic 
mechanism of a Chinese herbal formula. This study developed a platform and 
provided the methodology for evaluating the synergistic actions in the TCM formula. 
The mechanisms of action of the CHM herb-pair were successfully explained at a 
cellular level. The observed synergistic actions of DS-SQ analysed in a scientific 
manner provide mechanistic evidence and support the traditional use of herbal 
combination in CHM clinics. 
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1.1 Challenges presented by Chinese herbal medicine 
1.1.1 Background 
Traditional Chinese Medicine (TCM) is an integrated system of primary healthcare that 
originated in ancient China and evolved over 5000 years. It is one of the oldest and most 
long-standing healthcare systems in the world, and was rooted in the ancient Chinese 
philosophy of Taoism. It is prevalent throughout east and south-east Asian countries, 
including Japan, Korea and Vietnam. TCM encompasses many different practices, including 
Chinese herbal medicine (CHM), acupuncture, moxibustion, Tui Na, dietary therapy, Tai Chi 
and Qi Gong. Notwithstanding this diversity, CHM is the mainstay and principal form of 
TCM practice (Liang et al., 2014). 
 
TCM has also been a rich source for drug discovery. More than two-thirds of the active 
agents introduced to pharmaceutical drugs between 1980 and 2010 were directly or indirectly 
derived from natural plants (Newman & Cragg, 2012). For example, artemisinin (Qing Hao 
Su), a relatively new drug used for malaria caused by Plasmodium falciparum, was derived 
and synthesised from a Chinese medicinal herb (Artemisia annua) which has been used in 
China to treat malaria fevers for over 2000 years. Artemisinin was extracted and tested by a 
research group from the China Academy of Chinese Medical Science in 1971, led by Tu 
Youyou. Based on its public health impact for malaria sufferers in the context of the growing 
parasite resistance to existing antimalarial drugs, Tu Youyou was awarded the 2015 Nobel 
Prize for Medicine. 
 
CHM is in great demand in Asian countries and has been the subject of renewed interest 
internationally, with a growing market. The latested updated data showed that CHM export 
worldwide was almost US$1.2 billion in 2007 (Jokiniemi, 2010), and it has grown to US$83 
billion in 2012, up by more than 20% since 2011, as reported by the World Health 
Organization (WHO) traditional medicine strategy 2014–2023 (WHO, 2015). Depending on 
different definitions and calculations, CHM represents 20–50% of the herbal medicine market 
share worldwide (Xu & Yang, 2009). In Western countries, CHM has been recognised as a 
popular complementary and alternative medicine, with the belief that CHM incurs fewer side 
effects than Western medicine (WM), as it is generally extracted from natural products and is 
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without artificial additives (Liu et al., 2008). For example, in the USA Ginkgo and Ginseng 
were among the ten top-selling herbs between 1997 and 2000, accounting for up to United 
States (US) $300 and $216 million sales volume, respectively (WHO 2015). In Australia, it 
was estimated that the total national CHM expenditure for the 12-month period was US$0.21 
billion in 2007 (Xue et al., 2007). CHM are still in common use in Asian countries after 
thousands of years of use. In the Republic of Korea and Singapore, 76% and 86% of the 
respective populations commonly use CHM (WHO, 2015). China remains the biggest 
country for CHM cultivation, manufacturing and export. In 2015, the CHM industry was 
expected to generate $28.3 billion, up 13.4% from 2014 (WHO, 2015). 
 
CHM manufacture is a huge and growing industry in China. The majority production forms 
of CHM are raw herbal medicines, sliced herbal medicine and patent medicines (Blumenthal 
& Hsiao, 2005, Liang & Guo, 1997). In 2014, Ms Wang Guihua (the China Association of 
Traditional Chinese Medicine Secretary-General) reported that over 1500 manufacturers 
produced Chinese patent medicines, and over 800 manufacturers produced sliced herbal 
medicines (Wang, 2014). Further, up to 152 herbal resource centres have been approved to 
grow Chinese Materia Medica, with a Good Agriculture Practice (GAP) certificate reported 
by May 2014 (Guo et al., 2014). About 5000 traditional remedies are available, accounting 
for 30–50% of total medicine consumption (Li, 2000). Although WM and TCM are 
commonly integrated, about 90% of general hospitals and 75% of health centres in China 
have TCM departments (WHO, 2015). Even in WM hospitals, around 40% of medicines 
prescribed are CHM. Over 80% of Chinese patients have received TCM treatment at some 
point in their lives (Xu & Yang, 2009). 
 
CHM comprises a pharmacopoeia of thousands of medicinal substances, primarily plants and 
some minerals and animal substances (Zhu, 1998). According to the National Survey of 
Chinese Medicine resources in the 1990s, there are up to 12,807 Chinese medicinal herbs in 
total (Song, 1999). Among them, 8980 Chinese medicinal herbs have been documented in 
Chinese Materia Medica (Zhong Hua Ben Cao) (Song, 1999), which is considered the most 
comprehensive compilation of traditional Chinese drugs and Chinese medicinal plants. The 
official Pharmacopoeia of the People's Republic of China (PPRC) (2010) Volume I (the latest 
version) contains 2165 monographs of Chinese Material Medica, prepared slices of Chinese 
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crude drugs, vegetable oil, fats and extracts, patented Chinese traditional medicines and 
single ingredients of Chinese crude drug preparations (National Pharmacopoeia Committee, 
2010). In clinics, 200 to 600 medicinal herbs are routinely utilised by Chinese medicine 
practitioners, with 50 considered ‘fundamental’ herbs (Ergil et al., 2002). 
 
There are various ways of delivering CHM, including oral consumption (as a water decoction, 
powder, honey pill or tablet), nasogastric administration, topical applications, intravenous, 
intramuscular, subcutaneous injections, vaginal and rectal preparations, and ear and eye 
preparations (Ergil et al., 2002; Bensoussan & Myers, 1996). CHM is not only used as 
primary health care for the regulation, improvement and promotion of the function of the 
human body, but it also treats a very broad range of diseases and relieves symptoms (National 
Pharmacopoeia Committee, 2010). Conditions that CHM is used to treat covers both acute 
and chronic health problems, from minor ailments to life threating diseases, including 
insomnia and fatigue, digestive disorders, constipation and diarrhoea, irritable bowel 
syndrome, common cold and influenza, depression and anxiety, rheumatoid and osteoarthritis, 
menopause, cardiovascular diseases and cancer (Bensoussan & Myers, 1996). 
 
Although TCM has been clinically practiced for thousands of years, most CHM products do 
not possess modern scientific evidence for their claimed clinical use. Dr Zhang Qi (the head 
of Traditional and Complementary Medicine Unit in WHO) stated that the main challenges 
for the practice of traditional and complementary medicines, including CHM, faced by WHO 
member states (total 129) are efficacy issues, which include: a lack of research data (105/129), 
lack of mechanisms to control and regulate advertising and claims (83/129) and a lack of 
appropriate mechanisms to control and regulate herbal products (78/129) (WHO, 2015). With 
a steadily growing industry and popular use of CHM worldwide, increasing effort has been 
directed towards providing scientific proof and clinical evaluation for the continuous 
development of this ancient medical system (Chen et al., 2006). 
 
The keywords ‘Chinese herbal medicine’, ‘Chinese medicinal herbs’, ‘Chinese herbs’ and 
“Chinese Materia Medica” were used to search in four English and Chinese databases: 
Medline (English), PubMed (English), CNKI (Chinese) and WANFANG (Chinese). Related 
publications from 2005 January to 2016 December were searched. From this search it is 
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evident that the number of publications is generally growing each year (Figure 1.1). However, 
the majority of research on CHM is still conducted in the Chinese language: the number of 
publications in Chinese is substantially greater than English articles each year (although there 
was a slight fall in 2015 in the WANFANG database), which would largely restrict access for 
readers and researchers who are non-Chinese speakers. Hence, a bilingual literature review 
was conducted to provide a complete view of CHM, specifically on current issues regarding 
quality, safety and efficacy. The complexity of these issues, possible solutions and future 
directions are also introduced here. 
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Figure 1.1 Histogram showing the steady increase in CHM-related publications between 2005 
January and 2016 December from a bibliographic search in (A) Medline and PubMed, (B) 
CNKI and WANFANG database. 
 
1.1.2 Practice of CHM 
1.1.2.1 Nature/basis theory of CHM remedy 
CHM is a unique medical system that adopts a systematic approach to diagnosis and 
treatment. Typical TCM diagnostic methods include inspection, auscultation, olfaction, 
inquiry and palpation (Xu & Yang, 2009). It focuses on the body’s natural responses 
Chapter 1: Introduction 
7 | P a g e  
(reflected as TCM symptoms) towards the disease, rather than the pathological changes 
causing it. In TCM, symptoms are considered to reflect the underlying ‘imbalanced’ state of 
the patient, and are regarded as protective reactions from the body’s self-defending system to 
outside stimulants. Thus, CHM aims to improve the self-healing system and guide the body 
back to a state of health, or eliminate the adverse effects that impede the process of self-
recovery (Jiang, 2005). The visible signs and symptoms (such as a cough) of patients are 
analysed to identify the type of internal maladjustments (e.g., hyper-response). The overall 
maladjustments in the body are evaluated and the pattern of maladjustment (Zheng in TCM) 
is classified by determining the nature and location of the maladjustment (e.g., heat-pattern). 
Based on this ‘pattern-differentiation’ therapeutic strategy, different treatments are adopted 
and the respective herb formula is prescribed, which aims to guide the body back to the 
balanced or harmonised condition. 
 
The fundamental theories behind TCM revolve around the idea of a strong interrelationship 
between the environment and bodily functions, the balance of Yin and Yang, Qi (energy), and 
Wu Xing (five elements) that characterise the state of the organs according to their ‘elemental 
traits’ (fire, wood, water, earth and metal) (Cheng, 2000; Maciocia, 1989; Qiu, 2007). It is 
believed that once a harmonisation of the energy and Wu Xing within bodily functions and 
between the environments is achieved, the body has been maintained or restored to a healthy 
state. The illness starts with an imbalance of energy. 
 
Chinese herbs regulate and strengthen the body’s energy (Qi) and Blood, improve and 
normalise proper functions, restore health and prevent and treat illness. Unlike WM, which 
utilises mono-substance therapy, CHM usually applies a formula that consists of two to 20 
herbs to form herb formulations (Fu Fang in TCM). Herbal formulae are usually tailored to 
each person’s condition with non-uniform herb ingredients and doses. The composition may 
change as the condition improves/deteriorates. Therefore, this practice contrasts substantially 
with the more standardised treatment approaches in WM. 
 
1.1.2.2 Prescription of CHM 
Since CHM prescription emphasises the maintenance and restoration of balance in the overall 
functions of the body, most prescriptions are given as a herb formula that contain multiple 
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herbs, which are needed to target various aspects of the body’s responses in a holistic manner 
(Yuan & Lin, 2000). The key mechanism of the treatment of herbal formulae relies on the 
interactions among the multiple ingredients and the multi-target actions on the body (Figure 
1.2). A well-constructed formula maximises the effectiveness of treating a particular 
condition, while counteracting and minimising the unwanted effects of an individual herb. 
The typical characteristics of TCMs are the holistic, multi-target approach by a mixture of 
compounds (Jiang et al., 2010). Thus, CHM does not prescribe single chemical compound as 
WM does; instead, it utilises a whole herb plant or mixture of different herbs that contain 
different chemical components (a comparison between WM and CHM therapy is shown in 
Figure 1.2). 
 
The herb ingredients in a formula play a specific role and are combined following the Jun-
Chen-Zuo-Shi theory (‘Emperor-Minister-Assistant-Servant’). Jun is the main herb in a 
formula, with a relatively higher ratio to directly target the main symptoms; Chen is an 
adjuvant herb to promote the therapeutic effect of the key herb, or to target the accompanying 
symptoms with the second largest proportion; Zuo is usually used to reduce the side effects of 
the herbal formula; Shi guides the active ingredients to reach the target organs or to 
harmonise their actions. This theory highlights the synergistic principle in a formula with a 
systematic approach, enhanced therapeutic effects and reduced potential side effects (Chan, 
1995; Fan et al., 2006a; Kong et al., 2009a). A simple but well-constructed formula, Ma 
Huang Tang, can be used here to illustrate the Jun-Chen-Zuo-Shi theory. This formula 
consists of four herb ingredients (Ephedra, Cinnamomum cassia, Semen Armeniacae and 
fried Glycyrrhizae Radix) and is clinically used for treating influenza, acute bronchitis and 
bronchitis asthma (Luo et al., 2007). In the formula, Ephedra (Ma Huang) is the Jun herb, 
which targets the main symptoms to induce sweating, relieve coughs and asthma. 
Cinnamomum cassia (Gui Zhi) is the Chen herb, which assists Ma Huang to target the main 
symptoms as well as tackle accompanying symptoms and relieve pain in the limbs. Semen 
Armeniacae (Xing Ren) assists Ma Huang to alleviate asthma with a weaker effect, and acts 
as Zuo herb in the formula. Lastly, Zhi Gan Cao (fried Glycyrrhizae Radix) is the Shi herb 
that harmonises the strong effects from Ma Huang and Gui Zhi, which can harmonise the 
strong effects from other ingredients, and brings the therapeutic actions from Ma Huang and 
Gui Zhi to the targeted systems. The composition of a CHM formula can be customised on a 
patient-by-patient basis by adding or removing certain ingredients or increasing/decreasing 
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the dose of each ingredient based on the severity of a patient’s symptom. Thus, this strategy 
is frequently applied for chronic diseases (Yuan & Lin, 2000).  
 
 
Figure 1.2 A comparison between WM (one drug, one target, one disease) and CHM 
(multiple component, network targets, multiple diseases) (Liang et al., 2014). 
 
Different plant parts from the same herb may possess distinct TCM properties and are 
prescribed for different therapeutic purposes. For example, the root of Panax notoginseng 
(known as SQ in TCM) is traditionally used to heal wounds and promote blood circulation, 
whereas its flower part is used for dizziness, hypertension and acute sore throats (Ng, 2006, 
Jung et al., 2009). Additionally, herb ingredients are usually processed before being used as 
decoction pieces in a CHM formula. The main aims of processing are to enhance the 
therapeutic properties and/or reduce the toxicity of raw drugs. Processing methods for CHM 
can be divided into mechanical treatments, such as cleaning, cutting and grinding, and the 
more technical chemical method of stir-baking. After processing, all the herb substances are 
usually decocted together with water and given as an herb decoction. Standardised herb 
formulae (Chinese patent medicines) are also manufactured and made into pills, granules, 
tablets etc., for ease and convenience. 
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Overall, the philosophy, diagnosis, prescription principles and processing methods of CHM 
remedies are completely different to WM, and this has brought great challenges to quality 
control, efficacy evaluation and safety control of CHM products, as well as their development 
in a scientific and modernised manner. Major challenges that confront the development of 
CHM are discussed in the following sections. 
 
1.1.3 Challenges to CHM quality control 
1.1.3.1 Principal challenges determining CHM quality 
It is well-recognised that quality control is the foundation of the development of medicinal 
products, and plays a key role in safety and efficacy management (Jiang et al., 2010). Current 
quality issues of herbal medicines are mainly caused by three categories: the complex nature 
of plants, environmental influences and poor quality control processes (Zhang et al., 2012c). 
 
1.1.3.1.1 Complex nature 
The chemical composition of a plant is a complex mixture that contains hundreds of organic 
chemicals. Even a single plant can synthesise a bewildering variety of phytochemicals. For 
example, Salvia miltiorrhiza is a popular Chinese medicinal herb. It contains two major 
groups of chemicals — salvianolic acids (SAs) and tanshinones, and they demonstrate 
different biological targets, such as SAs for cardiovascular management and tanshinone 
groups for anti-cancer activity (Ji et al., 2000; Chen et al., 2014). The chemical composition 
can be much more complicated when several herbs are combined in a herbal formula, as the 
composition is not simply the sum of all the chemical substances from each ingredient, but 
may be altered (structure and/or amount) during possession or decoction, due to solvent 
polarity, heating effects or changed pH environment. For example, the main volatile chemical 
components present in Rhizoma Ligustici Chuanxiong (known as Chuanxiong in TCM) and 
Radix Paeoniae Rubra (known as Chishao in TCM), which are commonly used to promote 
blood circulation and remove stasis, were markedly altered when given together, due to the 
formation of non-volatilised, water-soluble salts during the decoction process (Li, 2014). 
Additionally, new compounds were found when herbs are prepared in combination in certain 
conditions. For instance, Wang et al. (2012) identified four new compounds in a Yuanzhi 
(Radix Polygalae) and Shichangpu (Acorus Tatarinowii) combination that were not detected 
in the individual extracts (Wang et al., 2012d). Therefore, the non-uniform and unpredicted 
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chemical components in an herbal formula make the standardisation of CHM formula 
products considerably more difficult than with conventional drugs. 
 
1.1.3.1.2 Environmental issues 
Different geographic origins, climatic conditions, time of harvest and growth environments 
(e.g. soil) can lead to large variance in the chemical compositions of a plant. For example, 
Zhao et al. (2011) found that the amount of the key chemical compounds varied statistically 
significantly among the Pueraria lobata (Ge Gen in TCM) samples collected from different 
regions in China: the biggest difference was up to 4.5-fold (Zhao et al., 2011). Climatic 
condition in different geographic regions is one factor that may impact the quality of a plant. 
For example, Chaudhary et al. (2007) compared the chemical fingerprint of extracts of 
Clematis huchouensis Tamura (Tie Xian Lian in TCM) collected from Hangzhou and Jiangsu 
Province in China, and revealed that the quantitative ratio of major compounds was 
significantly different in the samples that originated from diverse habitats. It was assumed 
that this was due to different climatic conditions such as altitude, temperature, and/or 
edaphalogical differences (Chaudhary et al., 2007). To investigate whether harvest time 
affects the quality of CHM, Dong et al. (2003) compared the contents of notoginsenoside R1, 
ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, dencichine, flavonoid and polysaccharide 
in Radix Notoginseng samples that were harvested in different months in a year. The results 
suggested that the amount of major compounds in the samples collected from August to 
November differed by over 30%, and the best season for the harvest is September to October 
(Dong et al., 2003). The growing condition was also considered to result in quality variation 
in CHM. For example, it was observed that pollution of the soil significantly damaged the 
condition of the plant. This possible contamination included heavy metal, microbes, pesticide, 
bacteria, moulds and mycotoxins, processing impurities and solvent residues (Chan, 2003). 
CHM products may contain heavy metals such as mercury, lead, arsenic (Kew et al., 1993) 
and corticosteroids in harmful amounts, due to the pollution of soil (Pal & Shukla, 2003). 
 
1.1.3.1.3 Poor quality manufacturing and handling 
Poor quality manufacturing and handling problems — such as adulteration, contamination, 
misidentification and incorrect labelling of the species/plant part—are likely to lead to critical 
efficacy and safety issues (Zhang et al., 2012c; Jordan et al., 2010). 
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Adulteration is a common issue for the quality control of CHM products, and is mainly 
economically motivated. Adulteration involves spiking orthodox drugs to herbal medicines, 
substitution of plant ingredients with fake or inferior plant materials, addition of foreign 
material, etc. For example, it was reported that nine batches of CHM products in China—
including Cortex Phellodendri (golden cypress), Corydalis Yanhusuo (corydalis) and Pollen 
Typhae (Pu Huang) — were dyed with auramine O, used to cover the bad quality of the crude 
material of the plant (China Food and Drug Administration Database [CFDA Database], 
2016). With long-term administration, auramine O can cause liver or kidney damage and 
cancer (Parodi et al., 1982). Additionally, it was frequently reported that Chinese Ginseng 
(Panax Ginseng) was substituted with Siberian Ginseng (Eleutherococcus senticosus) due to 
cost purposes, and that Jin Bu Huan (polygala chinesis) was adulterated with Stephania 
corydalis from poor manufacturing practice (Chan & Critchley, 1996). Further, adulteration 
was also reported outside China. Research by Zhang et al. (2009) indicated that a majority of 
pomegranate products commercially available in the US market are either adulterated with 
pharmaceutical agents or of a very poor quality (Zhang et al., 2009b). 
 
Soil pollution in China leads to contamination of CHM products with microbes, pesticide 
residues and heavy metal (Jordan et al., 2010). Up to 25 CHM products produced in nine 
famous Chinese medicine brand enterprises were detected to have pesticide residues seven 
times higher than the minimum standard (Han et al., 2008). As China is the largest CHM 
exporter, contaminated CHM products with toxic metals were detected in various countries, 
including Singapore, Germany, Nigeria, the US and Malaysia (Zhang et al., 2012c). Chinese 
herbal materials and patent medicines exported to other counties were less contaminated with 
heavy metal than those for domestic use, which indicated the higher quality standards in 
developed countries than China (Zhang et al., 2012c). 
 
Chinese medicinal herbs often have multiple names, including vernacular names that vary 
from region to region. Sometimes numerous names are given to a single herb, or a single 
name applies to multiple drugs. For instance, Panax notoginseng has multiple Pinyin names, 
including Sanqi, Tianqi, Dianqi, Shen San qi or Jin Bu Huan. Among these names, Jin Bu 
Huan is also the vernacular name for Ocimum basilicum in Cantonese speaking areas. The 
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Pinyin name Gegen is shared by two different species: Pueraria Lobata and Pueraria 
Thomsonii. Wong et al. (2013) tested 17 granules collected from China and Australia that 
labelled Gegen as the raw material, and found that the raw materials were different: four 
brands of granules were P. thomsonii and the others were actually P. lobata. The chemical 
compositions of these two species are largely different (Wong, 2014). Thus, labelling with 
the Pinyin name only is not sufficient. Plants that have similar appearance may also be 
misidentified and mislabelled, such as American Ginseng (Panax quinquefolius) and Asian 
Ginseng (Panax Ginseng), the interchangeable use of which can potentially lead to adverse 
reactions. 
 
All of these factors may affect the quality of CHM, thus emphasising the necessity of 
establishing quality standard and chemical requirements for a single herb product and each 
herb ingredient that goes into a TCM formulation and herbal products sold in the market 
(Yuan & Lin, 2000). 
 
1.1.3.2 Current approaches: Quality control guidelines 
Many guidelines have been developed for the quality control of herbal products and the 
ingredients that go into their formulation. TCM is a medical system, and CHM should be 
regulated as complex chemical drugs and biological products. In China, CHM is regulated 
alongside pharmaceutical drugs under the State Food and Drug Administration. Australia is 
the first Western nation that has admitted and regulated CHM as a complementary medicine 
under the Therapeutic Goods Act 1989 (The Act) (TGA). The European Medicines 
Evaluation Agency (EMEA) defines herbal medicinal products as medicinal products 
containing exclusively herbal drugs or herbal drug preparations as active substances (Busse, 
2000). However, in the US, most CHM products (including CHM raw herbs) have not yet 
been regulated as medicines; instead, they are marketed/used as food, dietary supplements 
and/or as ingredients in cosmetics, according to the Federal Food, Drug, and Cosmetic Act 
(“the Act”) or Public Health Service Act (“PHS Act”) under the Food and Drug 
Administration (FDA) (FDA, 2011; Fan et al., 2012b). 
 
As CHM are prescribed in different forms—including crude herb material, sliced decoction 
pieces and finished products (granule, tablet, capsule), quality control should be required for 
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each form. Regulations on the manufacture of CHM finished products were established in 
1989. However, regulations in Western nations over crude herb material and herbal extracts 
remain limited. For example in Australia, Good Manufacturing Practices (GMP) has been 
established to control manufacturing, packaging, labelling and importing activities (Zhang et 
al., 2012c). Evidence showing the quality of the herbal ingredients in a finished product, such 
as chemical composition, processing procedure, GMP controls and process validation 
throughout development and manufacture must be approved by the TGA before marketing 
(TGA, 2013). In contrast, there is generally no quality regulation under the TGA for the raw 
herb material that is directly dispensed by practitioners. Imported crude herbal materials are 
scanned by Australian Customs and Quarantine (to check for infestations, restricted 
substances and/or endangered species). That is, the actual quality control (e.g. identification) 
of the raw material are largely relied on TCM practitioners. Similarly, FDA regulations for 
CHM focus on manufactured products only including one or more of the following: robust 
chemistry, manufacturing and control. The evidence is provided by the sponsor (CDER, 
2004). China, conversely, applied PPRC as the major reference for quality control of CHM, 
which has specific quality control methods and standards for both crude herb material and all 
forms of the finished product (National Pharmacopoeia Committee, 2010).  
 
Environmental factors such as biological or geographical variation, 
cultivation/harvesting/drying conditions (microbial levels, aflatoxins, toxic elements), 
pre/post-harvest chemical treatment (pesticides, fumigants) profile and stability of the 
constituents are also taken into account by the current regulations, such as the TGA in 
Australia (TGA, 2013). The European Union, China and Japan have developed regional and 
national guidelines for good agricultural and collection practices for medicinal plants, which 
ensure that soil and irrigation water used for herbal material cultivation and propagation are 
within the safe limits, or free from harmful heavy metals, pesticides, herbicides and 
toxicologically hazardous substances (Sahoo et al., 2010). 
 
British Phamacopoea, Chinese Pharmacopoeia, the European Pharmacopoeia or an 
authenticated reference specimen are used as reference monographs for the identification and 
authentication of raw materials by the regulation guidelines in various countries (TGA, 2006). 
However, all of these quality control assessments in the monographs are designed a similar 
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way in terms of quality control of conventional drugs (a single compound). It has yet to be 
adapted to the complex composition and multi-constituents of Chinese formula products. 
 
The current qualitative assessment for single herbs and formulae is to check the basic 
chemical profile and the minimum amount of one or several chemical components. This, of 
course, does not represent the complete profile of the herb or formulation. Sometimes, it 
cannot even distinguish herbs with similar appearance and/or similar main chemical 
constitution. For instance, puerarin is the key marker compound for both Pueraria lobata and 
Pueraria thomsonii, but assessing the identity and amount of puerarin only cannot 
differentiate Pueraria lobata from Pueraria thomsonii. These two species share similar 
appearance but possess substantially different chemical compositions, and thus lead to 
different levels of biological activities (Wong et al., 2011, 2013). Therefore, to establish the 
standardised extract with full chemical profile or multiple essential markers presents a 
complete view for the quality control of herbal (formula) products. Besides, the 
standardisation of formula composition must be established to minimise variability in the 
chemical content, and thus the pharmacological and clinical outcome. 
 
China has established an Institute of Medicinal Plant Development (IMPLAD), which has 
been designated a WHO Collaborating Center for Traditional Medicine since 1983. It 
conducts research that involves establishing quality control methods for formula products, 
evaluating species variability and developing GAP farming practices for CHM. Additionally, 
the concern for the quality control of formula productions was taken into account for the 
PPRC 2015 version, and standards for the classical formulae and herbal granules (being 
extracts for single herbs or combination classical formulae) have been included in the 2015 
edition (Chinese Pharmacopoeia Commission, 2015). 
 
1.1.4 Challenges to the safety of CHM 
1.1.4.1 Principal challenges determining CHM safety 
CHM must conform to modern safety requirements in order to fulfil its role as a 
contemporary treatment option. CHM is generally derived from nature, and it can be toxic to 
humans. The general belief that CHM poses lower risk than synthetic drugs is a 
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misconception. In fact, any substances that affect the body’s defence or physiology may have 
various degrees of side effects. Despite the potential harm from several Chinese medicinal 
herbs with predictable risks, many safety issues are caused by poor quality controls, 
inappropriate prescriptions and administration and lack of safety instructions (Jordan et al., 
2010). 
 
1.1.4.1.1 Inherent toxicity 
A number of Chinese herbs are toxic to humans. One of the most extensive modern records, 
the Encyclopaedia of Materia Medica (Zhong Yao Da Ci dian) (1977), documents 495 out of 
5,767 medicinal herbs as toxic (Nan Jing University of Traditional Chinese Medicine, 1977). 
For example, Ephedra (known as Mahuang in TCM) was withdrawn from the Australian 
market because of the risk that it promotes heart valve problems and liver toxicity. 
Aristolochic acid, isolated from Aristolochia debilis (known as Madouling in TCM), can lead 
to rapid kidney failure, seen in a group of women who had all taken the same weight-loss 
supplement (Debelle et al., 2008). Liquorice root (Glycyrrihza spp.) and its extracts are often 
used in CHM to regulate the stomach, as an expectorant, a corrective adjunct and a 
harmonising ingredient in many formula preparations (Fenwick et al., 1990). It contains 
mineralocorticoid, which can cause adverse effects such as oedema, hypertension and 
electrolyte imbalances (Isbrucker & Burdock, 2006). Ginseng (Panax Ginseng) is one of the 
most popular TCM herb used for a variety of conditions, including tiredness and poor 
circulation. However, it has been associated with an ‘abuse syndrome’ characterised by 
insomnia, irritability and excitability (Vazquez & Agüera‐Ortiz, 2002). 
 
The vast majority of toxic CHM substances cause safety issues that are predictable, and can 
be avoided with proper process, clinical instructions, prescription and regulated by relevant 
restrictions (such as the Standard for the Uniform Scheduling of Medicines and Poisons 
[SUSMP] in Australia). With a long history of clinical practice, the toxicity and warnings for 
commonly used medicinal herb are well documented in many TCM textbooks, monographs 
and pharmacopoeias. As CHM products often consist of multiple herbs and other ingredients, 
toxicity from the single herbal ingredients can be significantly reduced in a well-constructed 
formula, according to the Jun-Chen-Zuo-Shi theory. 
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Based on the TCM compatibility theory, there are seven principles of combining medicinal 
substances in a formula, and three are associated with toxicity minimised or induced by 
combining certain herbal ingredients in constructing a formula. They are the Xiang Wei, 
Xiang Sha and Xiang Fan principles. Xiang Wei and Xiang Sha describe the reduction and 
elimination of toxicity of one substance by another. In contrast, Xiang Fan describes ‘toxicity 
induced by combining of two herb ingredients which neither of individual is toxic’ 
(Bensoussan & Myers, 1996). When constructing a formula, ingredients that are Xiang Wei 
and Xiang Sha can be used, and ingredients that are Xiang Fan should be avoided. For 
example, Zingiberis Rhizoma Recens (Shengjiang) is frequently prescribed together with 
Pinelliae Rhizoma (Banxia) to suppress its mucosa membrane irritation, based on the Xiang 
Wei principle. The Xiang Sha principle is used in many herb pairs, such as Moschus 
(Shexiang) and is prescribed with Armeniacae Semen Amarum Xingren to eliminate toxicity. 
Phaseoli radiati Semen (Lvdou) counteracts the toxicity of Crotonis Fructus (Badou), and so 
on. Herb ingredients that are Xiang Fan should not be used together, such as Glycyrrhizae 
Radix (Gancao) with Cirsii Japonici Herba (Daji), Veratrum nigrum (Lilu) with Salviae 
Miltiorrhizae Radix (Danshen [DS]), and so on. In the Shi Zao Tang formula (Ten-Jujubie 
decoction that is traditionally used for suspending fluid and oedema in TCM), Ten-Jujubie 
has no therapeutic effects. However, they are added to harmonise the fierce effects on the 
body, as well as to offset toxicity (fluid and electrolyte imbalance) induced by other 
ingredients (Liu, 2011). Thus, due to the interactions of herbal ingredients in a formula, there 
is uncertainty over drawing conclusions about the toxicity of mixtures based on the known 
toxicity of each specific individual ingredient (McCarty & Borgert, 2006). Providing an 
accurate assessment of toxicity associated with the formulation of products is still a great 
challenge for modern scientific studies (Jordan et al., 2010). 
 
1.1.4.1.2 Safety risks in the practice of CHM 
The knowledge and qualification of practitioners has a direct bearing on patient safety (WHO, 
2015). The safety risks identified in CHM practice include misdiagnosis, poor prescribing, 
failure to observe and/or explain contraindications, inappropriate dosage and duration of 
therapy, and failure to avoid known interactions with pharmaceuticals and precautions 
associated with a particular substance (Bensoussan & Myers, 1996). The first adverse 
reactions case related to CHM due to bad practice that drew worldwide attention was in the 
1990s, when a group of Belgian women were taking Chinese herbs for weight-loss and 
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developed end-stage kidney failure (Novella, 2012). This was attributed to the doctors who 
misidentified Aristolochia fangchi (Guangfangji), which is toxic, as Stephania tetranda 
(Hanfangji), which is nontoxic (Maciocia, 2003). It was also incorrect to prescribe Hanfangji 
to relieve pain and to promote diuresis (Maciocia, 2003). Another severe reaction due to 
illegal prescribing was reported in 1994, when a 32-year-old man suffered a severe heart 
attack 30 minutes after he was administered a herbal decoction for aching joints by a Chinese 
herbalist in Sydney. Analysis showed that the decoction preparation contained aconite 
alkaloids, considered as toxic ingredient and banned in Australia. The herbalist was fined 
$2000 for administering a restricted substance. 
 
The processing of herbal slices is an important step in CHM preparation and is frequently 
done to decrease toxicity. For example, heat processing can make the bitter almond enzyme 
lose activity and then decrease the toxicity of almond, which contains cyanophoric glycoside 
(Zhang et al., 2015). Failure to specify the processing preparation to the patient can cause 
severe adverse effects. For instance, Aconitum carmichaelia (Wutou in TCM) contains 
aconite, which is an alkaloid that can be lethally toxic. However, the alkaloids are rendered 
less toxic when the herb is soaked in water and boiled for a specific time (Chan & Critchley, 
1996). There was one case that a TCM practioner failed to clarify the processing step to a 
patient, which led to death of the patient 15 hours after the ingestion of Aconitum 
carmichaelia (Tomlinson et al., 1993; Chan et al., 1993a; Fatovich, 1992). There have also 
been several other cases of aconite poisoning due to accidental overdose (Chan et al., 1993b). 
 
Incorrect practice can be mainly attributed to two reasons: lack of regulation and low 
training/education. According to a WHO report from 129 member states, up to 43.5% of 
traditional medicine practitioners were not regulated in 2012, and 56% of these practitioners 
did not have university-level education (WHO, 2015). A survey conducted in Australia in 
1996 revealed that many TCM practitioners still frequently prescribed a range of prohibited 
Chinese herbs for oral use, either in raw form or contained in proprietary Chinese medicines 
such as Herba Ephdra (Mahuang), Aconiti carmichaeli praeparata radix lateralis (Fuzi), 
Moschus secretio (Shexiang), aristolochiae radix (Qingmuxiang) (Bensoussan et al., 2000). 
Regulation is required for safe practice by Chinese practitioners. Fifty-eight WHO member 
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states considered that lack of education and training for TCM providers to be one of the 
difficulties facing regulatory issues for TCM (WHO, 2015). 
 
 
 
 
 
 
1.1.4.1.3 Poor quality control 
Poor quality control includes adulterated herbal products, misidentification/mislabelling and 
contamination (heavy metals). These can lead to adverse reactions. 
 
Adulteration 
Instances of herbal medicines being adulterated with orthodox drugs have repeatedly been 
documented. Pharmaceutical drugs that are commonly used for adulteration include non-
steroidal anti-inflammatory agents, sedatives and corticosteroids such as ibupropfen, 
indomethacin, ketoprofen and mefenamic acid (Shyur, 2012). This affects the safety of the 
product. Ernst (2002) conducted a systematic review that summarised the data of CHMs 
adulterated with conventional drugs collected from six databases (Medline, Embase, Biosis, 
Amed, Cochrane Library and CISCOM) and revealed that the adulteration in the CHM 
products has led to 18 adverse reaction case reports, two cases serious and four analytical 
investigations identified, one fatality (Ries & Sahud, 1975) and at least six potentially life-
threatening (Forster et al., 1979; Offerhaus et al., 1979; Hughes et al., 1994; Vander Stricht et 
al., 1994; Goudie & Kaye, 2001; Ernst, 2002). In 2001, 19 patients suffered from severe 
adverse reactions from a Chinese patent medicine Huang Bo capsule, manufactured by 
Guangxi Banzhou Pharmaceutical Company. This product did not meet the China Food and 
Drug Administration (CFDA) national quality standard and was also adulterated with the 
expired drug tetracycline. The degradation of substances from tetracycline, 
epianhydrotetracycline, can lead to gastrointestinal tract dysfunction, liver and kidney 
damage. This adulterated Huang Bo capsule was withdrawn from the market by the CFDA. 
The only CHM adulteration case reported in Australia occurred in 1995 in Victoria, and 
involved a cortisone steroid cream in a CHM for skin conditions, resulting in severe toxicity 
(Bensoussan & Myers, 1996). 
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Misidentification/mislabelling 
Misidentification and mislabelling due to poor quality manufacturing can lead to side effects. 
For instance, the name ginseng can be used for two herbs: American ginseng (Panax 
quinquefolius), and Chinese ginseng (Panax ginseng). They were interchangeably applied in 
clinics as the same herb, even though the two herbs possess distinct therapeutic qualities in 
TCM. American ginseng is normally used in persons with excessive Yang who need a tonic 
to strengthen their resistance but cannot tolerate yang medicines like Chinese ginseng, which 
may aggravate the problems they already have (Leung, 2006). The California Department of 
Health Services investigated a poisoning case in which the herbal ingredient was found to be 
Podophyllum emodi (which contained podophyllotoxin) rather than the supposed Clematis 
chinensis (Weilingxian). The misidentification led to permanent peripheral neuropathy in the 
patient (Ko, 2004). 
 
Unclear nomenclature in the labelling of CHM products can raise potential safety risks for 
consumers. If a drug is labelled with the common English name only, it can be difficult to 
trace its species, pharmaceutical names and botanical name. For example, ginseng products 
should specify the pharmaceutical name as Panax Ginseng, or Siberian (Eleutherococcus 
senticosus) or other ginsengs (Chan & Critchley, 1996). Wrong indication and dosage due to 
poor handling can also cause severe safety problems. Over-dosage of Ephedra (Mahuang) 
was reported to induce at least a dozen deaths, heart attacks and strokes (Lee et al., 2000; 
Haller & Benowitz, 2000). 
 
Contamination with heavy metal and other substances 
Failure to detect and regulate the excessive contamination of heavy metal in CHM products is 
a health hazard or fatal if consumed. Posadzki et al. (2013) published an overview of 26 high 
quality systematic reviews that summarised and critically evaluated the evidence of the 
contamination of herbal medicinal products. It reported that most commonly, herbal medicine 
products were contaminated with dust, pollens, insects, rodents, parasites, microbes, fungi, 
mould, toxins, pesticides and/or toxic heavy metals (Posadzki et al., 2013). The most severe 
adverse effects caused by these contaminations were agranulocytosis, meningitis, multi-organ 
failure, perinatal stroke, arsenic, lead or mercury poisoning, malignancies or carcinomas, 
hepatic encephalopathy, hepatorenal syndrome, nephrotoxicity, rhabdomyolysis, metabolic 
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acidosis, renal or liver failure, cerebral oedema, coma, intracerebral haemorrhage and death 
(Posadzki et al., 2013). In 2015, a group of researchers from Curtin University, Murdoch 
University and the University of Adelaide conducted genetic analysis to assess the molecular 
content of 26 widely available CHM products, and reported that 90% were not fit for human 
consumption. Their results showed that more than 90% of the tested products were detected 
to have some form of contamination and/or substitution. Further, mass spectrometry revealed 
heavy metals including arsenic, lead and cadmium, one with a level of arsenic >10 times the 
acceptable limit and beyond the safe ingestion recommendations (Coghlan et al., 2015). 
 
Self-medication 
Most CHM products can be obtained by a practitioner prescribing it as well as over-the-
counter (OTC) self-prescription in both Asian and Western countries. During self-
prescription there is no guarantee that safety information is fully available or that customers 
will follow the safety instructions, which may pose a risk for self-prescribed patients (Pal & 
Shukla, 2003). A number of self-poisoning adverse reaction cases have been reported against 
CHM. A cross-sectional telephone survey conducted in Hong Kong Chinese adults in 2011 (n 
= 1100) with informed verbal consent revealed that 71.7% (789/1100) reported using OTC 
traditional CHM in the past year, and 2.3% (25/1100) reported at least one adverse event in 
that time. Of the 27 adverse event cases reported among OTC -CHM users, the most common 
were allergic reactions (n = 11) dizziness (n = 5) and gastrointestinal problems (n = 4) (Kim 
et al., 2013). 
 
In some cases, patients may use traditional and conventional medicine simultaneously 
without informing their GP. The likelihood of adverse reactions has been repeatedly reported 
through drug-herb interactions (Biloba, 1999; Valli & Giardina, 2002; Izzo & Ernst, 2009). 
For example, DS was reported to exaggerate the anti-coagulant response to warfarin (Chan, 
2001). Ginseng was also associated to interact with warfarin and decreased INR. Ginkgo 
biloba was suspected to interact with some anti-coagulant drugs for extending bleeding times. 
Since the mechanism of the interactions is not clear, it can certainly raise safety concerns for 
self-medicating if this is done without instructions and not carefully monitored (Pal & Shukla, 
2003). 
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For OTC CHM products, consumers rely on product labels for safety information. However, 
limited accessibility of reliable information on product labels has been reported, attributed to 
the potential risks for self-medicated patients. Raynor et al. (2011) evaluated the label 
information provided by five commonly used herbal products (St John’s wort, Asian ginseng, 
echinacea, garlic and ginkgo) which were bought from pharmacies, health food shops and 
supermarkets in the United Kingdom (UK), regarding the key safety messages on precautions, 
interactions with orthodox drugs, and side effects included in the monographs of the US 
National Center for Complementary and Alternative Medicine. Their analysis showed that 51 
of 68 products (75%) contained none of the key safety messages (Raynor et al., 2011). 
Moreover, the TCM indications—such as ‘dispelling dampness’ or ‘normalising the gall-
bladder’—were difficult for consumers to understand and interpret, as TCM terminology 
requires professional knowledge of TCM concepts (Kim et al., 2013). Another barrier was the 
perception that reliable knowledge of OTC CHM products could not be obtained from 
Western medical professionals (Kim et al., 2013). It was reported in Canada that reliable and 
readily accessible information sources on herbal medicines were limited, and pharmacy 
customers accessed safety information mainly from complementary and alternative medicine 
practitioners, friends and family, books, newspapers, magazines and the Internet, so the 
information may not be correct or reliable (Cramer et al., 2010). In fact, a survey evaluated 
the information available online for three popularly used medicinal herbs, including ginseng, 
ginkgo and St John’s wort, and found that 25% contained statements that could cause harm to 
users and 97% omitted information (Walji et al., 2004). Therefore, self-management of health 
using OTC CHM with limited accurate and reliable safety information has the potential to 
lead to inappropriate use and safety issues. 
 
1.1.4.2 Current approaches 
1.1.4.2.1 Documentation of toxicity for CHM 
Based on thousands of years of accumulated traditional knowledge and clinical practice, the 
precautions, warnings and contraindications for commonly used CHM individual herbs and 
formulae are documented in pharmacopoeias, monographs and databases in Chinese. There 
are many encyclopaedias and monographs in Chinese (some translations into English are in 
progress) that can be referred to for safety information, such as PPRC, Duju Zhongyao 
Gujinyong (Toxic Chinese Materia Medica: Past and Present) (Yang, 1991), Youdu 
Zhongcaoyao Da Cidian (Encyclopedia of Toxic Chinese Materia Medica) (Guo, 1992), 
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Duyao Bencao (Toxic Drugs Herbal) (Yang, 1993) and Xiandai Zhongyao Dulixue (Modern 
Toxicology of Chinese Materia Medica) (Leung, 2006). 
 
Modern scientific works on CHM toxicity documentation are primarily based on 
compilations of data generated from isolated chemicals. For example, the TGA established 
the ‘poison standard’ that consists of decisions regarding the classification of medicines 
(including toxic compounds and herbal ingredients from CHM) and poisons into Schedules, 
for inclusion in the relevant legislation of the States and Territories. For example, aconite has 
been included in Schedule 4 of the Standard for SUSMP, and can only be prescribed by 
registered medical practitioners, dentists or veterinarians and dispended by registered 
pharmacists. In 2015, the Chinese Medicine Board of Australia (CMBA) commissioned 
National Institute of Complementary Medicine to produce a new Nomenclature Compendium 
for CHM, which extracted restrictions and warnings from SUSMP and PPRC for over 600 
most commonly used Chinese medicinal herbs, which greatly save researchers’ time and 
efforts for referring safety information for CHM. However, due to the nature of CMM 
practice, which relies totally on direct clinical experience with humans over time, there are 
limited precise toxicity data like those of modern pharmaceuticals generated from animals 
and in vitro experimentation (Leung, 2006). Presently, adequate data regarding toxic herbs, 
toxic target organs, safe dose range, safety window of effective dose, and minimum toxic 
dose are still lacking (Zhang et al., 2015). 
 
1.1.4.2.2 Regulation and education of TCM practitioners 
To avoid the safety issues caused by inappropriate use and practice, greater attention and 
efforts have been made to ensure the education level and to strengthen the regulation of TCM 
practitioners. It is recommended that general practitioners (GPs) and pharmacists be trained 
with the safety knowledge of CHM so that patients can be instructed (Pal & Shukla, 2003). In 
China, all TCM practitioners are required to receive education and pass a Chinese medicine 
teacher qualification examination to be registered and practice legally. All TCM practitioners 
are regulated under the State Administration of Traditional Chinese Medicine. However, no 
Western countries have conducted regulation of TCM practitioners nationally, only state by 
state (with the exception of Australia). Australia is the only country that has already 
introduced national registration for Chinese medicine practitioners, since 2012. All TCM 
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practitioners must be registered under the national registration and accreditation scheme with 
the CMBA to practice. They are required to master knowledge of the toxic and restricted 
herbs to lower the safety risks of prescribing CHM in Australia. As most Western nations 
have yet to start official regulation for TCM practitioners nationally, the WHO put this 
concern into their Traditional Medicine Strategy report 2014–2023, as well as relevant 
strategies and actions to strengthen the safe use of CHM products by practitioners worldwide 
(WHO, 2015). 
 
 
1.1.4.2.3 Restricted quality control guidelines for finished products 
Safety issues caused by contamination, heavy metal and adulteration are mainly attributed to 
the limited quality control regulations. For the regulation of the finished herbal products, 
GMP has provided a framework to ensure the quality and ability to deal appropriately and 
quickly with problems when they do arise. Each Australian manufacturer of herbal medicine 
products must hold a manufacturing licence and comply with the Australian Code of GMP 
for Medicinal Products regarding manufacturing, packaging and labelling (Jordan et al., 
2010). The herbal ingredients/chemical substances contained in the formula or CHM products 
that may cause potential toxicity to humans should follow the regulation. Some 
environmental related factors can be controlled by implementing standard operating 
procedures (SOP) including GAP, good laboratory practice (GLP), good supply practice 
(GSP) and GMP. 
 
1.1.4.2.4 Updating regulatory guidelines with raw herb materials and herbal extracts 
There is an urgent need to establish a quality testing system for raw herb materials and their 
extract preparations, to reduce safety issues, especially in Western nations. The examination 
of restricted substances and endangered species by Quarantine and Customs is evidently 
insufficient for its medicinal practice. To avoid potential safety issues, proper quality control 
processes for identification and quantification based on monographs and/or pharmacopoeias 
should be conducted, including examination of appearance, microscopic/macroscopic 
analysis and chemical fingerprinting. Chemical approaches (i.e., mass spectrometry, DNA 
fingerprinting) that would detect any contamination, and the presence of pollutants. Any 
study conducted on whole plants or extracts must use only botanically/chemically 
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authenticated material. It is recommended that the quality control of raw herbs and extracts, 
which are equally important as the finished products, be considered and regulated officially. 
 
1.1.4.2.5 Greater scrutiny and improved surveillance 
OTC CHM-product related adverse events are an underappreciated public health issue that 
may require greater scrutiny and improved surveillance. Improved surveillance of 
complementary medicines should be prioritised by governments in order to provide more 
comprehensive safety information for health professionals and consumers. It is a necessity 
that the information about precautions, interactions and side effects are clearly and accurately 
stated with the product and provided to consumers when they purchase herbal products 
(Routledge, 2008). To avoid adverse reactions caused by the interactions between Western 
pharmaceuticals and CHM, consumers should be encouraged to communicate with their 
healthcare practitioners about any use of herbal products, and practitioners should consider 
initiating such discussions (Smith & Boon, 1999). It is also recommended that pharmacists 
and GPs should have basic knowledge of complementary medicines including CHM, so that 
they can be aware of and avoid potential interactions between orthodox drugs and CHM if 
co-administered by patients. Most pharmacy customers in Australia agreed that pharmacists 
should provide full and accurate safety information about herbal products (Braun et al., 2010; 
Cramer et al., 2010). Greater dialogue between TCM manufacturers, retailers and Western 
health professionals is required to develop effective safety measures for OTC users. 
 
1.1.5 Challenges to the efficacy of CHM 
As a medical system that has been practiced for thousands of years, CHM has accumulated a 
rich clinical experience with repeated testing, and has proven effective, at least at the 
individual and community level. However, with the modernisation of the medical system, 
questions have been raised about the scientific evidence for this efficacy (Pal & Shukla, 
2003). The multi-component and multi-target mechanism of CHM is inherently distinct from 
the mono-substance and mono-target model of WM, so utilising the Western evaluation 
paradigm to investigate the efficacy of CHM is not adequate and efficient (Leung, 2006). 
With the difficulty of developing suitable and efficient research methodology that is suitable 
to study the complex nature of herbal formula, and in order to reach a stage where CHM 
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formula products of assured efficacy, there are still many challenges facing CHM (Pal & 
Shukla, 2003). 
 
1.1.5.1 Principal challenges determining CHM efficacy 
1.1.5.1.1 Non-uniformed chemical composition leading to inconsistent therapeutic 
effects 
The inconsistent quality of herbal products is likely to induce fluctuated levels of therapeutic 
effects, which represent one of the major concerns for their effectiveness. Various factors (e.g. 
complex nature, environmental factors) can affect the chemical composition and content of 
active components in a CHM product, and that may be the reason for inconsistent therapeutic 
effects. For example, Kam et al. (2013) used pomegranate as a case study and suggested that 
herbs collected from different origins can have significantly different levels of anti-oxidant 
effects. The polyphenolic content and their corresponsive anti-oxidant capacities of the 
methanol extracts of pomegranate peel were compared among samples collected from 
Australia, China and the US. The results showed that pomegranate peel from China generally 
had a significantly stronger total anti-oxidant capacity than that from Australia and the US, 
which strongly correlated to the higher total phenolic and flavonoid contents (Kam et al., 
2013). Additionally, different solvent systems used for the extraction of herb extracts yield 
various chemical compositions, and that may ultimately affect bioactivity. A study conducted 
by Akowuah et al. (2005) showed that different solvent systems including distilled water, 50% 
aqueous methanol, methanol, 70% aqueous acetone and chloroform used for extracting leaf 
powder of Orthosiphon stamineus yielded different amounts of chemical components. 
Among them, 70% aqueous acetone extract gave a high yield of 30-hydroxy-5,6,7,40-
tetramethoxyflavone, which also exhibited a higher radical scavenging activity than other 
solvent extracts (Akowuah et al., 2005). Hence, these studies highlighted that the non-
consistent chemical composition of CHM has greatly affected biological activity, which 
requires restricted quality standardisation of CHM products in the first place. 
 
1.1.5.1.2 Multiple clinical endpoints 
According to the diagnosis system of TCM, an herb formula is usually designed by TCM 
patterns to improve the overall function of the body. From TCM’s point of view, a disease 
presents in a whole and dynamic way; that is, it involves interactions between many 
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biological systems in the body and these interactions change as the disease improves or 
worsens. Thus, the ‘endpoint’ of TCM treatment is the pattern that reflects multi-system 
changes. Benefits produced by herbal medication include not only the regulation of several 
crucial biological targets but more importantly, the modulation of other associated general 
changes that delay the healing process. Therefore, it is common that an herb formula can be 
used to treat several Western diseases that may relate to the same TCM pattern (Jiang, 2005). 
For example, Liu Wei Di Huang Wan (LWDH) is a classic TCM formula used for the TCM 
pattern ‘Yin deficiency and tonify Kidney’. Nowadays, pharmacological studies have proven 
that this formula is effective for multiple diseases, including metabolic syndrome, diabetes 
and cardiovascular disease, based on the long history of clinical experiences and 
pharmacological studies. As there is no direct interpretation between TCM patterns and 
Western pathophysiology, to elucidate the pathological mechanisms and translating TCM 
indications into Western clinical endpoints remains a great challenge. 
 
1.1.5.1.3 Non-standardised ratio of herb ingredients 
The dose of herbal ingredients is an essential part of a formula. The ratio of herb ingredients 
(calculated by dosage) in a formula follows the Jun-Chen-Zuo-Shi theory (see Section 
1.1.2.2). TCM practitioners may adjust the ratio of ingredients in the formula with the 
improvement or aggravation of the symptoms, in order to achieve an optimal therapeutic 
effect. That is, different proportions of herb ingredients in a formula may totally alter the 
therapeutic effects and lead to different clinical outcomes. For example, a bigger proportion 
of DS is used in the DS-SQ formula for cardiovascular management. However, the dosage of 
DS should be reduced when the formula is used for haemostasis (Zheng et al., 2009). In TCM 
clinics there is no standardised ratio for a formula, especially when it is prescribed as a 
decoction. The ratio is designed by the TCM actioner based on clinical experience or 
traditional knowledge. It is difficult to systematically review the ratios used in the formulae 
and explain the rationale. The standardised ratio in Chinese patent medicines for specific 
clinical indications may give a clue for research. However, due to inadequate intellectual 
protection for CHM products in China, several manufacturers have kept the ratio confidential 
for their patent products. For instance, the Yun Nan Bai Yao formula is one of the most 
popular CHM products and is used for traumatic injury, pain relief and to dispel swelling, but 
the herbal ingredients and the doses are confidential. The non-standardised proportion of herb 
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ingredients in traditional herbal decoctions make it difficult for researchers to establish their 
efficacy, as the therapeutic effects may not be optimal if the dosage of ingredients is incorrect. 
 
1.1.5.1.4 Synergistic mechanism 
Most of the current research on CHM is on the single compound from the herb, and so far, 
millions of compounds have been isolated from plants and characterised and screened for 
therapeutic activities. However, to understand the action for the single compound is far from 
fully understanding the therapeutic activity of the whole herb and herbal formulation (Pal & 
Shukla, 2003). As CHM is constituted by multiple herbal ingredients and chemical 
compounds, therapeutic effects depend on the overall interactions among all components 
(Yuan & Lin, 2000). It is believed that the interaction exerts synergistic effects so that the 
optimal clinical outcome can be obtained, and the key step of unravelling the efficacy of 
CHM is to understand its synergistic mechanism. 
 
Synergy is an intrinsic part of the philosophy of CHM, and it is an essential concept for 
constructing an herbal formula (Jia et al., 2004). The synergistic concept in CHM involves 
enhanced therapeutic effects, reduced toxicity, network-target actions and promoted 
bioavailability (Jia et al., 2004). The synergy concept in CHM formulae is introduced as 
compatibility principles, including Xiang Xu (synergism), Xiang Shi (assistance), Xiang Sha 
(elimination), Xiang Wei (detoxification), Xiang Wu (antagonism) and Xiang Fan (rejection) 
(Jia et al., 2004). These principles are well established and extensively applied in TCM 
clinics, but the scientific rationale is still lacking. With the increasing popularity of Western 
drug combinational therapy, mathematic and computational models, computer bioinformatics 
technology and systems biology have been developed to quantitatively determine synergy. 
These models were then gradually applied to explore the synergistic mechanism on CHM 
formulae. However, it is argued that these models cannot yet effectively reflect the concept 
and draw useful conclusions for a holistic insight into CHM (Gu & Chen, 2013). Due to the 
limits of current methodologies and laboratory techniques, CHM still confronts great 
challenges in investigating synergy to fully elucidate its efficacy. 
 
1.1.5.1.5 Low quantity and quality of efficacy studies 
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As indications of CHM are obtained mainly from a long history of clinical experiences, most 
CHM products are not subjected to scientific efficacy research before marketing — until now. 
Scientific research on CHM is mainly published in the Chinese language (see Figure 1.1) 
(Yuan & Lin, 2000). The majority of these studies in Chinese are compromised by 
methodological flaws. For example, a systematic review reported that more than 2000 clinical 
trials can be found for Xiao Yao San (a classic TCM formula used for insomnia for over 
2000-year history) published in Chinese databases, and only two have met the standard of 
double/single blinded randomised controlled trials (Zhang et al., 2012d; Wang et al., 2007; 
Bian et al., 2006). Since an herbal formula is designed to treat TCM patterns rather than 
modern diseases, with treatment according to ‘syndrome differentiation’, and the formula 
ingredients are usually tailored to each person’s condition, this is rather difficult for the 
design and methodology of research (for both clinical trials and pre-clinical studies). There 
are a large number of animal studies in Chinese that show the overall effect of a single herb 
or a formula, but the mechanism at the cellular, molecular and protein/gene levels is still 
quite limited. Moreover, a significant proportion of CHM has been subject to little scientific 
investigation to support clinical indications and potential for therapeutic benefit (Liang et al., 
2014). 
 
1.1.6 Summary of the challenges presented by CHM 
This review has summarised the current status of CHM and outlined the major challenges for 
the development and modernization of Chinese herbal medicines. Due to CHM’s unique 
philosophy, diagnosis and prescription that are completely different from WM, thus it has 
brought great challenges for the quality standardisation, safety control, and efficacy 
evaluation confronting the development of CHM in a modernised scientific manner. 
The key problems regarding quality control of CHM relates to its complex chemical 
composition, growth environment, and manufacturing and handling. The current approaches 
to cope with the challenge include the quality control standardisation and regulation 
guidelines. The factors that determine the safety of CHM include inherent toxicity, formula 
construction, practitioner instruction, safety information and quality control. To address these 
problems, documentation of the herbal toxicity is continuously updated, the research for the 
safety of herbal formula are encouraged, advanced training and education for TCM 
practitioner is recommended, and greater scrutiny and improved survelliance is suggested. 
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Lastly, factors including chemical composition, multiple clinical endpoints, ratio of the herbal 
ingredients, and synergy actions pose challenges for the efficacy evaluation for CHM. It has 
been discussed that by using Western medicine one-compound-one target paradigm to 
evaluate the mechanism of CHM holistic approach is not sufficient. Due to low quantity and 
quality of the efficacy studies on CHM, the scientific evidence to support claimed 
effectiveness is lacking.   
To address the current challenges confronting CHM, this thesis aims to elucidate approaches 
to the study of the efficacy of CHM, specifically by examing for the synergistic actions 
among the ingredients in the formula. The aims are listed below.  
 
1.2 Aims  
My thesis addresses in particular the challenges for efficacy evaluation presented by the 
complexity of CHM formulations. In particular, the thesis aims to:  
 
1) determine the chemical profile of the individual and combination herbal extract before the 
commencement of the biological studies.  
 
2) investigate the possible synergistic interaction among herbal ingredients in a formula.   
 
3) investigate the synergistic interactions among chemical compounds in the tested herbal 
formula for specific biological target.  
 
 
4) identify the optimized ratio of the herbal ingredient in a formula to act on a specific 
biological target.   
 
5) development of compound formulations that have synergistic interactions 
 
To have a deeper understanding of these synergistic actions in CHM, a literature review on 
the synergistic interactions in CHM needs to be conducted. The experimental models for 
synergistic interactions of chemical constituents within a herb and herbal ingredients in a 
formula is reviewed, as well as the strengths and limitations for the current mathematics and 
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computer models applicable for the synergism study on CHM, which can provide guidance 
for the substudies. 
In addition, a literature review is conducted for the selection of the case study which can be 
used as an example for Chinese herbal formula. The biological targets and the literature on 
the possible interactions for this particular formula is reviewed for the preparation of the 
experimental studies.  
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2.1 Synergistic mechanism of CHM  
(This Section 2.1 is largely as in Zhou X, Seto SW, Chang D, Razmovski-Naumovski V, Chan K, Bensoussan A 
(2016). Synergistic effects of Chinese herbal medicine: A comprehensive review of methodology and current 
research. Frontiers in Pharmacology, 7, 201. doi: 10.3389/fphar.2016.00201) 
 
The ‘one drug, one target, one disease’ approach has remained the conventional 
pharmaceutical approach to the development of medicines and treatment strategies for 
decades. However, over the last decade, this mono-substance therapy model has gradually 
shifted towards the adoption of combination therapies, in which multiple active components 
are employed. This change has been partly driven by the limited effectiveness in chronic 
disease, treatment resistance and the side effects of synthetic mono-drugs. Recent evidence 
has demonstrated that combination therapy could provide greater therapeutic benefits for 
diseases such as AIDS, cancer, atherosclerosis and diabetes, all of which possess complex 
aetiology and pathophysiology so are difficult to treat using a single drug-target approach 
(Devita et al., 1975; Chesney et al., 2000; Jukema & van der Hoorn, 2004; Weber & Noels, 
2011). Combined drug therapies are formulated to augment the total effects in treating the 
target condition, reduce the side effects via dose-sparing of the active components or to 
address different metabolic interdependence, mediators or risk factors of diseases through a 
variation of independent biomolecular targets. Moreover, advances in analytical chemistry 
and molecular biology methods have broadened understandings of therapeutic targets of 
diseases and potential multi-target treatment approaches. Significant progress has been made 
in the study of the synergistic effects of drugs. For instance, a recent study has demonstrated 
the synergistic effect of the combination of metformin and aspirin in treating pancreatic 
cancer (Yue et al., 2014). Research into the synergistic interactions of multi-component 
herbal preparations and their interactions with pharmaceutical drugs has also attracted great 
interest in recent years. However, due to the limitation of the methodology currently 
available, it is still difficult to identify the best possible combinations from the large number 
of the existing drugs, evaluate their molecular interactions and establish their efficacy and 
safety (Orloff, 2005). 
 
Substantial progress has been made over the last decades to study the efficacy and mode of 
actions of some commonly used herbs and formulations in TCM (Lam et al., 2006; Seto et 
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al., 2009; Kong et al., 2009a). In contrast to Western-style combined drug therapies where 
chemical properties and pharmacological effects of individual compounds are well defined, 
Chinese herbal formulations are constructed according to TCM theories (Peiwu and Jun-
Chen-Zuo-Shi). Despite the long history of clinical use and a solid theoretical basis, the 
multi-component and multi-target nature of CHM poses a huge challenge to the study of the 
mechanisms of action, including the synergistic effects underpinning the complex herbal 
formulations (Wang et al., 2009). With the advance in mathematic modelling (e.g., CI and 
isobologram) and computer technology (e.g., systems biology analysis), there has been a 
growing number of systemic and mechanistic studies over the past two decades that have 
aimed to provide better scientific evidence and understanding of the synergistic effects of 
Chinese herbal formulation. However, evidence to support the synergistic effects of multiple 
herbs and their active components remain controversial. For example, some studies have 
suggested that the meaningful synergistic and therapeutic effects of herbal formulations 
were unlikely due to the low/extremely low levels of active compounds existing in the herbs 
(Williamson, 2001; Danz et al., 2002). This has led to scepticism, and the suggestion that 
herbal therapies are merely a placebo (Tausk, 1998). In contrast, numerous studies have 
demonstrated that herbal extracts as a whole and/or multiple herbs in complex formulations 
offer better efficacy than equivalent doses of individual active ingredients and/or herbs when 
used alone, highlighting the significance of synergistic action in herbal therapies (Leonard et 
al., 2002; Scholey & Kennedy, 2002; Zhang et al., 2014). This section aims to present a 
comprehensive review of the current status of research on the synergistic effects of CHM 
and how they are effectively measured. 
 
2.1.1 Definition of synergy 
Synergy is generally defined as the interaction of two or more agents to produce a combined 
effect greater than the sum of their individual effects (van Vuuren & Viljoen, 2011). In 
medicinal research however, the understanding of synergy is complicated. Spinella (2002) 
has classified the concept of synergy broadly into two main categories based on the mode of 
actions: pharmacodynamics and pharmacokinetic synergy (Spinella, 2002). The first type of 
synergy describes two or more agents that work on the same receptor or biological target, 
which result in enhanced therapeutic outcomes through their positive interactions. The 
second type of synergy results from interactions between two or more agents during their 
pharmacokinetic processes (absorption, distribution, metabolism and elimination), leading to 
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changes in the agents’ quantity in the body and hence their therapeutic effects (Spinella, 
2002). However, synergy is often described in a more holistic way that covers both 
pharmacodymamics and pharmacokinetic synergy. 
 
It is important not to confuse synergistic effect with additive effect. Synergy occurs when 
two or more drugs/compounds are combined to produce a total effect that is greater than the 
sum of the individual agents (Chou, 2010; Breitinger, 2012), while an additive effect is an 
add-up of individual effects, where each individual agent is not affecting the other (no 
interactions). The concept that the additive effect of two drugs is their ‘arithmetic sum’ is a 
misconception. The additive effect is not simply a sum of the effects of A plus B. For 
instance, if agents A and B exert an inhibitory effect as 60% and 70% at certain dosage 
levels, it is incorrect to state that their additive effect is 130% at this dosage. The additive 
effect needs to be determined using a more complex mathematical algorithm equation. 
 
Comparing combination activity to individual activity at the same dosage or effect level is a 
common error in synergy studies. Many studies were found to report synergistic effects 
when the ED50 value of a combination was significantly lower than that of each individual 
component with a P-value less than 0.05. This approach seems logical, but it actually cannot 
distinguish between an additive effect and a synergistic effect, as it is still the comparison 
between combination and individual effects, not combination between the sum of the 
individual effects. Similar errors are very common in animal and clinical trials where it is 
difficult to apply rigorous synergy determining methods due to practical reasons (e.g., cost, 
duration of the study, ethical issues). In these studies, researchers estimated synergism by 
simply comparing the effect of the combination with that of individual components, which 
unfortunately would lead to a wrong conclusion. Thus, more efficient and practical models 
need to be developed to determine synergistic effects of multi-component preparations in 
animal and human studies. 
 
2.1.2 Methods of quantifying synergy 
Currently, no uniform agreed methodology is available for synergy research to facilitate the 
different understandings of the mode of action of synergy. This has led to the question of 
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whether the drug interactions observed are genuine synergistic effects (Chou, 2010). 
However, several methodological approaches have been developed and are used for 
combination drug therapies. Loewe additivity and Bliss independent models are the two 
oldest and most referenced approaches to the study of the synergistic interaction (Tang et al., 
2015). Loewe additivity is usually applied in cases where the drugs have similar modes of 
action on the same target or pathway (pharmacokinetic) (Tang et al., 2015). In contrast, the 
Bliss independence model is expected to hold true for non-interacting drugs that elicit their 
responses independently (pharmacodynamics) (Tang et al., 2015). In recent years, many 
models based on these two theories have been developed and adapted for the study of 
synergistic effects of multi-component preparations. Some of the most popular models—
including the combination index (CI) and isobole method (both derived from Loewe 
additivity), systems biology analysis (used for multi-target synergy) and several specific 
assays for synergistic studies of antimicrobial agents—are discussed here. The strengths and 
limitations of these methods are summarised in Table 2.1. 
 
2.1.2.1 CI method  
It has been demonstrated that synergy follows physicochemical mass-action law, which 
briefly states that the ratio between the concentration of reactants and products is constant 
for a chemical reaction mixture that is in equilibrium. Further developed from mass-action 
law, a simplified mathematic equation for the combination index (CI) was developed for the 
quantitative determination of synergy (Chou, 2010). Synergism occurs when the CI value is 
< 1 (the more the CI value approaches 0, the stronger the synergistic effect); additive effect 
occurs when the CI value is equal to 1 and antagonism happens when the CI value is >1. 
 
The CI is a practical model used for the analysis of synergy of a multi-component 
combination in a fixed ratio. To calculate the CI, the dose-response curves (inhibitory effect, 
stimulatory effect, etc.) of individual components A and B and their combinations (AB) in a 
fixed ratio are determined using the same assay. The doses of each individual component 
that achieves a specified effect (e.g., 50%, ED50) are determined. Further, the doses of A and 
B required in the combination to produce the same level of effect can be calculated. The 
interaction of synergism/addition/antagonism is based on Equation 1 below for two agents 
and Equation 2 for multiple agents. Additionally, computational software, including 
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‘CalcuSyn’ and its third-generation ‘CompuSyn’, have been developed, which greatly 
facilitate the CI analysis (Chou & Hayball, 1996; Chou & Martin, 2005). By inputting the 
dose-effect data of agents A and B and their combination (AB), the software can generate a 
CI – Fa (effect level) curve, which demonstrates a complete dataset of CI values 
(representing antagonistic/additive/synergistic interactions) at all tested doses. Also, a CI-Fa 
(effect levels) can be generated (see Figure 2.1). This model can also be applied for the 
determination of interactions among multiple agents in a mixture. The calculation is based 
on equation 2, which demonstrates n-drug combination at x% inhibition. Examples using CI 
model for the determination of synergistic interaction in CHM are discussed further below. 
CI = 𝐷𝐷1
𝑑𝑑1
 + 𝐷𝐷2
𝑑𝑑2
 (Equation 1) 
n(CI)x = ∑ (𝐷𝐷)𝑗𝑗(𝑑𝑑)𝑗𝑗
𝑛𝑛
𝑗𝑗=1  (Equation 2) 
n(CI)x = combination index for n drugs at x% inhibition 
D1 and D2 = doses of individual constituent alone, required to produce a chosen effect level 
(usually ED50) 
d1 to d2 = the doses of individual constituent in the combination required to produce the 
same effect, respectively. 
 
Many studies also reported a synergistic effect when certain pharmacological effects can be 
observed with a drug combination, but not with one or more of its individual components. 
This effect is classified as potentiation or augmentation rather than synergism, based on 
Chou’s theory (2010). If an individual component does not generate an effect when used 
alone, the D1 value is equal to 0, thus the synergy cannot be determined in the CI equations. 
This potentiation or augmentation effect can be considered as a form of complementary 
interaction. 
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Figure 2.1 Utilisation of the CI model to determine synergy for the combination of agents A and B (agent AB) in certain fixed ratios. (1A), Dose-
effect curves for agent A, B and AB, respectively. (1B), CI value- Fa (Fa: fraction affected level) curve for AB on the same test generated from 
CalcuSyn based on the dose-response curves shown in 1A. It demonstrated that there are synergistic effects starting from 60% effect level (Fa = 
0.6, equals to 60% effect level) and this synergistic effect continued to increase (CI<1) at higher effect levels when the herbs were combined. 
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2.1.2.2 Isobole method 
The isobologram was first introduced by Fraser in 1870, based on Loewe additivity 
(Fraser, 1872). This method has been widely accepted as one of the most practical 
models for showing the synergistic/additive/antagonistic interactions, in terms of 
experimental design and effectiveness. Similar to the CI model, the isobole method 
requires the determination of a dose-response relationship of the combination and its 
individual components independently, to assess if synergism exists. This is expressed 
as a dose-response curve on an isobole graph (see Figure 2.2). The isobole is an ‘iso-
effect’ curve, in which a combination of components (A or B) at different dose levels 
are represented on the graph, the axes of which are the dose-axes of the individual 
constituent (A and B). The dashed line joining the points (i.e., ED50 of A and B) 
represent the same dosage required from the combination as the sum of the 
individual component to reach the same effect. The dots of the combination falling 
on this dashed line represents an additive effect; that is, no interactions between 
components A and B. If synergy occurs, the curve becomes ‘concave’. The opposite 
applies for antagonism, represented by a ‘convex’ isobole (Figure 2.2). It is also 
possible to have synergy at one dose combination and antagonism at another, with 
the same substances. This would give a complicated isobole with a wave-like or even 
elliptical appearance. 
 
In theory, isobologram and CI-Fa plot are both based on the same CI equation so 
should yield an identical conclusion. However, isobologram explains synergy from a 
dose-oriented perspective (reaching the same therapeutic activity but with a lower 
dose level required), while CI-Fa plot from an effect-oriented perspective (resulting 
in a higher therapeutic activity at the same dosage level). Additionally, CI-Fa plot 
can be used to determine multi-component interactions, whereas isobologram is only 
feasible for a two-drug combination as it is not possible to construct 
multidimensional isobologram curves. 
 
Both CI and isobologram models are designed for evaluating the 
synergistic/antagonistic interaction between two or more single-entity agents acting 
on the same target/receptor. Even though these models have been recently used for 
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analysing possible synergistic interactions in simple herbal formula (herb-pair), they 
are generally less adequate for evaluation of the complex interactions among 
multiple bioactive components of CHM formulations (Gu & Chen, 2013). 
 
 
Figure 2.2 The isobole method for synergy study. Dose A and Dose B are the 
individual concentrations of components A and B; Dose AB are the concentrations of 
A and B in the combination. The dashed line shows zero interaction between A and 
B, which represents a simple additive effect. The effect of the combination equals the 
sum of the effects from individual components. A. Effect of synergy: the dot in 
underneath the dashed line. B. Effect of antagonism: the dot is above the dashed line; 
Addition: the dot is on the dashed line. 
 
2.1.2.3 Systematic analysis/System to system (S2S) method 
The CI and isobologram methods both require combination-by-combination 
evaluations of individual components in a mixture specifically acting on the same 
target/receptor. However, for a complex combinational therapy—especially TCM 
multi-herb formulations—it is technically impossible to use these two models to 
evaluate all combinations of bioactive components on each of the targets individually. 
 
A S2S approach—integrating literature, experimental data, and computational 
sciences—has recently been developed to address the multi-target synergistic actions. 
To conduct this analysis, the three-dimensional structures of individual compounds 
in the combination are obtained from relevant databases, handbooks or literature and 
the known crystal structures of all the key genes/proteins associated with targeted 
disease are retrieved from relevant data banks or databases. The network 
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constructions between agents and targeted protein/genes are then constructed via a 
molecular docking approach. Molecular docking is usually applied for computer-
assisted drug design, which predicts the predominant binding mode(s) of a ligand 
with a protein of known structure. Here, it is used to analyse binding modes between 
the potential active compounds and their corresponding target proteins based on their 
structure binding modes, in order to generate a drug-target network. The predicted 
interaction between bioactive and targeted receptors from the generated network can 
either be confirmed by literature or validated through experimental studies (Wang et 
al., 2012c; Leung et al., 2013). This model investigates the multi-target mechanisms 
of action of multi-constituent mixtures and identifies the key active components, 
which can bind to most of the corresponding targets. Additionally, this method can 
be used in drug development through selecting and combining the most active 
components that act on the maximum amount of the protein or gene targets. This 
minimal effective composition with definite constituents and controllable quality can 
optimise the composition of the mixture while maintaining their curative effects (Li 
et al., 2012e; Liang et al., 2012). 
 
The S2S approach has gained popularity as a promising and valuable tool to evaluate 
synergy of complex herbal formulations (Lee, 2015). However, due to poor 
understanding of the chemical and pharmacological properties of bioactive 
constituents of many TCM herbs, the application of this method in studying the 
synergistic effects of TCM herbs to gain insight of the holistic approach of CHM 
remains a challenge (Wang et al., 2012c). 
 
2.1.2.4 Methods used in microbiology studies 
In microbiology, several bioassays and mathematics models have been developed 
and applied to investigations of the synergistic antibacterial effects of individual 
bioactive components of Chinese herbs and antibiotic agents, including diffusion 
assay, chequerboard array and time-kill assay. 
2.1.2.4.1 Diffusion assay 
This is a simple, visual and qualitative microbiology assay that can be used to 
investigate the combinational effect of individual components used together. 
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Inhibition/kill studies in agar or broth, microscopy and molecular analysis are used to 
investigate the mode of action of antimicrobial agents. In this method, each 
individual test sample (A or B) and their combination (A+B) are placed in separate 
wells or discs on agar containing pathogenic organisms, and their inhibition zones 
are compared. If the inhibition zone of the combination is larger than that from A or 
B, positive interactions are noted. Should the inhibition zone of the combination be 
smaller than A or B independently, then negative interactions are noted. Since it only 
compares the inhibition zone of combination with individual component, it cannot 
differentiate synergism from additive effect. Moreover, this method is subjected to 
many variables that may affect the results, and is used as a qualitative guide only. 
 
2.1.2.4.2 Chequerboard array 
This method is used to evaluate synergistic interactions of antimicrobial agents 
against bacteria or fungi. In this method, the effects of interactions are assessed 
through the serial dilution of two agents A and B (two-fold dilution to four times of 
estimated minimum inhibitory concentration [MIC]) (Hsieh et al., 1993). A 
checkerboard is constructed in a two dimension array with the same number of series 
dilutions of agent A and agent B in x and y-axis. Thus, each tube/well in the middle 
of checkerboard contains a unique combination of agent A and B being tested. With 
the addition of cell viability dyes such as resazurin or 3-(4,5-Dimethylthiazol-2-Yl)-
2,5-Diphenyltetrazolium Bromide (MTT), the inhibitory activity of individual and 
the combination of components can be visually assessed and quantified by fractional 
inhibitory concentration (FIC). Additionally, the turbidity of the wells prior to and 
after incubation with the microbe can be assessed for their difference, which can then 
also be used as an indicator of MIC. This method is easy to conduct and interpret the 
interactions between two agents, and multi-concentrations can be tested 
simultaneously. However, factors such as compound/herb solubility in the wells, 
biofilm formation and interactions between the compounds/herbs with the indicator 
dyes (all of which can be problematic for the turbidometric and/or colorimetric 
readings) can result in the inaccurate assessment of viability of the test microbe. 
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2.1.2.4.3 Time-kill assay 
This method provides descriptive information on the relationship between 
bactericidal activity and the concentration of a test substance. The principle involves 
exposing the inhibitor to a selected pathogen and, at selected time intervals, aliquots 
are sampled and serially diluted. The dilutions are plated out, incubated at optimum 
conditions for the test organism and the colony for forming units (CFU) are counted 
and plotted logarithmically against time. Depending on the curve of the dose 
response, either an additive, synergistic or antagonistic effects is determined. Since 
this method can monitor the bactericidal effect over different time-points, it is quite 
labour intensive and requires a number of steps, during which variables may be 
introduced. It is difficult to interpret the results because relatively few antibiotic 
concentrations are examined. 
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Table 2.1 Comparison of current models of synergy methods. 
General methods Brief description  Strengths Limitations 
Combination index A scientific term to quantitatively depict 
synergism (CI < 1), additive effect (CI = 
1), and antagonism (CI > 1) 
1) A practical method experimentally 
2) The most demonstrative method for the proof of 
synergy effects 
3) No limitation for the number of ingredients in 
the tested combination  
1) Must be able to determine dose response of individual 
constituents and combination 
 
Isobole method A graphical procedure that can either 
represent additive, synergistic or 
antagonistic interactions, depending on the 
position of thc dose of combination to the 
‘iso-effect’ linear line  
1) The oldest and most well established method 
2) A practical method experimentally  
1) Must be able to determine dose response of individual 
constituents and combination 
2) Generally only applicable for two-drug combination  
Systems biology  A computational and mathematical model 
for predicting and understanding the 
network of components and protein/gene 
targets binding biological system 
1) Suitable for study of synergy of multi-
components, prodrugs, and novel targets 
2) Being able to investigate the mechanisms of 
action of a combination, and identify the key 
active components 
1) Large data sets including chemical, chemogenomics, 
pharmacological data and the compounds’ potential 
targets information are required 
 Brief description  Strengths  Limitations 
Diffusion assays  Positive/negative interactions in the 
mixture are observed via comparing the 
bacteria growing inhibition zone diffused 
in the agar with that of individual agent 
1) Impact on microorganism can be investigated in 
vitro 
2) Simple, visual qualitative representation of 
synergistic (or antagonistic) effect of individual 
components used together 
1) These assays are subject to many variables that may affect 
the results, and should at the most be used as a qualitative 
guide 
2) Cannot differentiate synergism from additive effect 
Chequerboard 
array  
The combination of two agents is 
constructed on a chequerboard in a two-
dimensional array, and the 
1) Clear visualisation on a single plate of 
contribution of the individual components 
2) Can test multiple concentrations 
1) Assessment of viability is not always accurate when 
replying on turbidometric readings 
2) Laborious for combination of three; not feasible for 
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positive/negative interactions are 
determined by comparing the 
combinational and individual inhibitory 
activity, which can be quantified by FIC 
simultaneously 
3) Easy to conduct and interpret 
combinations of four or more 
3) Rely on a linear dose-response curve for all components 
4) All plants in the combination tested required to be at 
equal ratios 
Time-kill assay Positive/negative interactions among 
multi-components in the mixture are 
determined via comparing individual and 
combinational bactericidal activity over a 
series of time intervals 
1)  One of the best methods for studying synergy 
of antimicrobial agents 
2) The bactericidal effect is monitored over time, 
which is not possible with the frequently used 
MIC assays 
1) The method is labour intensive and requires a number of 
steps, during which variables may be introduced 
2) Difficult to interpret results because relatively few 
antibiotic concentrations are examined 
3) Rely on the reading at one time point (usually at 24 hours) 
as the sole determinant of the interaction 
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2.1.3 Current status of synergy research in CHM 
In order to have a deeper understanding of the application of current aviable models 
to the synergistic studies of CHM, a literature review of current status of synergy 
research in CHM is shown below. We conducted a thorough literature search 
(keywords used: ‘synergism’ or ‘synergy’ or ‘synergistic’ and ‘Chinese herbal 
medicine’ or ‘Chinese medicinal herbs’) in PubMed and Google Scholar from the 
period 1990 to 2015. The numbers of studies using proper synergy models are shown 
in Figure 2.3. Key studies identified are summarised in Table 2.2. The detailed 
review and discussions on these key studies are catogrised as follows: synergy 
reflected in chemical fingerprint, synergistic interactions within single herb/multi-
herbal combination/herb and drug combination, and synergy of CHM and antibiotic 
in microbiology.  
 
 
Figure 2.3 Histogram showing the general increase in publications on the synergy of 
CHM from 1999–June 2015 from a bibliographic search in PubMed and Google 
Scholar databases, conducted in June 2015. 
 
0
2
4
6
8
10
12
14
16
19
99
20
00
20
01
20
02
20
04
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
N
o.
 o
f P
ub
lic
at
io
ns
Year
Total No. of papers regarding
synergy in CHM
No. of papers with proper
mathmatic/computional
method to determine
synergy for CHM
Chapter 2: Literature Review 
47 | P a g e  
 
2.1.3.1 Synergy reflected in chemical fingerprint 
Chemical fingerprint studies utilising high-performance liquid chromatography 
(HPLC), gas chromatography, liquid chromatography, mass spectrometry and 
chemometric resolution methods have been conducted to detect changes in the 
amount of pharmacologically active compounds in individual herbs, when given in 
combination (Han et al., 2007; Wang et al., 2011b; Kaliappan et al., 2014). During 
the decocting preparation, the chemical composition is often altered due to solvents, 
polarity, heating effects or changed pH environment (Li, 2014). These changes in 
chemical composition could account for the increased therapeutic effects and/or 
reduced side effects of the individual herbs. Li et al. (2006) demonstrated that the 
amount of main volatile chemical components present in Rhizoma Ligustici 
Chuanxiong (Chuanxiong) and Radix Paeoniae Rubra (Chishao), which are 
commonly used to promote blood circulation and remove stasis, were markedly 
altered when given together, due to the formation of non-volatile, water-soluble salts 
during the decoction process (Li et al., 2006). Additionally, the amount of aconitine, 
a toxic component of Aconitum carmichaeli Debx. (Fuzi) is significantly reduced due 
to its chemical reaction with tannine under high temperature. 
 
Chemical fingerprint studies have also shown that new compounds are formed when 
herbs are given in combination during the preparation. For instance, Wang et al. 
(2012) identified four new compounds in a Radix Polygalae (Yuanzhi) and Acorus 
Tatarinowii Rhizoma (Shichangpu) combination that were not detected in the 
individual extracts (Wang et al., 2012d). Although the biological effects of these new 
compounds were not evaluated in this study, it provides a possible explanation for 
the changes in pharmacological properties when herbs are used in combination. 
 
2.1.3.2 Synergistic interactions within a single herb analysed by CI or 
isobologram method 
Individual herbal extracts consist of a complex mixture of bioactive compounds, 
concomitant agents and other minor substances among which interactions can occur 
leading to synergistic effects. For example, Ginkgo biloba extract has been shown to 
possess an anti-platelet aggregation property (Dutta-Roy, 1999), which could 
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contribute to its therapeutic effects for vascular cognitive impairment through 
enhancing cerebral blood flow (Zhang & Xue, 2012). Synergistic interaction between 
ginkgolides A and B, two bioactive components of Ginkgo biloba, has been 
demonstrated in a platelet aggregation test using the isobole method (Williamson, 
2001). 
 
Lin et al. (2007) found that the anti-cancer property of four H2O subfraction 
phytocompounds (indole-3-caroxyaldehyde, wedelolactone, luteolin and apigenin) 
from Wedlia chinensis were evaluated using three different androgen receptor-
dependent cancer cell lines (human PCa22 Rv1, 103E and LNCaP cells) (Lin et al., 
2007). As revealed by the CI analysis using CalcuSyn software, a significantly 
stronger anti-cancer effect was observed when the four compounds were combined at 
the same ratio as in the original herb extract when compared to that of each 
individual compound, highlighting the synergistic property of these compounds 
present in Wedlia chinensis. The anti-cancer activity was significantly reduced when 
any one of these bioactive compounds was removed from the combination, 
indicating the significance of the four bioactive compounds acting as a whole. 
 
Kan et al. (2008) demonstrated the synergistic anti-cancer activities of the three 
major phthalides mixture (butylidenephthalide [BLP], senkyunolide A [SKA] and z-
ligustilide [LGT]) from Angelica sinensis with the same ratio as they were in the 
extract on colon cancer HT-29 cell line. Although the three phthalides mixture 
demonstrated synergistic cytoxic effects, it was shown that the anti-proliferative 
effects of the whole Angelica sinensis extract was still significantly higher than that 
of the corresponding phthalide mixture. Therefore, it suggested positive interactions 
of active components and other co-existing components within the herb (Kan et al., 
2008). 
 
2.1.3.3 Synergistic interactions within multi-herbal combinations 
2.1.3.3.1 Synergistic interactions in herb-pair analysed by CI or isobologram 
method 
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Multiple herbs are commonly used in Chinese herbal formulations, and pose further 
methodological challenges in synergy research. Salvia miltiorrhiza (DS) and 
Pueraria lobate (Gegen), are commonly used in combination for the treatment of 
coronary heart disease (Sieveking et al., 2005; Koon et al., 2011; Ng et al., 2011). A 
study conducted by Cheng et al. (2012) demonstrated that the anti-atherogenic 
effects of DS-Gegen combination in a 7:3 (w/w) ratio produced synergistic, additive 
and antagonistic effects in anti-inflammation, anti-foam cell formation and anti-
vSMC proliferation, respectively. This was the first study demonstrating the 
feasibility of applying CI analysis in the synergy study of herbal combinations 
(Cheung et al., 2012). 
 
Several other studies have been conducted to investigate synergistic interactions of 
two-by-two combinations in complex formulations. For example, synergistic effects 
of five commonly used medicinal herbs extracts — thyme (Thymus vulgaris), 
rosemary (Rosmarinus officinalis), sage (Salvia officinalis), spearmint (Mentha 
spicata) and peppermint (Mentha piperita) — were tested in an in vitro study (Yi & 
Wetzstein, 2011). Individual extracts were paired at a 1:1 ratio and their anti-cancer 
activities were compared in SW-479 colon cancer cell line using CI model by 
CalcuSyn software. The sage and peppermint combination (1:1) produced the 
strongest synergistic inhibitory effects on cancer cell growth at doses ranging from 
31.25 to 125 μg/mL when compared to that of individual single extracts and other 
combinations (CI value of 0.67 ± 0.09). Similarly, Adams et al. (2006) investigated 
the interactions among five popular herbs (Scutellaria baicalensis, Rabdosia 
rubescens, Panax-pseudo ginseng, Dendranthema morifolium, Glycyrrhiza uralensis 
and Serenoarepens) in 22Rv1 cell line using the isobolographic analysis, and 
revealed that the effects of the four extract combination were significantly greater 
than that of individual extracts alone and the two-by-two combinations (Adams et al., 
2006). 
 
2.1.3.3.2 Identifying active chemical consistituents contributing to synergistic 
interactions 
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In 2014, a new methodology combining CI model and fractionation technique was 
developed for identifying and isolating synergistic interacted active constituents. For 
example, Xu et al. (2014) reported the synergistic anti-oxidant activities of 
Astragalus membranaceus (AME) and Paeonia lactiflora (PL) combination. In this 
study, AME and PL extract residues were combined, and different fractions were 
obtained by further sequential extraction with different solvents. Their anti-oxidant 
effects were then tested using free radical scavenging assay (DPPH), and total 
phenolic and flavonoid contents assays. The fraction combination that showed 
synergistic effects by CI model was selected for further fractionation. Eventually, the 
optimised fraction producing the strongest synergistic effect was subjected to HPLC, 
mass spectrometry and liquid chromatography (HPLC-MS/MS) analyses, and seven 
components were successfully identified, which contributed to the anti-oxidant 
activity of AME-PL combination, including oxypaeoniflora, catechin, calycosin-7-O-
b-D-glucopyranoside, fomononetin-7-O-b-Dglucopyranoside, 9,10-dimethoxy-
pterocarpan-3-O-b-D-glucopyranoside, quercetin and 29-dihydroxy-39,49-dimethyl-
isoflavan-7-O-b-D-glucopyranoside (Xu et al., 2014). A similar study was conducted 
by Wang et al. (2014) in a Radix Astragali and Cimicifuga foetida combination 
(Wang et al., 2014a). The most potent fraction combinations were identified by 
comparing different fractions from each herb and their combinations using DPPH 
and ferric ion reducing anti-oxidant power (FRAP) assays. Several bioactive 
components were identified by HPLC-ESIMS/MS, including calycosin and 
formonoetin from Radix Astragali, and ferulic acid and isoferulic acid from 
Cimicifuga foetida (Wang et al., 2014a). 
 
These studies have clearly demonstrated a relatively efficient method of isolating and 
identifying active compounds from herbal combinations, providing an example for 
mechanistic study of synergistic effects of CHMs. However, the fractionation 
method employed in these two studies discarded the ‘inactive’ fractions, and 
therefore their possible interactions with the active compounds were not 
tested/considered. Indeed, it has been demonstrated that the anti-oxidant effects of 
the active components isolated from Salvia plebeian R. Br. were much weaker than 
that of the crude extracts, indicating that the components ‘inactive’ may play a role in 
the pharmacological effects of the herbal combinations (Gu & Weng, 2001). 
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2.1.3.3.3 Systematically determine synergistic interactions within multi-herb 
formulations 
S2S or ‘systematic analysis’ methods that integrate chemomic and systems biology 
have recently been employed in the study of synergistic effects of complex herbal 
formulations. This method analyses the multi-target actions of mixed chemical 
constituents with a system of targeted protein/receptors, so it is more suitable for the 
complex nature of TCM formula. For example, LWDH is a classic TCM formula 
used to manage various complex diseases such as hypertension and oesophagus 
carcinoma. It consists of six herbal ingredients, including Shu Di Huang 
(Rehmanniae Radix Praeparata), Shan Zhu Yu (Corni Fructus), Mu Dan Pi (Moutan 
Cortex), Shan Yao (Dioscoreae Rhizoma), Fu Ling (Poria) and Ze Xie (Alismatis 
Rhizoma), each of them was found to have multiple pharmacological effects. Liang 
et al. (2014) attempted to evaluate the mechanisms underlying the interactions of 
hundreds of chemical constituents in the formula on their potential biological targets 
by utilising a novel network pharmacology approach. It was found that the key 
synergistic interactions occur on multiple systems, including maintaining 
homeostasis in the endocrine system, immune system and metabolism. However, the 
significance of this study is limited as not all potentially bioactive ingredients from 
the formula were identified, nor their pharmacological properties thoroughly defined. 
Nevertheless, the results have demonstrated the holistic mode of action of an herb 
formula targeting network-based multi-systems, and highlighted the difficulties 
associated with synergistic research in CHM (Liang et al., 2014). 
 
Li et al. (2012) attempted to illustrate the synergistic mechanisms underpinning the 
Jun-Chen-Zuo-Shi theory of CHM in a study of compound Danshen formula (CDF) 
using a systems-pharmacological network model. CDF is commonly used for 
cardiovascular diseases (CVDs) consisting of DS (Radix Salviae Miltiorrhizae) as 
the key (Jun) herb, SQ (Panax Notoginseng) as the adjuvant (Chen) herb and 
Borneol (Borneolum) as the courier (Shi) herb. In this study, major bioactive 
compounds with high oral bioavailability from each herb were screened and selected 
through a robust in silico model, OBioavail 1.1. Based on the available 
pharmacological data of these candidate compounds, their potential targets were 
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searched through PharmMapper Server, and those targets that were related to the 
pathological processes of CVD were selected. Thus, the compound-target network 
was constructed, and the interactions/relationship of the compounds from each herb 
working on the same or different targets for CVD was investigated. 
 
The results demonstrated that candidate compounds from DS tackled 39 out of the 
total 41 validated CVD targets (except eNOS and ACE2), whereas those from SQ 
interacted with 36 potential targets, 34 of which overlapped with DS’s targets. 
Further, the network analysis showed that the compounds from DS targeted the 
whole CVD system, whereas that of SQ placed emphasis on the modulation of 
vascular smooth muscle cells, providing evidence to support the former as the 
Jun/key herb and the latter as the Chen/adjuvant herb in the formula (Li et al., 2012e). 
In a similar study, the underlying cardio- and cerebrovascular protective mechanism 
of a complex formula consisting of Radix Curcumae (Yujin), Fructus Gardeniae 
(Zhizi), Moschus (Shexiang) and Borneolum (Bingpian) was assessed by network 
reconstruction method through matching bioactive components with good oral 
bioavailability, with their potential targets on cardio- and cerebrovascular systems. 
The data showed that 58 bioactive compounds identified from the herbs in the 
formula were shown to interact with 32 potential targets relating to cardiovascular 
and cerebrovascular diseases (CCVD). It was suggested that Radix Curcumae was 
the key herb in this formula, as it contained the most candidate compounds that 
possessed high degree distribution on CCVD-related targets (eight targets), followed 
by Fructus Gardeniae as the minister herb (five targets), Moschus (two targets) as 
the adjuvant herb and Borneolum (zero targets) as the messenger herb (Tao et al., 
2013). 
 
Systems biology can also be used to screen the active components from the complex 
formula that act on the major therapeutic targets. Shuanglong formula (SLF), 
consisting of Panax ginseng and Salvia miltiorrhiza, is a popular Chinese herbal 
formulation for the treatment of myocardial infarction (MI) (Liang et al., 2012). 
Liang et al. (2012) employed an S2S method using cell lines, isolated tissue and 
animal models to optimise the phytochemical composition of SLF, and revealed that 
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the cardiac protective effect of SLF was primarily through synergistic interactions 
between ginsenosides and salvia acids from Panax ginseng and Salvia miltiorrhiza, 
respectively (Liang et al., 2012). Based on these results, a new formulation—
NFSL6—consisting of total ginsenosides and total SAs at a ratio of 7:3 was 
successfully developed, using pharmacological screening. Similarly, Wang et al. 
(2013) applied systematic analysis in the study of Yinchenhao decoction (consisting 
Artemisia annuaL., Gardenia jasminoids Ellis and Rheum Palmatum L.), a classical 
formula used to treat hepatic injury syndrome. Three major active components—
including 6,7-dimethylesculetin (D), geniposide (G) and rhein (R)—were found to be 
the main contributors to the efficacy of the formula. The DGR combination 
synergistically reduced histologic changes and hepatocyte apoptosis, reversed the 
relevant metabolic biomarkers and modified 15 target protein expressions in the rat 
hepatic injury model (Wang et al., 2013). 
 
These studies have demonstrated that the S2S, or ‘systems-pharmacological network’, 
models are applicable to the study of synergistic effects in complex herbal 
formulations. The results appear to support the rationality of the Jun-Chen-Zuo-Shi 
theory of complex Chinese herbal formulations, and promote the understanding of 
the multi-component interactions in these formulations. Additionally, by exploring 
the active fractions/components from a formula, it facilitates the development of new 
formulations and/or new drug candidates. However, these methods rely heavily on 
the availability of chemical and pharmacological data concerning the active 
components in some well-studied herbs/herbal formulae, and therefore are not 
applicable to many herbs or herbal formulae in which their active components are 
unknown and molecular targets unclear. 
 
2.1.3.4 Synergistic interactions between CHM and pharmaceutical drugs 
Due to the rapid expansion of the concurrent use of pharmaceutical medicines and 
CHM, research into their interactions and the underlying mechanisms is urgently 
needed. Some of these interactions may be therapeutically beneficial via synergism, 
enhancing therapeutic effects, or via antagonism, reducing side effects. Most of the 
synergistic studies available relate to anti-cancer therapies. For example, the anti-
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cancer properties of Polyphyllin I (PPI, an active component from Rhizoma of Paris 
polyphyllin) and Evodiamine (EVO, an active component from Evodia rutaecarpa) 
are well documented (Lee et al., 2005; Adams et al., 2007; Chan et al., 2009; Kong et 
al., 2010), but their efficacy is generally weaker than that of chemotherapeutic agents 
such as platinum (Pt), 5-Fluorouracil (5-Fu) and irinotecan (CPT-11). However, 
when PPI or EVO were combined with Pt or 5-Fu, a significantly stronger inhibition 
rate was produced than Pt or 5-Fu alone on patients’ freshly-removed gastric cancer 
tissues. The CI values were found to be < 1 in all combinations at fraction affected 
(Fa) = 80%, indicating a synergistic anti-cancer effect (Yue et al., 2013). 
 
Lin et al. (2014) demonstrated that the combination of aqueous extract of the leaves 
and fruit of Camptotheca acuminate (AE-CA) and cisplatin (platinum analogues) 
exerted synergistic cytotoxicity effects in HEC-1A and HEC-1B human endometrial 
carcinoma cells. This study also demonstrated that the cytotoxic effect of the mixed 
AE-CA extracts was significantly stronger than that of camptothecin (CPT), a 
chemotherapeutic drug isolated from AE-CA. However, the AE-CA extracts 
produced similar effects on cell-cycle regulation and the accumulation of cyclin-A2 
and B1 as CPT. Therefore, the existence of synergistic effects among the individual 
components in AE-CA extracts remains unclear (Lin et al., 2014). Similarly, the 
synergistic effects of bioactive dichloromethane (DCM) subfraction of Strobilanthes 
crispus (SCS) leaves and tamoxifen (an antioestrogen drug) were investigated using 
oestrogen receptor-responsive and nonresponsive breast cancer cells (MCF-7 and 
MDA-MB-231 cell lines). SCS extracts alone induced around 50% cell death after 24 
hours’ treatment. When combined with low doses of tamoxifen (which did not exert 
any significant cytotoxic effect on its own), the combined extracts produced 80% cell 
death after 24 hours’ treatment, which was proven to be a synergistic effect based on 
the method of CI using Calcusyn software (Yaacob et al., 2014). 
 
Seo et al. (2014) demonstrated that a mixture of curcumin, a main bioactive 
component of Curcuma longa, and NVP-BEZ 235 (a potent dual inhibitor of PI3K 
and mTOR) can synergistically induce apoptosis in human renal carcinoma caki cells. 
The mixture of 2 μM NVP-BEZ235 and 30μM curcumin significantly provoked cell 
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shrinkage, membrane blebbing and chromatin damage in the nuclei and DNA 
fragmentation. None of these effects were as significant when curcumin and NVP-
BEZ235 were used alone. Analyses of isobologram demonstrated synergistic 
activities between curcumin and NVP-BEZ 235. 
 
2.1.3.5 Synergistic interactions between CHM and antibiotics in microbiology 
studies 
The synergistic effects between antibiotics and herbal medicine have also been 
extensively studied. Agar diffusion assay is often used to screen the antibacterial 
activity of individual agents, and used as a qualitative guide for positive/negative 
interaction for agents’ mixture. For example, four active constituents (pseudolaric 
acid B, gentiopicrin, rhein and alion) extracted from CHMs (herbal sources were not 
stated in the paper) were tested on agar diffusion assay, and only pseudolaric acid B 
showed significant fungicidal activity with growth inhibition zones ranging from 8 to 
25 mm against C. albicans, C. glabrata, C. krusei, C. tropicalis, C. dubliniensis, and 
C. parapsilosis. Further, a positive interaction was observed between pseudolaric acid 
B and fluconazole in the agar diffusion assay on the same disc, where there was no 
microcolony growth in the cross-sectional area of pseudolaric acid B and fluconazole 
observed (Jiang et al., 2010). Additionally, checkerboard array and time-kill assay 
are commonly used methods to quantitatively determine the 
synergism/addition/antagonism interactions. Jang et al. (2014) explored the 
synergistic antibacterial activities of baicalein, a flavonoid originally isolated from 
the root of Scutellaria baicalensis Georgi, with ampicillin and/or gentamicin against 
a range of oral bacteria strains. Their results showed that both baicalein-ampicillin 
and baicalein-gentamicin combinations demonstrated synergistic bactericidal effects 
evidenced by FICI ≤ 0.5, determined by checkerboard array (Jang et al., 2014). 
Additionally, time-kill array results confirmed the positive interaction between 
baicalen-ampicillin and baicalen–gentamicin respectively, which showed 
substantially stronger bactericidal effect in the combination compared with 
individual effect from 0–24 hours (Jang et al., 2014). Similarly, Hwang et al. (2013) 
also utilised checkerboard array to analyse the synergistic effect between 
amentoflavone (biflavonoid class of flavonoids, isolated from Selaginella 
tamariscina) and antibiotics such as ampicillin, cefotaxime and chloramphenicol. 
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Their results showed that amentoflavone had a considerable antibacterial effect and 
exerted synergistic interactions with antibiotics against all bacterial strains tested 
(FICI ≤ 0.5), except for Streptococcus mutans. This synergistic effect was suggested 
to be largely mediated by the formation of hydroxyl radical by nicotinamide adenine 
dinucleotide phosphate (NADH) depletion (Hwang et al., 2013).  
 
2.1.4 Summary of the literature review on synergistic mechanism of 
CHM  
The definition of synergy has been articulated here with regards to two aspects: 
pharmacodynamics (enhanced therapeutic actions on the same target) and 
pharmacokinetics (no direct interaction but with multi-target behaviour). The 
common misconceptions of synergy were also elucidated. It is critical to distinguish 
between synergistic effects and simple additive effects of individual herbs or active 
ingredients in a complex herbal formulation. Several rigorous analytical methods 
such as isobolographic analysis, CI and systems biology have been developed for the 
quantitative evaluations of synergistic effects. These methods have greatly facilitated 
the development and standardisation of combination therapies (e.g., chemotherapy 
treatment) in conventional WM. However unlike WM, in which the chemical and 
pharmacological properties of individual drugs are clearly defined, herbal medicine 
often contains numerous active ingredients, many of which may contribute to their 
synergistic effects. This poses a considerable challenge for the study of synergistic 
effects of herbal medicine and a different research approach is needed to accurately 
evaluate and quantify these effects. 
 
The current available methods for the study of synergistic effects of herbal medicine 
were summarised. These methods have been successfully used to determine the 
nature (synergistic, additive or antagonistic) of the interactions within single herbs, 
multiple herbal formulations or between pharmaceutical drugs and herbal medicine. 
Each of these methods has strengths and weaknesses, so careful consideration should 
be given when designing a synergistic study of herbal medicine. For example, the CI 
and isobologram models are relatively fast and simple and are ideal for studying the 
interactions of a small number of active components or herbal extracts in which their 
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chemical and pharmacological properties are well defined. However, the CI or 
isobologram methods are still designed for mono-target therapies, and are limited in 
demonstrating the associated molecular mechanisms and how the formula may 
systematically target the disease. S2S mode/systems biology methods approach the 
issues from a systematic perspective, consistent with the holistic approach of Chinese 
medicine. This network system may be more suited to the study of synergistic 
mechanisms underlying complex herbal formulations. However, these methods rely 
on large amounts of existing data, which are absent at the moment for most of the 
herbs and herbal formulations. More research into the chemical and 
molecular/pharmacological bases of herbal medicine and their bioactive components 
is needed before these analyses can be applied broadly. 
 
Generally, synergy research on CHM is still in its infancy. However, reviewing the 
currently available methods and their application on CHM study has provided 
guidance and allowed the design and establishment of synergistic research on the 
therapeutic mechanism of a simple Chinese formulation. To systematically study the 
synergistic mechanism for CHM, a simple and popular CHM herb-pair used for the 
management of complex multi-faceted disease that requires multi-target actions is 
selected as a case study for this project. A literature review on this herb-pair for 
vascular diseases is presented in section 2.2.  
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Table 2.2 Summary of in vivo and in vitro studies on Chinese herbal extracts or active ingredients that have been reported to 
produce synergistic effects on various biology activities. 
Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
Combination index In vitro Escin and cisplatin Anti-cancer Escin (10 and 15𝜇𝜇M) combined with cisplatin (3 𝜇𝜇M) 
resulted in a significant synergistic (CI = 0.256 and 0.186) 
cytotoxic effect in Panc-1 cells.  
Rimmon et al., 
2013 
In vitro AME and Paeonia lactiflora Anti-cancer Seven substances were identified from active fraction 
combination, which represents the synergistic effect for 
two-herb combination on anti-oxidant activity.  
Xu et al., 2014 
In vitro AE-CA and its component camptothecin plus 
cisplatin 
Anti-cancer  Both AE-CA extract (0.01 to 5 mg/mL) and its isolated 
compound camptothecin (0.05 to 1 𝜇𝜇M) demonstrated a 
synergistic effect (CI<1) in the HEC-1A and HEC-1B 
cells when combined with cisplatin (1–50 𝜇𝜇M).  
Lin et al., 2014 
In vivo  Polyphyllin I (a steroidal saponin extracted from 
Rhizoma of Paris polyphyllin) and evodiamine (a 
kind of alkaloid from Evodia rutaecarpa) 
Anti-cancer Combination of Polyphyllin I (200 μg/mL) and platinum 
(20 μg/mL), evodiamine (200 μg/mL) and platinum (20 
μg/mL), evodiamine (20 μg/mL) and 5-FU (300 μg/ml) 
had higher inhibition rates than any single drug (CI <1).  
Yue et al., 2013 
In vitro AME and Cimicifuga foetida Anti-cancer  The combination of isoferulic acid and calycosin (isolated 
from each herb) at a dose ratio of 1:1 resulted in 
significant synergy (CI50=0.77) in scavenging DPPH 
radicals and FRAP assay. This combination also exhibited 
synergistic effects at a dose of 1:1 (CI = 0.442) and 2:1 
(CI = 0.636) in HepG2 cell-based assay. 
Wang et al., 
2014a 
In vitro Four anti-proliferative phytocompounds in Wedelia Anti-cancer  Four bioactive compounds were identified in W. chinensis Lin et al., 2007 
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Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
chinensis to inhibit androgen receptor activity in prostate cancer 
cells, and the four active compounds acting together 
exerted strong synergism (CI = 0.39–0.78). 
In vitro Mentha piperita L. and Salvia officinalis L. Anti-cancer At 31.25, 62.5, and 125 µg/mL dosage levels, cancer cells 
treated with Mentha piperita L. plus Salvia officinalis L. 
combinations (1:1) showed significantly lower viability 
than calculated values based on individual extracts (CI = 
0.67 ± 0.09 (<1)). 
Yi & 
Wetzstein, 
2011 
In vitro Xanthorrhizol (isolated from curcuma 
xanthorrhizza) and curcumin (not stated for the 
source) 
Anti-cancer Synergistic activity (CI<1) was commenced from the 
combination xanthorrhizol-curcumin 3:7 to 1:9, to induce 
MDA-MB-231 cells’ death. 
Cheah et al., 
2009 
In vitro Scutellaria baicalensis, Rabdosia rubescens, 
Panax-pseudo ginseng, Dendranthema morifolium, 
Glycyrrhiza uralensis and Serenoarepens 
Anti-cancer  S. baicalensis and D. morifolium when combined 
(equipotent quantities and at 1⁄2 and 1⁄4 fractions of their 
IC50 value) were additive with a trend towards synergy, 
whereas D. morifolium and R. rubescens together were 
additive. The remaining two-extract combinations showed 
antagonism. The four extracts together were significantly 
more effective than the two-by-two combinations and 
individual extracts alone. 
Adams et al., 
2006 
In 
vivo/in 
vitro 
Realgar-Indigo naturalis formula: tetraarsenic 
tetrasulfide (from realgar), indirubin (from Indigo 
naturalis) and tanshinone IIA (from Salvia 
miltiorrhiza) 
Anti-cancer Tetraarsenic tetrasulfide, indirubin and tanshinone IIA at 
concentrations ranging from 0.25 to 1 μM had CI values < 
1, indicating synergic effects on human 
acute promyelocytic leukemia cell differentiation.  
Wang et al., 
2008b 
In vitro Chong Lou Fu Fang (CLFF): Rhizoma Paridis, Anti-cancer The synergistic analysis indicated that CLFF (0.05–0.35 Liu et al., 2011 
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Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
Fructus Forsythiae and Radix Codonopsis plus 5-
FU (chemotherapeutic agents) 
mg/mL) with 5-FU (0.75–75.25 μM) had a synergistic 
cytotoxicity effect in a relative broad dose inhibition 
range (20–95% fraction affected in SGC-7901 cell lines 
and 5–65% fraction affected in BGC-823 cell lines), 
while the synergistic interaction between CLFF and 
oxaliplatin or docetaxel only existed in a low dose 
inhibition range (≤50% fraction affected in both cell 
lines).  
Interaction index  In vitro Anti-asthma herbal medicine 
intervention (ASHMI) formula and its components: 
aqueous extracts of Lingzhi (Ganoderma lucidum), 
Kushen (Sophora flavescens) and Gancao 
(Glycyrrhiza uralensis) 
Anti-asthma By comparing the interaction index values, constituents in 
ASHMI (individual extracts in the percentages of 35, 45 
and 20 of Lingzhi, Kushen and Gancao) synergistically 
inhibited eotaxin-1 production as well as Th2 cytokine 
production.  
Jayaprakasam 
et al., 2013 
Median-effect 
analysis/combination 
index 
In vitro Three main phthalides from Angelica sinensis: n-
BLP, senkyunolide A (SKA) and z-ligustilide 
(LGT) 
Anti-cancer Three main Angelica sinensis phthalides (the composition 
ratios identical to those in the extracts of Angelica 
sinensis and Ligusticum chuanxiong) in Angelica sinensis 
extract yielded a synergistic effect (CI < 1) whereas 
Ligusticum chuanxiong extract exerted an antagonistic 
effect (CI > 1) on the inhibition of cell proliferation in 
colon cancer cells at the tested doses. 
Kan et al., 2008 
CI and isobologram In vitro SCS and tamoxifen Anti-cancer The combined SCS (8.5 μg/ml or 10.0 μg/ml) and 
tamoxifen (2.5 to 15 μM) treatment displayed strong 
synergistic inhibition in MCF-7 (CI = 0.32–0.40) and 
MDA-MB-231 (CI = 0.29–0.52) cell growth at low doses 
Yaacob et al., 
2014 
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Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
of the antiestrogen. 
 In vitro Rhizoma Corydalis and Rhizoma Curcumae Anti-cancer A combination of two herbal extracts exhibits the 
strongest anti-cancer cell proliferation effect at the ratio of 
3:2 (ezhu to yanhusuo).  
Gao et al., 2009 
Isobologram In vitro Curcumin (extracted from the rhizomes of 
Curcuma species) and NVP-BEZ235 
Anti-cancer Combined treatment of NVP-BEZ235 (0.5–4 mM) and 
curcumin (30 μM) demonstrated synergistic effects on 
apoptosis in human renal carcinoma Caki cells.  
Seo et al., 2014 
 In vitro Berberine (from Coptis chinensis Franch.) and 
evodiamine (from Evodiae Fructus) 
Anti-cancer Berberine (0–0.1 μM) and evodiamine (0–0.18 μM) 
mixture showed the highest inhibition effect (50%) 
compared with berberine and evodiamine used 
individually (20.24% and 16.33%, respectively) to induce 
apoptosis on human hepatocellular carcinoma SMMC-
7721 cells over 48 hours.  
Wang et al., 
2008c 
S2S mode/system 
biology 
In 
vitro/in 
vivo 
Panax ginseng and Salvia miltiorrhiza Myocardial 
ischaemia  
An optimised minimal phytochemical composition (new 
formula NSLF6) was achieved from Pananx ginseng-
Salvia miltiorrhiza combination, which has activity for 
treatment MI through synergistic therapeutic efficacies 
between total ginsenosides and total SAs via promoting 
cardiac cell regeneration and myocardial angiogenesis, 
antagonistic myocardial cell oxidative damage. 
Liang et al., 
2012 
 In 
vivo/in 
vitro 
Compound DS formula (Salvia Miltiorrhiza, Panax 
Notoginseng and Borneol) 
Cardiovascular 
diseases 
Radix Salviae Miltiorrhizae (DS) tackled 39 of the total 
41 validated CVD targets (except eNOS and ACE2), 
which acted as the emperor (key herb) in this formula, 
whereas Panax Notoginseng interacted with 36 potential 
Li et al., 2012e 
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Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
targets, and 34 overlapped with DS’s targets and serve as 
minister and courier drugs. 
 In 
vivo/in 
vitro 
Radix Astragali Mongolici, Radix Puerariae 
Lobatae, Radix Ophiopogonis Japonici, and Radix 
Salviae Miltiorrhiza 
Cardiovascular 
diseases 
The structural properties of molecules in four herbs have 
substantial differences, and each herb can interact with 
significant target proteins related to CVD. The bioactive 
ingredients from different herbs potentially act on the 
same molecular target (multiple drug, one target) and/or 
the functionally diverse targets but with potentially 
clinically relevant associations. This study has 
demonstrated the multiple drug, multiple target, one 
disease therapeutic pattern of TCM formula.  
Wang et al., 
2012c 
 In vivo Panax ginseng (PG) and Salvia miltiorrhiza (SM) Myocardial 
ischaemia 
SLF (SM: PG = 3:7) exerted synergistic therapeutic 
efficacies to exhibit better effect on MI than PG or SM. 
Liang et al., 
2011 
 In 
vivo/in 
vitro 
Radix curcumae formula: Radix Curcumae, Fructus 
Gardeniae, Moschus and Borneolum 
Cardiovascular 
diseases 
The pharmacological system generated 58 bioactive 
ingredients from the Chinese herbal Radix Curcumae 
formula, and predicted 32 potential targets related to the 
CCVD. The results indicate that Radix Curcumae share 
the most common targets with Fructus Gardeniae (15), 
and less common targets with Moschus and Borneolum (8 
and 1, respectively). Integrated network shows that Radix 
Curcumae represents the principal component for the 
prevention of CCVD, and three other medicines serve as 
adjuvants to assist the effects of the principal component, 
which together probably display synergistic actions. 
Tao et al., 2013 
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Method of synergy 
determination 
Study 
type  
Interacting components  Therapeutic 
activity 
Evidence of synergy  Reference 
 In vivo Yinchenhao decoction: Artemisia annua L. 
Gardenia jasminoids Ellis and Rheum PalmatumL. 
Hepatic injury 
syndrome (HI) 
Three major active compounds combination—DGR (6,7-
D, G and R)—from Yinchenhao decoction exert a more 
robust therapeutic effect than any one or two of the three 
individual compounds, by hitting multiple targets in a rat 
model of hepatic injury.  
Wang et al., 
2013 
 In vivo Yin-Chen-Hao-Tang: Artemisia annua L. (monarch 
herb), Gardenia jasminoides Ellis (minister herb), 
and Rheum Palmatum L. (assistant and servant 
herb): 6,7-D, G and R were extracted from those 
herb ingredients, respectively. 
H) DGR combination could increase the plasma level, slow 
elimination rate and exert a more robust therapeutic effect 
than any one or two of the three individual compounds by 
hitting multiple targets in a rat model of HI.  
Zhang et al., 
2011a 
Checkerboard dilution 
method 
In vitro Pseudolaric acid B (herbal source was not stated) 
and fluconazole 
Anti-fungal FICI showed a synergism of pseudolaric acid B and 
fluconazole (0128 to 0.125 µg/mL) against azole-resistant 
clinical isolates of C. albicans, whereas there was no such 
reaction with other Candida species. 
Yan et al., 2012 
 In vitro Glabridin (from the root of Glycyrrhiza glabra) and 
17β-E2 
Estrogenic 
effect 
When glabridin was treated together with 17β-E2 (1:1), 
synergistic estrogenic effect was observed, with a slight 
decrease in cell proliferation than treatment by 17β-E2 
alone. 
Su Wei Poh et 
al., 2015 
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2.2 Case study: A popular herb-pair used for vascular 
diseases 
In this section, the herbal samples and their therapeutic targets used for the case 
study of the synergistic interaction of CHM are introduced here. The therapeutic 
targets are selected revolving around vascular diseases, and a literature review for the 
herbal samples targeting on vascular diseases is conducted and stated here.   
 
2.2.2 Vascular diseases 
2.2.2.1 Background 
CVDs include peripheral artery disease, aneurysm, peripheral venous disease, blood 
clotting disorders and lymphedema. They involve complex pathological mechanisms, 
are a great challenge to modern medicine and a burden to society. Vascular disease 
describes the pathological changes in the blood vessels, including the arteries and 
veins, and any conditions that affect the circulatory system of the body. Disorders in 
the blood vessel system can cause a range of health problems that can be severe or 
fatal (National Organization for Rare Disorders [NORD], 2016). In Australia, a 
domestic health survey report for 2011–12 indicated that more than one million (5%) 
Australians had heart or vascular diseases, or had suffered a stroke (Australian 
Institute of Health and Welfare, 2014). Further, CVDs were the leading cause of 
disability and the most costly diseases group in 2008–2009, accounting for $7.74 
billion and 10.4% of total allocated health expenditure for Australasia (Australian 
Institute of Health and Welfare, 2014). 
 
Hypertension, smoking, obesity, diabetes, high cholesterol levels, stress and DL-
homocysteine (Hcy) are some of the risk factors that could accelerate the formation 
of vascular pathological changes (Saydah et al., 2004). Current medical treatment has 
not been very successful in coping with the complexity of vascular diseases. Most 
pharmaceutical medicines concentrate on blood clot prevention or intervention, and 
have remained largely ineffective for vascular outcomes. The symptoms of vascular 
diseases cannot be observed until the arteries and veins become severely damaged, 
the blood flow to vital organs and muscles is compromised and causes lack of 
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mobility, pain and tissue death. As limbs do not receive adequate blood flow to keep 
up with needs, pain, cramping, numbness and/or weakness result, and can 
significantly affect normal daily function. Approximately 50% of patients end up 
with a disability as there are no effective therapies for improving daily function and 
recovery after symptoms develop (Lo et al., 2003). Presently, risk factor modification 
and lifestyle change is recommended, and have been shown to reduce the need for 
subsequent surgery. 
 
2.2.2.2 Pathologies and biological targets 
Vascular diseases are chronic and accumulate over a long period. Vascular 
endothelial dysfunction is an important early indicator of vascular disease 
(Endemann & Schiffrin, 2004), and describes an abnormal pathological condition in 
which the vascular haemostasis balance is interrupted with diminished vasodilation 
factors, leading to a pro-inflammatory state and prothrombic properties (Endemann 
& Schiffrin, 2004; Alp & Channon, 2004; Szmitko et al., 2003). Mechanisms 
underlying the reduced vasodilatory responses in endothelial dysfunction involve 
reduced endothelial nitric oxide synthesis (eNOS) generation, excessive oxidative 
stress and decreased production of hyperpolarising factors (Matz et al., 1999; Heitzer 
et al., 2001; Cai & Harrison, 2000). The endothelial dysfunction can result in 
structure changes in blood vessels, with penetration of macrophages and 
lymphocytes, smooth muscle cell proliferation, inflammatory reactions and the 
formation of plaque. It leads to thickening of the vessel wall and can result in 
restricted blood supply to tissues and organs, thus leading to their dysfunction and 
various vascular diseases (i.e., ischaemic, atherosclerotic) (Cai & Harrison, 2000). 
Endothelial dysfunction is a reversible disorder, and current therapeutic strategies 
aimed at reducing cardiovascular risk factors are the lowering of cholesterol, 
antihypertensive therapy, improving endothelial health, regulating endothelial 
function mediators and the promotion of anti-oxidants (Mombouli & Vanhoutte, 
1999). It is evident that endothelial dysfunction is a multi-faceted disorder that 
involves a number of risk variables and biological targets. Some essential ones are 
outlined below. 
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2.2.2.2.1 Inflammatory mediators 
Substantial evidence supports the involvement of pro-inflammatory mediators (e.g., 
NO, TNF and MCP-1) in playing an essential role in every facet of the onset and 
pathological development of endothelial dysfunction (Wu et al., 2012). Three 
isoforms of nitric oxide synthase (NOS) produce NO, described as neuronal (nNOS), 
inducible (iNOS) and eNOS (Sun et al., 2005). As the major mediator of 
endothelium-dependent relaxation, NO is primarily generated by eNOS in a normal 
condition, which plays an important protective role by preserving endothelial and 
vascular integrity and physiology (Zhang et al., 2009a). However, when endothelial 
dysfunction develops, excessive expression of NO induced by iNOS were produced, 
in contrast with decreased release of eNOS. Studies have shown that iNOS is 
associated with nitrative stress and impaired endothelial function, the expression of 
which is typically induced in inflammatory vascular diseases (Chauhan et al., 2003). 
It has also been suggested that inhibited expression of iNOS leads to a better 
preservation of vascular function, which may be mediated by reduced oxidative 
stress and increased eNOS production (Escames et al., 2004; Xia & Zweier, 1997; 
Mungrue et al., 2002). 
 
As a major inflammatory mediator, TNF stimulates endothelial cells1, which results 
in impaired production of vascular vasodilatory mediators and induces the onset of 
vascular diseases (Zhang et al., 2009a; Zhang et al., 2006). Accumulating in vitro and 
in vivo evidence suggests that TNF has a direct impact on down-regulating eNOS 
expression, which impairs endothelium-dependent and NO-mediated vasodilation 
(Zhang et al., 1997; Gao et al., 2007; Paz et al., 2003). Further, TNF also plays an 
important role in pro-inflammation responses, which are linked to other vascular 
disease risk factors, including lipid metabolism, normal ageing, high-fat and high-
carbohydrate diets (Zhang et al., 2009a). 
 
                                                 
1 A type of cell located on the surface of the blood vessel, which plays an important role in the 
biological function of the blood vessel. 
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As a major pro-inflammatory chemokine, MCP-1 acts as a key player in the 
recruitment of monocytes from the blood into early atherosclerotic lesions in 
endothelium dysfunction (Szmitko et al., 2003; Weber et al., 1999). Increased 
expression of MCP-1 interacted with monocyte receptor ccr2 to induce the 
monocytes to transmigrate into the tunica intima, the innermost layer of the arterial 
wall, passing between the endothelial cells (Zhang, 2008). The up-regulation of 
adhesion molecules induced by the generation of MCP-1 further exacerbates the 
formation of atherosclerotic lesions and thrombin, which ultimately contributed to 
the triggering of vascular events (Charo & Taubman, 2004). Hence, the suppression 
of pro-inflammatory agents such as NO generated by iNOS, TNF and MCP-1 may be 
a potential therapy for the prevention and treatment of vascular diseases (Tang et al., 
2011). 
 
2.1.1.1.2 Homocystine and adenosine 
There is increasing evidence of the importance of DL-homocystine (Hcy) as a new 
and important risk factor for vascular diseases. An accumulation of Hcy, often lead 
to hyperhomocysteinaemia, is considered to be an independent predictor for 
atherosclerotic vascular disease, ischaemic heart diseases and stroke (Collaboration, 
2002). Experiments on human and animal arteries have shown that an elevated level 
of Hcy is an independent risk factor for atherosclerotic vascular disease affecting the 
coronary, cerebral and peripheral arteries. It can transform the low-density 
lipoprotein (LDL) cholesterol in the body into oxidised LDL and change the 
coagulation factor levels to encourage blood clot formation. It also causes the smooth 
muscle cells that support the arterial wall to multiply as part of the atherogenic 
process, and induces platelets to aggregate as part of the clotting process. 
Additionally, several reports have highlighted the importance of Hcy with the 
presence of adenosine (Ado) in the pathogenesis of vascular complications. 
Extracellular Ado levels increase in response to Hcy-induced cell injury and stress, 
such as in ischaemia (Li et al., 2012c; Riksen et al., 2003), whereas the accumulation 
of intracellular Ado was in the form of S-adenosylhomocysteine (AdoHcy), which 
resulted in impaired eNO expression on cultured human endothelial cells (Barroso et 
al., 2012; Jiang et al., 2005). Further, animal and cellular studies have shown the co-
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existence of Hcy and Ado sensitised TNF cytotoxicity in endothelial cells, as well as 
directly impaired angiogenesis (Kam et al., 2012, 2014; Zhang et al., 2011b). 
 
2.1.1.1.3 Oxidative stress 
The fact that excessive production of ROS induced oxidative stress plays an essential 
role in endothelial dysfunction has been extensively studied (Madamanchi et al., 
2005). It can directly quench the production of eNOS and up-regulate the 
degradation of existing eNO, which onsets and exacerbates endothelium dysfunction 
(Förstermann, 2010). Further, the excessive accumulation of ROS can induce 
endothelial cellular injury by modulating a series of intracellular signalling pathways, 
which in turn lead to endothelial dysfunction (Simon et al., 2000; Taniyama & 
Griendling, 2003). Hydrogen peroxide (H2O2) is the major source to stimulate the 
endogenous ROS production in oxidative stress environment underhypoxia and 
ischaemia reperfusion injury (Ballinger et al., 2000). It was reported that over 200 
µmol/L of H2O2 induces endothelial apoptosis, and this model has been extensively 
used to induce cellular injury caused by oxidative stress in in vitro models (Coyle et 
al., 2006). 
 
2.1.1.1.4 Angiogenesis 
Angiogenesis is a regenerative response triggered in the injured tissue adjacent to the 
ischaemic core to rebuild the blood vessel and deliver the oxygen to distant organs. It 
is an essential physiological process for maintaining blood vessel homeostasis by 
facilitating nutrient transportation, as well as promoting tissue growth and repair 
(Potente et al., 2011). Insufficient angiogenesis can complicate conditions such as MI 
and ischaemic stroke, which are associated with inadequate blood supply (Potente et 
al., 2011). Presently, therapeutic angiogenesis is a novel approach for improving the 
outcome of ischaemic vascular diseases. In such conditions, the therapeutic goal is to 
stimulate angiogenesis to improve perfusion, deliver survival factors to sites of tissue 
repair, mobilise regenerative stem cell populations, and ultimately restore form and 
function to the tissue (The Angiogensis Foudation, 2016). The in vitro angiogenesis 
is usually established by three major bioassays: endothelial cell proliferation, 
endothelial cell migration and tube formation. 
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2.1.1.1.5 Endothelial cell apoptosis 
Endothelial cell apoptosis may contribute to impaired endothelial function 
(Endemann & Schiffrin, 2004; Cai & Harrison, 2000; Cines et al., 1998; Kofler et al., 
2005). Apoptosis is the programmed suicide of a cell (Hinshaw et al., 1994). In 
normal physiology, the apoptosis of endothelial cells is essential for blood vessel 
remodelling, morphogenesis and lumen formation. However, improper function of 
endothelium resulting in uncontrolled apoptosis is reported to be associated with 
several vascular pathologies, in particular with atherosclerosis and thrombosis 
(Endemann & Schiffrin, 2004; Dimmeler et al., 1998; Tricot et al., 2000). 
Endothelial cell apoptosis was detected in atherosclerotic plaques, and may provide 
an important step in the transition from a stable atherosclerotic plaque to a plaque 
with overlying thrombosis (Tricot et al., 2000). Therefore, endothelial cell apoptosis 
is considered an important biological target for the research on atherosclerotic types 
of vascular diseases. 
 
An ideal treatment strategy would be multi-target, which can address all the 
associated risk variables and biological targets, as well as improve the post-treatment 
daily function, to effectively tackle the complexity of vascular diseases. 
 
2.2.3 Salviae Miltiorrhizae Radix et Rhizoma 
2.2.3.1 Background  
In TCM, vascular diseases are considered to be a ‘blood stagnation’ syndrome, 
leading to blood dysfunction and other symptoms such as pain, swelling, bleeding, 
oedema and so on. Based on the TCM syndrome differentiation and treatment 
strategy (Bian Zheng Lun Zhi), CHM treatment for vascular diseases are activating 
blood circulation to dissipating blood stasis (Huo Xue Hua Yu in TCM). Thus, 
Chinese medicinal herbs that manage blood activity are candidates for vascular 
dysfunctions. The dried root and rhizome of Salviae Miltiorrhizae Radix et Rhizoma 
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(known as DS in TCM), is a prominent and widely used traditional Chinese 
medicinal herb for blood stasis. It was first recorded and described as a very valuable 
herb in Shennong Bencao Jing (A Divine Farmer’s Materia Medica) (Cheng, 2007; 
Leung, 2006). The Chinese market alone for these DS commodities was reported to 
exceed one billion RMB in 2007, which accounted for 34.42% of the total market 
share. According to the CFDA database, up to 936 manufacturers are currently 
producing Chinese herbal products containing DS (China Food and Drug 
Administration, 2016). Cultivation of DS is widespread across most provinces of 
China; Shanxi, Sichuan, Hebei, Henan and Shandong Provinces are recognised as 
traditional primary production areas, yielding high quality DS (Zhong et al., 2009). 
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2.2.3.2 Chemical composition  
Numerous studies have analysed the chemical profile of DS. The chemical 
constituents of DS were isolated as early as the 1930s, and there are more than 70 
components structurally identified from DS and classified according to their 
lipophilic or hydrophilic nature (Zhou et al., 2005; Li et al., 2009). More than 30 
lipophilic compounds—mainly diterpene chinone compounds—have been separated 
and identified, including tanshinone I (TI), cryptotanshinone (CT), 
dihydrotanshinone I (DT) and tanshinone IIA (TIIA). Hydrophilic compounds 
include danshensu (DSS), protocatechuic aldehyde, protocatechuic acid and phenolic 
acids. Phenolic acids are the main type of hydrophilic components that include 
salvianolic acid (SA) and salvianolic acid B (SB). The hydrophilic components are 
rich in the DS extract, with DSS and SB having the highest content among all 
components, accounting for over 1% and 3–5% of total dried weight, respectively 
(Zhao et al., 2008). The structures of these active components from DS are shown in 
Figure 2.4 below. Among them, SB and TIIA are currently used as reference 
standards for Chinese DS in the PPRC (State Pharmacopoeia Committee, 2010). 
 
 
Figure 2.4 Chemical structures of seven major components in DS. 
 
2.2.3.3 TCM clinical use  
DS was traditionally reported to be highly effective in activating circulation and 
dispersing stasis or sludging of blood (Cheng, 2007). In Asian countries, DS products 
are popular for treating CVDs, acute ischaemic stroke, hyperlipidaemia and 
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cerebrovascular diseases (Zhou et al., 2005). The purported functions of DS are listed 
in Table 2.3. 
 
2.2.3.4 Pharmacological activity related to vascular disease 
The associated biological targets for vascular diseases can be classified into three 
main angles: anti-inflammation, angiogenesis and anti-apoptosis. Here, we have 
reviewed the studies on DS as a single extract and its bioactives on these biological 
targets. A review of the literature is conducted below. 
 
2.2.3.4.1 Anti-inflammation 
There has been renewed interest in DS as an herb for treating vascular diseases 
through their inhibition of excessive expressions of inflammatory mediators, 
including NO, TNF and MCP-1. It was reported that DS (125 mg/kg/day) 
significantly (P<0.001) decreased the expression of TNF in male BALB/c mice when 
administrated for 38 days prior to receiving an intraperitoneal injection of LPS (20 
mg/kg) (Wan et al., 2006b). An in vitro study showed that DS (100 and 400 µg/mL) 
reduced TNF levels significantly (P<0.05) in RAW 264.7 macrophages cells induced 
by LPS (1 µg/mL). Meng Li (2012) revealed that DS lipid-soluble fraction reduced 
the NO production in response to LPS RAW 264.7 cells, and this was associated to 
the suppression of iNOS mRNA and protein expression. The same study 
demonstrated that this inhibited the effects on pro-inflammatory cytokines (TNF, IL-
1β and IL-6) through inhibiting the degradation of IkB-α and NF-kB nuclear 
translocation p65 (Li et al., 2012a). Further research showed that chemical 
compounds of TIIA and SB inhibited the LPS-induced gene and protein expressions 
of iNOS, NO, TNF, IL-1β, and interleukin-6 (IL-6) in macrophages via the same 
pathway, which was consistent with Meng Li’s study (2012) (Ren et al., 2010; Xu et 
al., 2011a). 
 
2.2.3.4.2 Angiogenesis 
DS has been used widely in Asia to treat angiogenesis and haemostasis-related 
diseases, such as atherosclerosis, thromboembolism and angina. Several studies 
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showed that DS were active in rebuilding blood vessels, with phenolic acids playing 
the major role (Fan et al., 2006a). It has been reported that the enhanced angiogenic 
response using the DS (10 μg/mL) and SB (0.14–14 μM) on the murine SVR 
endothelial cell line was associated with the up-regulation of VEGF and its receptor 
genes (Lay et al., 2003). In contrast, tanshinones (CT, DT and TIIA) were reported to 
inhibit the proliferation and migration of these cells (Wang et al., 2005). Similarly, 
Tsai (2011) demonstrated the anti-angiogenic effect of TIIA (1–10μM) on the 
chorioallantoic membrane in chicken embryos and human umbilical vascular 
endothelial cells (HUVECs) by the transwell migration assay (Tsai et al., 2011b). CT 
and DT were found to have prevented angiogenesis on bovine aortic endothelial cells 
and HUVECs, with IC50 at 10 μM and 1.28 μg/mL, respectively (Hur et al., 2005; 
Bian et al., 2008). Jin et al.’s 2008 study found that this may be related to the 
inhibition of Akt phosphorylation, down-regulation of ERK and c-jun 
phosphorylation, as well as prevention of NF-kB and AP-1 DNA-binding. Since the 
amount of phenolic acids in DS outweighs tanshinones, it may explain the overall DS 
extract still exert enhanced angiogenic activity so as its phenolic acids group. 
 
2.2.3.4.3 Anti-apoptosis 
A number of studies have demonstrated the protective effects of DS on endothelial 
cells injury/apoptosis induced by various stimulants. Two in vivo studies revealed 
that DS prevented oxysterol-induced endothelial cell apoptosis in Sprague-Dawley 
rats (Nakazawa et al., 2005) and reduced the infarct volume size in cerebral 
ischaemia reperfusion (CIR) rats (Liang et al., 2013). Recent studies have shown that 
the aqueous DS exhibited anti-apoptotic activity using platelet-derived growth factor 
(PDGF)-BB (20 ng/mL) and TNF (10 ng/mL) stimulated-HUVECs. This was 
suggested to be related to mitogen-activated protein kinase (MAPK) and NF-κB 
signalling pathways (Cho et al., 2013). 
 
For the chemical compounds in DS, no study was found on protecting endothelial 
cells, but many studies suggested the anti-apoptotic effects of phenolic acids on other 
various cell lines, including SA (Guo et al., 2012; Zhang et al., 2012a; Wang & Xu, 
2005) and SB (Wang et al., 2012a; Sun et al., 2012b; Tian et al., 2008; Sun et al., 
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2012a). Observed anti-apoptotic activities were associated with inhibiting oxidative 
stress, increasing stress tolerance ability and regulating Bax/Bcl2 ratio. Additionally, 
DSS was shown to inhibit cardiac cell death by activating the phosphatidylinositol 3-
kinase (PI3K)/Akt pathways (Chong et al., 2013; Yin et al., 2012). As the most 
abundant tanshinone, TIIA also exhibited protective effects against cerebral 
ischaemia injury in vitro by increasing the anti-apoptotic protein Bcl-2 to pro-
apoptotic protein Bax ratio (Jia et al., 2012; Fu et al., 2007; Wang et al., 2011a), 
decreasing the [Ca2+] influx induced by depolarisation (Wang et al., 2011a, Lin et al., 
2013), deactivation of caspase-3 protein (Fu et al., 2007; Chen et al., 2012), 
suppressing the oxidative stress (Xia et al., 2005) and the radical-mediated 
inflammatory insult (Dong et al., 2009; Lin et al., 2006). Additionally, Mahesh et al. 
(2002) and Zhang et al. (2009) investigated that CT (10–20 μM) inhibited sodium-
nitroprusside-induced apoptosis in Neuro-2a cells by activating the PI3K/Akt 
pathway (Mahesh et al., 2012). 
 
2.2.4 Notoginseng Radix et Rhizoma 
2.2.4.1 Background  
Notoginseng Radix et Rhizoma, the root and rhizome of Panax notoginseng (Burk.) F. 
H. Chen, commonly known as SQ (or Tianqi) in Chinese, is one of the most popular 
and highly-valued Chinese medicinal commodities for blood statsis. It was first 
recorded in Bencao Gangmu (Compendium of Materia Medica) in 1578, and was 
described as more valuable than gold (Zhao et al., 2012; He, 2008; Wang et al., 
2006a). It is native to the southwest region of China, such as Yunnan, Guangxi and 
Sichuan Provinces, at altitudes of 1500 to 1800 metres (Dong et al., 2003). SQ has 
been cultivated for nearly 500 years, and almost 90% of SQ products are sourced 
from Yunnan Province (Yang et al., 2008). 
 
2.2.4.2 Chemical composition  
The major active constituents in SQ are saponins of the protopanaxadiol and 
protopanaxatriol types, which are dammarane glycosides. Currently, 56 different 
saponins have been identified in SQ, including ginsenosides, notoginsenosides and 
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gypenosides (Gan & Zhen, 1992; Li & Fitzloff, 2001), such as ginsenoside Rb1 
(Rb1), ginsenoside Rb2 (Rb2), ginsenoside Rd (Rd), ginsenoside Re (Re), 
ginsenoside Rg1 (Rg1), ginsenoside Rg2 (Rg2) and notoginsenoside R1 (NR1) 
(Wang et al., 2006a). Other minor components include amino acids, dencichine, 
flavonoid and polysaccharide (Dong et al., 2003). 
 
The structures of the major components of Panax notoginseng saponins from SQ are 
shown in Figure 2.5. Rg1, Rb1 and NR1 are currently used as marker compounds for 
SQ in the PPRC (State Pharmacopoeia Committee, 2010). 
 
 
Figure 2.5 Chemical structures of major components in Panax notoginseng; Glc: β-
D-glucose; rha: α-L-rhamnose; xyl: β-D-xylose. 
 
Name R1 R2 R3 Molecular formula 
NR1 -H -Glc -Oglc(2-1)xyl C47H80O18 
Rg1 -H -Glc -Oglc C42H72O14 
Re -H -Glc -Oglc(2-1)Rha C48H82O18 
Rb1 -Glc(2-1)glc -Glc(6-1)glc -H C54H92O23 
Rb2 -Glc(2-1)glc -Glc(6-1)Ara(p) -H C53H90O22 
Rd -Glc(2-1)glc -Glc -H C48H82O18 
Rg2 -H -H -Oglc(2-1)rha C42H72O14 
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2.2.4.3 TCM clinical use  
SQ is a favourite medicine for both internal and external bleeding. Traditionally, SQ 
is used to regulate the blood, transform blood stasis, stop bleeding and prevent pain 
(Bensky et al., 2004). Current pharmacological studies have revealed that SQ 
possesses anti-platelet (Wang et al., 2008a; Lau et al., 2009) and anti-carcinogenic 
effects (Konoshima et al., 1999), haemostatic and fibrinolytic activity (Zhang et al., 
2012b), with protective effects on the cardiovascular and central nervous systems 
(Ng, 2006; Zhang & Zhang, 2007). In clinics it is used for angina pectoris in 
coronary heart disease, with insufficient blood supply from the cardiac muscle, due 
to heart Qi deficiency and blood stasis (He, 2008). The purported functions of SQ are 
summarised in Table 2.3. 
 
2.2.4.4 Pharmacological activity of SQ related to vascular diseases 
2.2.4.4.1 Anti-inflammation 
SQ has been shown to possess anti-inflammatory activity in vitro and animal studies, 
which are beneficial to the vascular system. A single dose of SQ methanolic fraction 
(0.5 mg/kg) administered to C57BL/6 mice significantly inhibited inflammatory cell 
infiltrates, TNF, TGF-β, IL-1β, and IL-6 levels in bronchoalveolar lavage fluid. 
Corresponding decreases in the expression of TNF and IL-6 levels were also 
observed in LPS-stimulated RAW 264.7 cells (Tsai et al., 2011a). Additionally, SQ 
ethanol fraction (35% Rb1 and 34% Rg1) could decrease IL-6 and TNF levels on 
LPS-stimulated RAW 264.7 cells (Rhule et al., 2006). Reverse 
transcription polymerase chain reaction (RT-PCR) was conducted to show that the 
expression of COX-2 and IL-1β mRNA was also attenuated by SQ (Rhule et al., 
2006). Another study showed that Panax notoginseng saponins (PNS) (including 
34.66% of Rb1, 26.34% of Rg1, 7.38% of R1, 8.18% of Rd and 4.28% of Re) at the 
dosage of 25–100 µg/mL reduced secretion of IL-6 and MCP-1 in LPS-stimulated 
THP-1 macrophages (Fan et al., 2012a). This study also demonstrated that PNS-
inhibiting pro-inflammatory response was associated with the PNS-induced blockade 
of NF-κB via LXRα. The major component in SQ, Rg1 (0.001 μM-10 μM), was 
shown to decrease the LPS-stimulated TNF and IL-6 production (Du et al., 2011). 
Additionally, Re was found to reduce pro-inflammatory cytokines on macrophage 
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cells as a single compound in SQ; however, the molecular mechanism has not been 
studied (Paul et al., 2012). 
 
2.2.4.4.2 Angiogensis 
Hong (2009) showed that PNS (100μg/mL) induced a stimulation effect on cell 
proliferation, invasion and tube formation in a dose-dependent manner compared to 
the vehicle control in HUVEC (Hong et al., 2009). Among all the bioactives from SQ, 
Rg1 was considered to be the most potent pro-angiogenic agent (Chan et al., 2013). 
The same study conducted by Hong (2009) found that Rg1 (10 μg/mL) exerted a 
similar effect to PNS (100 μg/mL) in HUVEC, and the mechanistic pathway was 
associated with enhancing vascular endothelial growth factor (VEGF) and kinase-
domain region/foetal liver kinase-1 (KDR/Flk-1) mRNA expression (Hong et al., 
2009). Additionally, it was revealed that Rg1 was more stable in enhancing 
angiogenesis than basic fibroblast growth factor (bFGF) (Lin et al., 2008). For 
example, the pH level or solvent species can significantly reduce bFGF effects on 
HUVEC, whereas the effect of Rg1 remained the same (Yu et al., 2007). Most 
studies agreed that PI3K/Akt pathway via glucocorticoid receptor (GR) was involved 
in Rg1-induced angiogenesis (Hong et al., 2009; Leung et al., 2006; Cheung et al., 
2011; Leung et al., 2011; Yin et al., 2011). 
 
2.2.4.4.3 Anti-apoptosis 
Although the effects of SQ and its chemical compounds have not been investigated 
on endothelial cell survival, several studies have shown the protective effects of PNS 
on various cell line injuries induced by oxidative stress. Qiang et al. (2010) 
demonstrated that PNS at 25–200 μg/mL concentration markedly attenuated H2O2-
induced apoptosis from 41.91% to 14.67% (P<0.01) in bone marrow stromal cells 
(BMSCs). Additionally, the pre-treatment of PNS significantly decreased the level of 
ROS and the caspase-3 expression (P<0.01), and regulated the Bcl-2/Bax ratio 
induced by H2O2 (Qiang et al., 2010). Li (2009) investigated the neuro-protective 
activity of PNS, and revealed that it was associated with the inhibition of caspase-3 
expression on transient middle cerebral artery occlusion (MCAO) rat models. 
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Another study found that PNS protected ischaemia myocardial cells by activating 
PI3K/Akt signalling pathway using H9C2 cells (Chen et al., 2011a). 
 
Among all major bioactives in SQ, Rd was the most extensively investigated 
compound for its anti-apoptotic activity in various cell lines (Li et al., 2012d; Ye et 
al., 2011a). It is reported that Rd (0.1, 1, 10 μM) significantly attenuated oxygen-
glucose deprivation (OGD)-induced hippocampal neuron cell death: from 37.2% to 
26.3%, 18.5% and 20.9%, respectively (Ye et al., 2009). Recent studies have found 
that Rd exerted neuroprotection after ischaemia by first reducing initial intracellular 
ROS and malondialdehyde production, and second, attenuating subsequent 
inflammatory damage through the suppression of microglial activation, iNOS and 
cyclooxygenase-2 expression (Ye et al., 2009; Ye et al., 2011b). Another study 
demonstrated that Rd (10 μM) potentiated H2O2-induced apoptosis of basilar artery 
smooth muscle cells by increasing cytochrome C release and caspase-9/caspase-3 
activations, reducing the stability of mitochondrial membrane potential (MMP) and 
the ratio of Bcl-2/Bax (Li et al., 2012d). 
 
Table 2.3 Summary of the nomenclatures and functions of DS and SQ in TCM 
Herb (Pin Yin) DS SQ 
Common English 
name 
Salvia Root. Notoginseng.  
Pharmaceutical name Radix Salviae Mltiorrhizae. Radix Notoginseng. 
Botanical name Salvia miltiorrhiza Bge. Panax notoginseng (Burk.) F.H.Chen  
Family  Labiatae. Araliaceae. 
Part used Root Root 
Taste and nature  Bitter and slightly cold. Sweet, slightly bitter and warm.  
Channel entered  Heart, pericardium and liver.  Large intestine, liver and stomach.  
TCM function  Quickens the blood and dispels stasis, 
cools the blood and disperses 
abscesses, clears the heart and 
eliminates vexation. 
Eliminates blood stasis and stops 
bleeding, promotes the regeneration of 
blood and promotes blood circulation.  
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Indication Menstrual irregularities, painful 
menstruation due to blood stasis, 
menstrual block, chest pain, 
abdominal and stomach pain, 
abscesses and sores, breast abscess 
due to heat toxins, pain in the limbs, 
palpitations and insomnia.  
Coughing of blood, vomiting of blood, 
nosebleed, blood in the stool, bloody 
dysentery, uterine bleeding, damp-heat 
dysentery, abdominal pain, tenesmus, 
swollen and painful abscesses, and 
bleeding due to external injury.  
 
Both DS and SQ have versatile effects on the vascular system, highlighting the 
potential of DS and SQ as a combinational therapy capable of targeting the 
complicated nature of vascular disease. In TCM, DS is usually used as the key herb 
in this herb-pair for targeting the main symptoms, and SQ is the assistant herb, 
believed to reinforce the activity of DS and treat other accompanying symptoms. 
 
2.2.5 Salvia Miltiorrhiza Radix et Rhizoma - Notoginseng Radix et 
Rhizome herb-pair 
2.2.5.1 Background 
Herb pairs consisting of two herbal ingredients are the most fundamental unit and the 
simplest form of CHM formulae (Wang et al., 2012b; He, 2008). In light of their 
simplicity and the basic characteristics of complex formulae, herb pairs are a good 
starting point for investigating the possible interactions among herbal ingredients in 
the TCM herbal formula (Ung et al., 2007). In this study, a typical Chinese medicinal 
herb-pair consisted of Salvia Miltiorrhiza Radix et Rhizoma and Notoginseng Radix 
et Rhizome (DS-SQ), which have great potential to address the multi-faceted 
complexity of vascular disease and is a good example to be evaluated for its 
synergistic mechanism. 
 
DS-SQ has been one of the most frequently prescribed herb pairs in China in the last 
30 years, specifically for the treatment of CVDs (Wei et al., 2007a). A patent 
formulation is listed in the official PPRC (Chinese Pharmacopoeia), the Fufang DS 
tablet/dripping pill/granule, consisting of DS and SQ as the main herbal ingredients 
(DS-SQ-Borneol, 450g-141g-8g), and is indicated for angina pectoris in coronary 
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heart disease (State Pharmacopoeia Committee, 2010). The Fufang DS pill is sold as 
a prescription drug in China, Vietnam, Pakistan, South Korea, India and the United 
Arab Emirates, and is reportedly taken by about 10 million angina and coronary heart 
disease patients every year (Herbal Medicine, 2016). In 2009, Chinese domestic sales 
brought in a reported US$148 million, which grew to US$252.5 million by 2013 
(Hutchison China Meditech Limited., 2013). Further, a similar DS-SQ preparation, 
called Dantonic (T89), has cleared FDA Phase II clinical trials in the US as a 
patented medicine, and is currently undergoing Phase III trials for the treatment of 
chronic angina. The popularity and extensive use of DS-SQ and its related products 
has highlighted the definite therapeutic effects on vascular diseases. 
 
2.2.5.2 Chemical analysis of DS-SQ herbal combination 
The chemical components in the DS-SQ combination have been determined using 
HPLC (Zeng et al., 2006a; Wei et al., 2007c), high-performance liquid 
chromatography/electrospray ionisation-mass spectrometry (HPLC/ESI-MS) (Wei et 
al., 2007b) and rapid resolution liquid chromatography (RRLC) (Xia et al., 2008). 
The major compounds—including phenolic acids, diterpenoid quinones and 
saponins—were detected in the mixed preparation. For example, Lu et al. (2006) 
established and validated a high-performance liquid chromatography–ultraviolet–
evaporative light scattering detection (HPLC-UV-ELSD) method for the 
identification and quantification of SAs, tanshinones and saponins in Fufang DS 
tablets, consisting of DS and SQ as the main ingredients. Additionally, they also 
revealed that 70% methanol can yield the highest extraction efficiency of DSS, TI 
and Rg1 from the Fufang DS tablet (Lu et al., 2007). 
 
By using high-performance liquid chromatography – diode-array detection (HPLC-
DAD), Wei et al. (2006) successfully developed and validated a method for the 
quality control of Fufang DS tablets manufactured from different pharmaceutical 
companies. This method can simultaneously determine seven major compounds, 
including saponins, phenolic acids and tanshinons, by using different detection 
wavelengths (Wei et al., 2007c). Additionally, Wei et al. (2007) further developed 
the high-performance liquid chromatography–diode-array detection-evaporative light 
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scattering detection (HPLC-DAD-ELSD) method and determined 12 chemical 
compounds, including saponins, tanshinones and phenolic acids from the Fufang DS 
dripping pill/tablet and Danqi tablet (Wei et al., 2007a). Further, Wei et al. (2006) 
established a high-performance liquid chromatography - electrospray ionisation-mass 
spectrometry (HPLC-ESI-MS) method and successfully characterised 14 saponins, 
13 phenolic acids and nine diterpenoid quinones from DS-SQ combinational 
preparation. This method can also be applied to determine the metabolic components 
of DS-SQ combination after oral administration, and 53 metabolic components 
(including 30 original components and 23 metabolic components) were detected and 
identified (Wei et al., 2007b). 
 
Another study conducted by Zhang et al. (2008) used the HPLC-ESI-MS technique 
and developed a method specifically for detecting saponins in the Fufang DS tablet. 
A total of 19 saponins, with 15 reported and four new previously unreported 
ginsenosides were detected (Zhang & Cheng, 2006). Finally, Li et al. (2008) used a 
RRLC system (1.8 m particle size) coupled with time of flight-mass spectrometry 
(TOF-MS) method, and comprehensively analysed up to 20 chemical constituents in 
various DS-SQ preparations. This method provided a more rapid analysis time and 
higher sensitivity than traditional HPLC methods. A representative total ion 
chromatogram (TIC) for one of the DS-SQ samples shows the chromatogram of 
major constituents in DS-SQ combination at positive and negative ion modes (see 
Figure 2.6). 
 
To investigate whether there are any changes in the chemical composition for DS and 
SQ when they are prepared together, Zeng et al. (2006a) applied a uniform HPLC 
method for DS, SQ and their combination, and compared the chemical ingredients 
between the single herbs (DS and SQ) and the complex prescription (FFDS). The 
results demonstrated that the components in the mixture originated from DS and SQ, 
and no new components appeared or disappeared in the DS-SQ mixed preparation 
(Zeng et al., 2006a). 
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Conversely, Li et al. (2003) suggested that new chemical substances were formed 
during the co-decoction of DS and SQ, detected and validated by ultraviolet-visible 
spectrophotometry, infrared spectroscopy, HPLC and TOF-MS (Li et al., 2003). It is 
likely that the different preparation process for the mixed decoction of DS and SQ in 
Zeng et al. and Li et al.’s studies led to the different results. Li et al. (2003) used 
aquous extract of DS-SQ, which may allow a higher yield of non-polar consistituents 
to be extracted and detected, whereas in Zeng et al.’s (2006a) study, ethanol and 
methanol were used, which may ‘wash out’ all the non-polar constituents. Further, 
the analytical techniques used in Li et al.’s study included IR and TOF-MS, which 
were much more sensitive than the HPLC used in Zeng et al.’s study for detecting 
chemical substances (Kakei et al., 2009). Additionally, Li et al. (2003) reported that 
the amount of chemical constituents from SQ was reduced when it was co-decocted 
with DS (Li et al., 2003). A chemical analysis study from Zeng et al. (2006) on DS-
SQ combinations suggested that the extraction yield of chemical constituents from 
DS was generally increased in the co-decocted DS and SQ mixtures prepared with 
various ratios. In particular, DS-SQ 5:3 yielded the highest amount of chemical 
constituent from DS among all tested ratios (Zeng et al., 2004). It was assumed that 
the co-decoction of DS and SQ increases the extraction yield of DS which is 
associated with extraction factors including pH, solvent system, chemical 
components interactions (Zeng et al., 2004). While contradictory, these studies 
indicated that the chemical composition of DS-SQ mixed preparation may not be 
simply the sum of chemical constituents from the single herb. Therefore, quality 
control and chemical analysis study is important and necessary to ensure the 
repeatability and accuracy of the following pharmacology studies. 
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Figure 2.6 Typical total ion currents in one of the representative DS-SQ samples: (A) 
in negative ion mode; (B) in positive ion mode. DS: Sodium Danshensu (P1), SB 
(P7), SA (P8), DT (D1), TI (D2), CT (D3) and TIIA (D4). SQ: NR1 (S1), Rg1 (S2), 
Re (S3), Rb1 (S4) and Rd (S5) (Xia et al., 2008). 
 
2.2.5.3 Pharmacological actions of the DS-SQ combination 
A number of studies have investigated the pharmacological effect of the DS-SQ 
combination on hypertension, CVDs, obesity and diabetes, including the biological 
targets associated with vascular targets. The studies available for DS-SQ 
combination that may be relevant to this study are summarised below. 
 
Several in vivo studies demonstrated the beneficial effects of DS-SQ on the 
cardiovascular system. Baek et al. (2009) showed that the mixed aqueous extract of 
DS-SQ (1:1,w/w, 62.5 to 250 mg/kg) lowered the blood pressure of spontaneous 
hypertensive rats after oral administration for five weeks, and this effect was 
mediated by altering the arterial myogenic response (Baek et al., 2009). The 
compound DS tablet was found to exert a protective effect on myocardial 
ischaemia/reperfusion in injured rats, via decreasing the infarct size, apoptosis, 
caspase-3 protein level and other related parameters, which was associated with Akt-
eNOS signalling pathway. Another in vivo study conducted by Wang et al. (2015) 
revealed that the mixed DS-SQ solution (1:1, w/w) exerted a protective effect on 
dyslipidaemia rats induced by myocardial ischaemia, which was found to improve 
plasma lipid metabolism by up-regulating this lipid transport pathway and lipid 
metabolism regulators, enhancing heart function and up-regulating ejection fraction 
(EF) by increasing the cardiac diastolic volume (Wang et al., 2015). 
 
Several clinical trials with positive outcomes suggested the potential beneficial 
effects of DS-SQ combination on the vascular system. For example, Lian et al. (2015) 
conducted a randomised, double-blind, placebo-controlled multicentre clinical trial 
of the Compound Danshen Dripping Pill (CDDP) on diabetic retinopathy (DR). 
Their results showed that the DR patients who received mid (540 mg) and high doses 
(810 mg) of CDDP for 24 weeks had significantly better improvements on the DR 
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parameters of fluorescence fundus angiography (FFA) and fundoscopic examination 
compared to the placebo group (P<0.05) (Lian et al., 2015). It was suggested that the 
improvement was due to the blood stasis transforming activity of DS-SQ. 
 
Additionally, Yang et al. (2014) demonstrated that pre-treatment with CDDP can 
decrease the occurrence of cervical intraepithelial neoplasia (CIN) in patients 
undergoing percutaneous coronary intervention (PCI), with significantly recovered 
creatinine clearance level (P<0.05) (Yang et al., 2014). As the pathological 
mechanism of CIN was associated with pathological factors including inflammation, 
endothelial dysfunction and oxidative stress, these findings indicated the potential 
beneficial activity of DS-SQ combinations on vascular systems by its anti-
inflammatory effect, protection of endothelial function and reduction of oxidative 
stress. Further, another clinical trial suggested that CDDP reduced the risk of 
stroke/ischaemic attack recurrence. It was found that the recurrence rate of the 
patient group taking CDDP was significantly lower than that of the control group 
(P<0.05), associated with its significantly decreased blood C reactive protein level 
(P<0.05). Therefore, it is assumed that this activity of DS-SQ was associated with 
anti-inflammatory effects (Xu et al., 2009). 
 
2.2.5.4 Synergistic study of DS-SQ combination 
A number of studies have investigated the synergistic mechanisms underlying the 
compatibility of DS and SQ in the combination. By applying a systems biology 
approach, Zheng et al. (2013) revealed that the chemical compounds from DS and 
SQ can bond with multiple protein targets associated with CVDs, which highlights 
the potential of multi-target modes of action on the multi-component from this 
combination (Zheng et al., 2013). Similarly, through the compounds-targets 
prediction model, Wang et al. (2014) predicted that the DS-SQ combination exerted 
the protective effects on heart failure through multiple signalling pathways. The in 
vivo experimental data has validated the assumption and shown that the protective 
effect was associated with the arachidonic acid metabolism pathway by down-
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regulating the TXB2 and up-regulating the PGI2, supressing COX-1 and COX2 and 
reducing the level of leukotrienes B4 receptor (Wang et al., 2014b). 
 
In addition, Xie et al. (2015) demonstrated the enhanced therapeutic effects of DS-
SQ prescription for treating diet-induced insulin resistance in vivo. A much lower 
fasting insulin, triglyceride, total and low-density lipoprotein cholesterol (LDL-C) 
level in plasma on high-fat diet-induced obese mice were detected in the DS-SQ 
treated group in this study (0.4g of DS + 0.4 g of SQ), compared to the group treated 
with the individual herbs. Additionally, only the DS-SQ treatment group can 
markedly increase glycogen deposition in mice liver, and this effect was not shown 
in the single herb treatment group. Thus, it was assumed that there was 
synergistic/additive effect in the DS-SQ combination with promoted anti-diabetic 
activity (Xie et al., 2015). However, Xie’s study did not analyse for synergism. 
 
2.2.5.5 Optimal ratios of DS-SQ on various therapeutic outcomes 
Several recent Chinese pharmacological studies have investigated the optimal ratios 
of DS and SQ when used in a combination on different therapeutic outcomes, and 
demonstrated that different proportions of DS and SQ in the combination exerted 
various pharmacological effects. For example, an in vivo study suggested that DS-SQ 
with a ratio of 10:6 exerted a long-lasting effect, whereas DS-SQ 10:3 had fast-onset 
action in improving symptoms on acute myocardio ischemia dogs (Shang et al., 
2003). Another study summarised previous available pharmacological data of DS 
and SQ on myocardio ischemia and applied experimental design-nonlinear dynamic 
modelling-multiple objectives trigeminy method for the optimal ratio investigation of 
DS-SQ. Their results supplemented Shang et al’s study (2003) by showing that the 
optimal ratio range for improving myocardial ischaemia was between 10:3 and 10:7 
for DS-SQ (Wang et al., 2006b). 
 
For protecting endothelial cell function, studies have shown that DS-SQ at 5:3 and 
1:1 showed significant protective effects on HUVECs cells against hypoxia (P<0.05), 
whereas other tested ratios (10:1, 5∶1, 3:5, 1:5 and 1:10) and single extracts of DS 
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and SQ were found to be ineffective (Zeng et al., 2006b). Additionally, Liu et al. 
(2002) demonstrated that the optimal ratio of DS and SQ for inhibiting platelet 
adhesion and aggregation on healthy New Zealand rabbits was 0:10 (2 g/kg) and 10:3 
(2 g/kg), respectively. The effects were both significantly stronger than other tested 
ratios including 10:0, 10:1, 10:6, 1:10 (Liu et al., 2002). 
 
A summary of current available literature regarding optimal ratios of DS-SQ on 
various therapeutic outcomes is shown in Table 2.4. These studies showed the 
importance of adjusting the proportions of DS and SQ to reach desirable 
pharmacological effects. To address the underlying mechanism, one study proposed 
that altered biological activity is associated with the extraction yield, stability and 
bioavailability influenced by different proportions of DS and SQ during preparation 
(Shang et al., 2003). 
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Table 2.4. Optimal ratios of DS-SQ combinations on various biological targets. 
Study 
type 
Animal 
model/cellular 
model 
Biological targets  Methodology Optimal ratios 
of DS-SQ 
References  
In vivo  Acute myocardio 
ischemia dogs 
Myocardial 
ischaemia 
Multi-
objective and 
fuzzy 
comprehensive 
assessment  
10:6 and 10:3 Shang et al., 
2003 
In vivo / Myocardial 
ischaemia 
Design-
nonlinear 
dynamic 
modelling-
multiple 
objectives 
trigeminy 
method 
10:3 to 10:7 Wang et al., 
2006 
In vitro Reoxygenation 
induced hypoxia 
endothelial cell  
Endothelial cells 
injury induced by 
hypoxia  
Dose-response 
curve 
5:3 and 1:1 Zeng et al., 
2006b 
In vivo Health New 
Zealand rabbits  
Inhibiting platelet 
adhesion and 
aggregation 
Dose-response 
curve 
1:10 and 10:3 Liu et al., 2002 
 
2.2.5.6 Interactions among chemical constituents in DS-SQ combination 
The mode of action of the chemical compounds from DS and SQ on various 
biological targets was investigated in several studies, but only one utilised a rigorous 
synergy model to analyse the interaction among compounds. Firstly, several Chinese 
studies revealed positive interactions between SAs and notoginseng saponins on 
ischaemia reperfusion, anti-oxidant levels, insulin sensitivity and CIR. A recent study 
showed that the combination of SA and notoginsenosides (NG) at the ratio of 1:5 
exerted a more pronounced cardio-protective effect against ischaemia reperfusion 
(IR)-injured rats than individual SA and NG (Yue et al., 2012). Gong et al. (2013) 
showed that total SAs and total notoginseng saponins combined at 0.05–0.5 and 5–50 
mg/L exerted synergistic effects on protecting cardiac cells (H9C2 cell line) against 
hypoxia-induced apoptosis (CI <1 at all tested dosages), which significantly 
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increased the cell viability and improved the energy metabolism function. Another in 
vivo study revealed that the combination of SAs and notoginseng saponins can 
regulate glycolipid metabolism, decrease the level of free fatty acids, improve anti-
oxidant activity and enhance insulin sensitivity, beneficial for type II diabetes. This 
effect was comparable to the DS-SQ combinational extracts, SAs and notoginseng 
saponins used alone, whereas tanshinones from DS were found to be ineffective 
(Huang et al., 2011). Additionally, Lu (2004) suggested that total SAs and 
notoginseng saponins at the ratio of 1:2 showed significantly stronger effects than 
other tested ratios (1:1 and 2:1) in reducing cerebral infarction and decreasing plasma 
MDA levels on the CIR rat model (Lu, 2004). Further, a metabolomics study 
investigated the synergistic contribution of TIIA, SB and Rb1, derived from CDF 
(DS-SQ-Borneol combination) on myocardial ischaemia. The results showed that the 
three major constituents together almost achieved the same pharmacological effect as 
CDF (Lu et al., 2011). 
 
2.2.6 Summary of the literature review on the case study  
Vascular disease is a typical example of a complex pathophysiological disease that 
involves many risk factors and therapeutic targets. The current unsatisfactory 
treatment strategy has left a heavy financial and social burden on society. To 
holistically manage the complexity of this type of disease, CHM combination 
therapy constructed may present a practical solution. DS and SQ are popular Chinese 
medicinal herbs that have been extensively used in combination for the treatment of 
vascular diseases in TCM clinics. Preliminary literature supports the potential effects 
of the DS-SQ combination on the vascular system. The biological effects of DS and 
SQ as single extracts have been extensively studied, although the extent of the 
combination effects of DS-SQ were as great.  The underlying molecular mechanisms 
of DS-SQ combination is lacking. However, few clinical trials and in vivo studies 
showed a promising beneficial effects of the combination.  
 
The multi-target behaviour of DS-SQ was investigated via systems biology method 
on cardiovascular system. However, the possible mutual enhanced effects of DS-SQ 
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combination on the same biological target (pharmacodynamic synergy) have not 
been confirmed by rigorous analysis. Moreover, several selected ratios of DS and SQ 
were reported to be superior to others on acting on certain biological targets. 
However, the ratio-biological activity relationship for DS-SQ has not been 
comprehensively studied. The optimal ratio is yet to be determined for the treatment 
of vascular targets. 
 
DS-SQ herb-pair is popular in China and has the potential to address vascular disease. 
The herb-pair represents sufficient complexity to examine the possibility of 
synergistic interactions, and represents a good case example through which to 
examine synergistic mechanisms in CHM. 
 
2.3 Hypotheses and aims 
2.3.2 Hypotheses  
DS and SQ are both popularly used Chinese medicinal herbs, and a combination of 
the two has been extensively used for a time. There is strong evidence for the use of 
both in the treatment of vascular diseases. However, there are gaps in the present 
knowledge for their use in combination, especially for the way in which compounds 
may behave synergistically. Therefore, studing this herb-pair provide further insight 
to the synergistic behavior in CHM. The hypotheses are: 
1. It is possible to design relevant studies to test synergistic activities within 
complex mixtures of herbal compounds. 
2. Synergistic effects can be detected from DS-SQ on vascular disease-related 
biological targets through both pharmacodynamic and pharmacokinetic 
approaches. 
3. The results can further explicate the efficacy of CHM formulations (e.g., 
optimising herb ratios, synergistically enhancing pharmacological effects) to 
strengthen targeted biological activities. 
 
Chapter 2: Literature Review  
Page | 90  
 
2.3.3 Specific aims for the case study 
This thesis addresses challenges to evaluating efficacy based on the synergistic 
interaction of components in the DS-SQ herb pair as a case study. The specific aims 
are: 
1) Prior to commencement: standardisation of chemical profile 
The standardisation of the chemical composition for individual DS and SQ herbal 
extracts and the mixture were aimed to be established before the bioassays were 
conducted. The amount of selected chemical compounds in DS, SQ and DS-SQ 
extracts was determined, respectively. The quality of the crude herbal samples of DS 
and SQ was compared against the standard levels of the (PPRC [2010]) used for the 
studies.  
2) Pharmacodynamic synergistic mechanism 
An aim of this study was to evaluate the possible enhanced biological effects of DS 
and SQ on the same biological targets including anti-inflammatory, angiogenesis and 
cell survival. The pharmacological effect of single and combinational extracts of DS 
and SQ were evaluated on these biological targets. Then, the pharmacological 
activity on vascular diseases of the combination and individual ingredients were 
compared, so the enhanced/suppressed bioactivity from DS-SQ due to their 
interaction on the same target could be analysed. 
3) Pharmacokinetic synergistic mechanism 
The bioactivity of active constituents acting on three biological targets including 
anti-inflammatory, angiogenesis and cell survival was to be investigated, so that the 
multi-component and multi-target actions could be elucidated. 
4) Optimised ratio determination of herb ingredients in a formula 
This study aimed to determine the optimised ratio of DS-SQ that can exert maximum 
pharmacological effects on vascular disease biological targets. 
5) Development of compound formulations 
The single bioactive that presents the most potent bioactivity from each herb was 
combined and tested on the biological targets, to develop a simplified formulation. 
This was performed to investigate whether active components can be isolated, and to 
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develop a compound combination for modern medicines and pharmaceutical drugs 
that still retains the prominent therapeutic effects from its herbal formula. 
 
The results from the proposed experiments will advance and strengthen knowledge 
of the synergistic mechanism of TCM combinational herb therapy for treating 
complex diseases. By investigating the mechanistic pathways, explaining the 
synergistic actions and identifying active constituents that contribute to the 
therapeutic actions, this study will help set up the efficacy profile of the optimised 
combination as a basis for further research on CHM. Ultimately, by setting up the 
synergistic mechanism research platform for DS-SQ formulation, these methods can 
be translated and applied to other herb combinations with potential synergistic 
behaviour.  
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Chapter 3: Methodology 1: Analytical Techniques for 
Quality Control of an Herb Formula Containing DS and SQ 
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The complex nature and non-uniform chemical composition of CHM poses a great 
challenge for the determination of efficacy of any formulation. Quality control must 
be conducted to ensure that the qualified crude herb material and finished product 
exert consistent and reliable bioactivity. This chapter introduces the principles and 
experimental process for chemical analysis and quality control of the individual and 
combination extract of DS and SQ used in this study, before the commencement of 
bioassay testing. 
 
3.1 Methods and materials 
3.1.1 Herbal sample preparation 
Crude herbal materials (DS1–DS2, DS4–DS6) and decoction pieces (DS3) for DS 
and SQ (SQ1–SQ6) were collected from different sources in China (mainland and 
Hong Kong) (see Table 3.1). All crude herb samples were authenticated by The 
Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic 
University according to the Hong Kong Materia Medica Standards and PPRC 2010. 
A voucher specimen of each sample was deposited in the NICM, Western Sydney 
University. 
 
To prepare the single aqueous extracts of DS and SQ, the crude raw materials of DS 
and SQ were ground to powder (sieved through 30-mesh size). Then, 1 gram of 
ground crude herb material was soaked with 10-fold water for 0.5 hours and refluxed 
in 30 mL boiling water for 30 min. The solution was then centrifuged at 3000 rpm 
for 5 min and evaporated to dryness. The dried residue was sonicated in 10 mL 
methanol for 30 min, followed by centrifugation at 3000 rpm for 5 min. The 
supernatant was collected and evaporated to dryness at 60 °C under vacuum. The 
dried residue was weighed and re-dissolved in the minimum amount of methanol for 
further analysis. 
 
To prepare the combinational extract of DS-SQ, the crude raw materials of DS and 
SQ were ground to powder (sieved through 30-mesh size), and mixed in various 
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ratios (9:1, 8:2….1:9, w/w). Then they were soaked with 10-fold water for 0.5 hours 
and refluxed in 30 mL boiling water for 30 min. The solution was then centrifuged at 
3000 rpm for 5 min and evaporated to dryness. The dried residue was sonicated in 10 
mL methanol for 30 min, followed by centrifugation at 3000 rpm for 5 min. The 
supernatant was collected and evaporated to dryness at 60 °C under vacuum. The 
dried residue was weighed and re-dissolved in the minimum amount of methanol for 
further analysis. 
 
Table 3.1 Information for DS and SQ raw herbs/decoction pieces samples which 
were collected from six different sources in China. 
DS samples Origin SQ samples  Origin  
DS1 Sichuan De Ren Tang TCM store, 
Sichuan, China 
SQ1 Sichuan De Ren Tang TCM store, 
Sichuan, China 
DS2 Anhui, China SQ2 Jili Brand, Hong Kong, China 
DS3* Kangmei Pharmaceutical Limited 
Co., Anhui, China 
SQ3 Yunnan, China  
DS4 Jili Brand, Hong Kong, China SQ4 PuraPharm, Hong Kong, China 
DS5 PuraPharm, Hong Kong, China  SQ5 TCM Scientific Optometry Hospital, 
Beijing, China  
DS6 TCM Scientific Optometry Hospital, 
Beijing, China 
SQ6 Jiang Su, China  
*Decoction pieces, Lot number is 10058561 
3.1.2 Standards preparation 
The selection of the major chemical compounds from DS and SQ for this study was 
based on the Herbal Chemical Marker Ranking System (Herb MaRS) (Bensoussan et 
al., 2015). After a brief literature review on the chemical compounds from DS and 
SQ, fourteen compounds were selected for the content quantification and bioassay 
testing, which were all ranked above 1 on this scale. The selected compounds include 
DSS, SB, SA, TIIA, DT, T1, CT from DS, and NR1, Rg1, Re, Rb1, Rb2 and Rg2 
from SQ. All the reference standards were purchased from Chengdu Biopurify 
Phytochemicals Ltd. (Chengdu, China; purity > 98%). The standard stock solution of 
the reference compounds were prepared in methanol at 2mg/mL and stored at 4 ºC 
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until further use. A series of concentrations of standard dilutes were prepared for the 
UPLC calibration curve; the concentrations were 0.1–2000 μg/mL for DSS, DT, CT 
and TIIA, 1–1500 μg/mL for SA, SB and T1, and 0.0125-1 mg/mL for Rg1, Rg2, Rd, 
Rb1 and NR1. 
 
3.1.3 Solvents and chemical reagents 
Acetonitrile, methanol and phosphoric acid (85%) were of HPLC grade, purchased 
from Fisher Scientific (Merck Pty Limited, Victoria, Australia). Ethyl acetate, 
sulphuric acid and chloroform were of analytical grade, from Ajax Finechem 
(Sydney, Australia). A Sartorius SE-2 micro analytical balance (National Weighing 
& Instruments, New South Wales [NSW], Australia) and a Mettler Toledo ML54 
analytical balance (Mettler Toledo Limited, Victoria, Australia) were used to weigh 
the samples and standards. A Powersonic 420 ultrasonic bath (Thermoline Scientific, 
Australia) was used to sonicate and extract herbal solutions. 
 
3.2 Analytical techniques for quality control 
There have been many attempts worldwide at developing techniques and methods for 
analysing the inherent chemical variability of CHM, including chromatography, 
DNA fingerprinting and other spectroscopic methods (Liang et al., 2004; Zhu, 1998). 
The analysis by chromatography is increasingly employed in the authentication and 
quality assessment of CHM. TLC and HPLC are two standard industry 
chromatography methods used for quality control of herbal products (Liang et al., 
2004). TLC has been used extensively for decades due to its simplicity, low cost and 
the easily obtainable chemical fingerprint (Liang et al., 2004; Yongyu et al., 2011). It 
is mainly used as an initial tool for identification and a semi-quantitative analysis for 
herbal products (Zhou et al., 2015). With the development of more advanced 
analytical techniques, UPLC is preferred over HPLC for the accurate quantification 
of maker compounds in herbal products and because of its higher sensitivity and 
resolution (Yongyu et al., 2011). 
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3.2.2 TLC 
3.2.2.1 Principle and procedure 
TLC is a planar chromatographic technique that can be used to separate and identify 
a single chemical substance in a compound mixture such as CHM (Sherma & Fried, 
2003). A quick identification of the herbal sample using the TLC technique can be 
achieved by confirming the identity of the separated compound in the sample to the 
reference marker compound, or matching the fingerprint of the sample extract to that 
of the standard extract. The principle of separating single compounds from a mixture 
mainly depends on the relative affinity (polarity) of the compound to the stationary 
and mobile phases used in the analysis (Sherma & Fried, 2003). The compounds with 
higher affinity to the stationary phase travel slower with the mobile phase, whereas 
the compounds that have higher affinity to the mobile phase travel faster on the TLC 
plate. Thus, separation of components in the mixture is achieved with different spots 
representing each separated compound on the plate. The separated sample spots can 
be seen either using visible light, or fluorescent ultra-violet (UV) light (366 nm or 
254 nm) by spraying derivatisation solution (El-Shanawany et al., 2005). The 
assigned retention factor (Rf) value is usually used to represent the different 
distances of each separated spot travelled from the initial spotting site to the solvent 
front (Wagner and Bladt, 1996). Measuring Rf value can be used to identify the 
unknown compound in the sample by comparing that to the reference marker 
compound. Thus, the identification of the herbal sample can be achieved in two ways: 
by comparing each observed spot in the mixture to those of the known marker 
compounds, or by matching the whole fingerprint picture to that of the standard 
extract, both by colour or position (Rf). 
 
TLC offers a simple, quick, versatile and cheaper tool for the elementary 
identification of CHM. The TLC protocols for most of the CHM are available from 
various pharmacopoeias, such as the Chinese Pharmacopoeia (State Pharmacopoeia 
Committee, 2010). Current literature has also developed a number of TLC methods 
for the identification of marker compounds in herbal formulae. Sophisticated TLC 
equipment has facilitated the development of TLC techniques that allow qualitative 
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and quantitative analysis of multiple marker compounds in several samples 
simultaneously. 
 
3.2.2.2 Instrumentation and chromatographic conditions 
A TLC kit (CAMAG Chemie-Erzeugnisse & Adsorptionstechnik AG, Muttenz, 
Switzerland) containing a Linomat 5 automatic applicator with 100-μL syringes and 
a software linked (winCATs ver.1.3.0 system) imaging device was used. TLC plates 
were evaluated using a CAMAG Scanner 3 with visible light, 366 nm light and 254 
nm light, and a camera (Canon PSG × digital camera). The TLC plates were silica 
gel 60 F254 plate (20 cm × 20 cm) (Merck KGaA, Darmstadt, Germany), and each 
plate was cut into 10 cm × 10 cm squares before use. The plates were places in a 
CAMAG Twin Trough chamber (10 × 10 cm) with a stainless steel lid containing 
about 6 mL of the mobile phase solution. The mobile phase was maintained in the 
tank for at least 30 min in a fume hood at an ambient temperature of 20 °C before 
chromatography for saturation. After, all samples and standards (6 μL) were applied 
to the plate according to the following settings: 8-mm band width, 2-mm space 
between tracks and eight tracks on each plate. The application position was 10 mm 
from the lower edge of the TLC plate. All remaining measurement parameters were 
default settings. The plate was developed vertically from the lower edge to 80 mm. 
After development, the plate was air-dried for 10 min before derivatisation at 366 nm. 
 
The TLC condition and equipment used for DS and SQ were identical except for the 
mobile system. The mixed solution used for DS and SQ were ethyl acetate: toluene: 
formic acid: methanol (15:20:10:10:1, v:v:v:v:v) and chloroform-ethyl acetate–
methanol-water (15:40:22:9, v/v/v/v), respectively. 
 
3.2.3 UPLC 
3.2.3.1 Principle and procedure 
Among all analytical methods available today, HPLC has been the predominant 
technology for the qualitative and quantitative analyses of CHM for decades, due to 
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its accuracy, sensitivity and wide applicability (Liang et al., 2004). As advanced 
liquid chromatography developed from HPLC, UPLC with superior separation 
efficiency (chromatographic resolution, speed and sensitivity), reduced developing 
time and solvent consumption has become a popular alternative to conventional 
HPLC (Swartz, 2005). UPLC is frequently combined with a spectroscopic detector, 
such as the photodiode array (PDA) to obtain structural information of target 
analytes in complex mixtures of CHM (Zhou et al., 2015; Li et al., 2010). 
 
The basic principle in UPLC for separating constituents in mixed substances is 
similar to TLC, which is based on the relative affinity of the compound distributed 
between the stationary phase and the mobile phase (Swartz, 2005; Novakova et al., 
2006). In this study, reversed-phase (RP)-UPLC is a method of choice for analysts 
for the separation of active constituents in CHM preparations. RP-UPLC uses a non-
polar stationary phase, such as silica, with the surface covered in C18 or C8 straight 
chain alkyl groups, and an aqueous, moderately polar organic mobile phase, such as 
methanol or acetonitrile (Swartz, 2005). Constituents in a sample are separated 
according to their polarity, with the polar components that bond stronger to the 
mobile phase eluting first, followed by the non-polar components with higher affinity 
to the stationary phase eluting over time (Swartz, 2005). Retention time is a measure 
of how long a constituent is retained on the column before it is eluted, detected and 
plotted onto a chromatogram. Increases or decreases in retention times can be 
affected by adjusting the ratio of aqueous:organic mobile phase. 
 
3.2.3.2 Instrumentation and chromatographic conditions 
UPLC-PDA analyses were performed using a Waters ACQUITY UPLC system 
(Waters, Milford, US), equipped with quaternary solvent manager, quaternary pump, 
sampler manager FTN, column compartment, PDA detector and connected to Waters 
Empower 3 software. UPLC separations were conducted using an Acquity UPLC 
BEH C18 column (150 mm × 2.1 mm, 1.7 μm) with an attached pre-column (2.1 mm 
× 5 mm, 1.7 μm) (Waters). The column and sample temperature were kept at 20 °C 
and 4 °C, respectively. The mobile phase systems used for DS, SQ and DS-SQ were: 
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1) DS: the system consisted of 0.1% phosphoric acid (A)-acetonitrile (B). 
Gradient conditions were based on a modification of a method described 
previously (Liu et al., 2007b), with a gradient elution of 0–5 min, A 90–75%; 
5–10 min, A 75–50%; 10–16 min, A 50–20%; 16–18 min, A 20–90%. The 
column was reconditioned isocratically with 90% A for another 2 min. The 
flow rate was 0.30 mL min−1 and the injection volume was 10 μL. The 
detection wavelength was 280 nm. 
2) SQ: the initial mobile phase consisted of water (A)-acetonitrile (B) (82:18, 
v/v). Gradient conditions were based on a modified method, as described 
previously (Guan et al., 2007), with a gradient elution of 0–5.5 min, 18–19% 
B; 5.5–6.0 min, 19–31% B; 6.0–9.5 min, 31–35% B; 9.5–12.0 min, 35–56% 
B, 100% B for 6 min and reconditioning the column with 18% B isocratically 
for 7 min. The flow rate was set to 0.30 mL min-1 and the injection volume 
was 1 µL. The detection wavelength was set at 203 nm. 
3) DS-SQ: the initial mobile phase consisted of Water (A)-acetonitrile (B). 
Gradient conditions with a gradient elution as follows: 0–6 min, 10% B; 6–11 
min, 40% B; 11–16 min, 10 0% B; 16–20 min, 10%. The column was 
reconditioned isocratically with 10% A for another 2 min. The flow rate was 
0.30 mL min−1 and the injection volume was 6 μL. The detection wavelengths 
were set as 203 and 280 nm, simultaneously. 203 nm wavelength was set up 
for monitoring SQ saponins (NR1, Rg1 and Rb1), and 280nm for phenolic 
acids (DSS, SA and SB) and diterpenes (DT, CT, T1, and TIIA) from DS. 
The wavelength at 203 nm and 280 nm were used to detect the compounds 
from DS and SQ, respectively. All solutions were filtered using 0.2-μm 
polytetrafluoroethylene membrane filters before injection. The identification 
of compounds in the samples was carried out by comparison of UV spectra 
and retention times. 
 
3.2.3.3 Validation procedure for UPLC methods 
The UPLC methods for DS, SQ and DS-SQ were validated in terms of linearity and 
repeatability. The validation procedure was conducted according to the AOAC 
International (AOAC) Guidelines for Single Laboratory Validation of Chemical 
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Methods for Dietary Supplements and Botanicals (AOAC Guideline, 2005). To 
validate the calibration of the standard curves, more than four concentrations for each 
standard compound were prepared, and the compound at each concentration was 
analysed in triplicate. Regression of the calibration was calculated as y = ax + b, 
where x and y were the concentration of the reference samples and the peak area, 
respectively. The limit of detection (LOD) and limit of quantification (LOQ) of the 
UPLC methods were calculated according to the equations as: LOD = 3.33 × 
(standard deviation [SD] of y-intercept/mean of slope) and LOQ = 10 × (SD of y-
intercept/mean of slope) (Lauwaars, 2005). The relative SD (RSD) was used as a 
measure of repeatability. The intra-day precision was evaluated by analysing four 
concentrations of each marker compound three times within a day, and the inter-day 
reproducibility was examined on three consecutive days. For details of the validation 
procedure, see Appendix 1. 
 
3.2.3.4 Quantification of marker analytes by UPLC analysis 
Each chemical compound was identified based on the retention time and/or UV-Vis 
spectra. The peak area was then recorded for each corresponding peak in the tested 
sample solution. By using the peak area (y) of the compound in the sample, its 
concentration (x) can be calculated based on the regression equation of y = ax + b. 
All data was expressed as the mean ± standard error of the mean of three independent 
experiments performed in triplicates. 
 
3.2.3.5 Data analysis 
Each of the sample extracts was analysed at least three times by UPLC, with the final 
quantitative results from UPLC instrumental analyses expressed as the mean ± SD. 
Quantitative results were reported as milligrams per grams of the dry weight (DW) of 
the crude herb material (mg/g). The UPLC quantitative data were analysed non-
parametrically and one-way analysis of variance (ANOVA) using GraphPad Prism 
version 5.01 (GraphPad Software Inc., CA, USA). A P-value of < 0.05 was 
considered statistically significant. 
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3.3 Summary of analytical techniques for quality control of 
an herbal formula containing DS and SQ 
This chapter introduces the DS and SQ sample preparation procedures including 
crude herb collection and sample extraction used for the quality control and 
following bioassays in this study. The selection and preparation for key biactive 
compounds used in this study are described. The TLC methods have been established 
for the identification of the DS and SQ crude herbal samples, respectively. UPLC 
methods have been developed and validated for DS, SQ and DS-SQ extracts, 
respectively. In addition, the statistical methods for the chemical analysis are 
described.   
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Chapter 4: Methodology 2: Evaluating the Bioactivity and 
Synergistic Interactions in a Herb Formula Containing DS 
and SQ 
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Biological response testing is a common and efficient way of evaluating the 
pharmacological activity of CHM. This chapter introduces the principles and 
experimental procedures for each of the bioassays used for evaluating the anti-
inflammatory, angiogenesis and anti-apoptotic activities of DS, SQ and DS-SQ 
extracts in this study. The potential pharmacokinetics synergistic/antagonistic 
interactions in the DS-SQ combination were evaluated by CI and isolobologram 
models. Whereas the potential pharmacodynamics synergy was investigated via 
testing the bioactivities of the chemical compounds from the two herbs on the three 
bioassays. In addition, the statistical analysis methods for the bioassay results are 
introduced in this chapter.  
 
4.1 Herbal extract preparation and chemical materials 
The preparation of herbal extracts and the major chemical compounds from DS and 
SQ used in the bioassays were detailed in Chapter 3. Human TNF recombinant 
protein, the cell culture reagents including Dulbecco's Modified Eagle's Medium 
(DMEM)/Ham’s F12 containing 15 mM HEPES and L-glutamine and foetal bovine 
serum were purchased from Life Technologies (Australia). Penstrep (penicillin and 
streptomycin) was purchased from Gibco™ (Australia). All chemicals and reagents, 
including Hcy and Ado, were from Sigma-Aldrich (Australia) unless otherwise stated. 
Wortmannin (a PI3K inhibitor), L-NIO dihydrochloride (eNOS inhibitor), U0126 
(MEK inhibitor), p-ERK1/2, ERK1/2, p-MEK, MEK antibodies, GAPDH and β-
actin and Cultrex Basement Membrane Extract (BME) were purchased from Cell 
Signalling Technology (US), Santa Cruz Biotechnology (US) and Trevigen (US), 
respectively. 
 
4.2 Bioassays 
5.1.1 Anti-inflammation bioassays 
4.2.1.1 Cell culture 
The murine macrophage RAW 264.7 cell line was supplied by NICM, Western 
Sydney University. RAW 264.7 macrophages were cultured at 37 °C in DMEM (Life 
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Technologies, Victoria, Australia) and supplemented with 5% foetal bovine serum 
(FBS) (Life Technologies, Victoria, Australia), 1% GlutaMAX and 1% penicillin-
streptomycin (Life Technologies, Victoria, Australia) in a humidified atmosphere 
containing 5% CO2 and 95% air. 
 
4.2.1.2 Griess reaction NO measurement 
4.2.1.2.1 Principle 
Griess reaction is one of the most widely used methods for measuring the nitrite 
(NO2-) production on the cellular model. The Griess reagents include 1% 
sulfanilamide in 5% phosphoric acid and 0.1% N-1-naphthylethylenediamine 
dihydrochloride (NED) in milli-Q water (Molecular Probes., 2003). The basic Griess 
reaction is shown in Figure 4.1. Sulfanilic acid (sulphanilamide dissolved in 5% 
phosphoric acid) is quantitatively converted to a diazonium salt by reaction with 
nitrite (stimulated from the cells) in acid solution (Miranda et al., 2001). Then the 
diazonium salt reacts with NED and forms an azo dye (pink colour) that can be 
detected spectrophotometrically under the wavelength of 540 nm (Miranda et al., 
2001). Thus nitrite production is directly proportionate to the density of the azo dye, 
and can be quantified by its absorbance. 
 
 
Figure 4.1 Chemical reactions of nitrite with the Griess reagent (Molecular Probes., 
2003) 
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4.2.1.2.2 Experimental procedures 
The NO production was measured by its stable metabolite nitrite based on the Griess 
reaction. Briefly, cells (density at 1×106/mL) were seeded on 96 well cell culture 
plate (Corning Costar, Sigma, Australia) and incubated for 48 hours in the cell 
incubator, followed by treatment with the DS, SQ, DS-SQ extracts. The stock 
solutions of the extracts were prepared in sterilised distilled water. LPS from 
Escherichia coli 0111:B4, purified by trichloroacetic acid extraction (LPS, Sigma, 
batch number 070M4018), was used to stimulate inflammatory mediators, including 
NO, TNF and MCP-1. After the cells were incubated with extracts for 2 h, 50 ng/mL 
of LPS was added to the cells and then incubated for another 24 h. After the 
stimulation, 80 μL of cells supernatant were collected and mixed with Griess reagent 
for NO release measurement. The other half of the supernatant was stored at -80 °C 
in a freezer for TNF and MCP-1 enzyme-linked immunosorbent assay (ELISA) assay. 
The plate with mixed supernatant and Griess reagent was monitored under 540 nm to 
get the absorbance. 
 
4.2.1.3 TNF and MCP-1 ELISA assay 
4.2.1.3.1 Principle 
A TNF ELISA kit (Peprotech, Australia) was used for the quantitative determination 
of TNF in cellular model, using 96-well plates and a microplate reader. The TNF 
solid-phase sandwich ELISA is designed to measure the amount of TNF target bound 
between a matched antibody pair. The principle of the ELISA action is shown in 
Figure 4.2. The amount of TNF present in the cell supernatant can be measured by 
the intensity of this signal from the concentration of bonded 2, 2'-Azino-Bis-3-
Ethylbenzothiazoline-6-Sulfonic Acid (ABTS) substrate, which is directly 
proportional to the concentration of target present in the original specimen. The TNF 
expression can thus be quantified by the absorbance under the wavelength of 410 nm. 
The principle for MCP-1 ELISA assay is the same as TNF ELISA assay. 
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Figure 4.2 Principle reactions of TNF sandwich ELISA assay (image modified from 
Zhang et al., 2014). 
 
4.2.1.3.2 Experimental procedures 
The stored supernatants were analysed for TNF and MCP-1 synthesis using a 
commercial ELISA kit (Peprotech, Queensland, Australia) according to the 
manufacturer’s instructions. The absorbance was measured at 410 nm. The 
concentrations of TNF and MCP-1 in the experimental samples were extrapolated 
from a standard curve. 
 
5.1.2 Angiogenesis bioassay 
Angiogenesis is often studied in vitro using vascular endothelial cells focusing on 
three basic steps (none is dispensable): cell proliferation, migration and capillary-like 
tube formation (Staton et al., 2009). In response to hypoxia, injury or impaired tissue, 
angiogenic factors were released and bind to their receptors on endothelial cells, 
which lead to their activation. Then the endothelial cells start the proliferation 
process and this is followed by cell migration. Finally, the cells were escaping from 
their stable location by breaking through the basement membrane, and the new 
outgrowth of endothelial cells was reorganised into a tubular structure with the 
assistant of activity adhesion molecules (Fan et al., 2006a). As each of these three 
steps is essential for angiogenesis activity, they are often used as popular bioassays 
to investigate the intervention of pro- or anti-angiogenic agents. 
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4.2.1.4 Cell line and culture conditions 
Human cardiovascular endothelial cell line (EAhy926) was provided by Monash 
University Central Clinical School, Australia. The cell line was cultured in 
DMEM/Ham’s F12 containing 15 mM HEPES and L-glutamine, and supplemented 
with 10% FBS, 100 U/mL of penicillin and streptomycin (Gibco BRL, Australia). 
The cell line was grown in a 5% CO2-humidified incubator at 37 °C. 
 
 
4.2.1.5 Crystal violet staining for cell proliferation assay 
4.2.1.5.1 Principle 
Crystal violet staining was applied to determine the cell proliferation rate on EAhy 
926 cells. Crystal violet is frequently used as a histological stain for classifying 
bacteria based on Gram’s Method (Bartholomew & Finkelstein, 1954). It also can be 
applied in the cellular model as a simple way of obtaining the cell number (Kueng et 
al., 1989). As it can bond well to the DNA of both adherent and non-adherent cells, 
the density of the colour stained to the cells can be quantitatively measured under the 
wavelength of 590 nm by microplate reader (Gillies et al., 1986). The absorbance of 
the density is directly proportional to the total number of cells. 
 
In this study, Hcy-Ado combination was used as a stimulus to impair cell growth. 
Untreated cells are considered to be a control and should reflect the normal cell 
growth rate with a maximum cell number (100%). The cell growth range of the 
tested sample against the damage from Hcy and Ado should be between the number 
of stimulated cells (with Hcy and Ado) and control cells (100%). This was calculated 
based on the following equation: 
Cell number of tested sample % = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝐴𝐴 𝑡𝑡𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡𝐴𝐴𝑑𝑑 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝐴𝐴𝐴𝐴𝑛𝑛𝑡𝑡𝐴𝐴𝐴𝐴𝑠𝑠 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴
 × 100 % 
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4.2.1.5.2 Experimental procedure2 
1.0 x 104 cells per well were seeded in a 96-well plate for 2 h, and then treated with 
Hcy, Ado and/or sample extracts (final dimethyl sulfoxide (DMSO) concentration 
0.1%) in a serum-free medium. After a 72 h incubation period, the cell supernatant 
was fixed with 3% buffered paraformaldehyde for 20 min. The cells were then 
stained with 0.2% crystal violet in 20% methanol for 5 min. The excess crystal violet 
stain was rinsed 4–5 times with distilled water and air-dried. Glacial acetic acid (33%) 
in Milli-Q water was added to extract the crystal violet stain. Finally, the optical 
density was measured using a microplate reader (BMG Labtech Fluostar Optima, 
Mount Eliza, Victoria, Australia) at the wavelength of 595 nm (Martin & Clynes, 
1993). 
 
4.2.1.6 Cell migration (scratch wound healing) assay 
4.2.1.6.1 Principle 
Wound scratch assay is a well-developed and widely used method for measuring the 
intervention of the tested sample on cell proliferation, migration and wound healing 
activity in vitro (Liang et al., 2007). The purpose of the wound scratch assay is to 
observe whether the gap closing activity (by the growth and migration of the cells) is 
either promoted or inhibited by the analyte co-incubated with the cells (Yarrow et al., 
2004). The decreased gap area either promoted or inhibited by analyte is monitored 
by a microscope and recorded by a camera. Computer software, such as Image J or 
Tscratch, are frequently used to quantify and compare the open area of the cells 
before and after (Poujade et al., 2007; Gebäck, 2009). Factors altering the motility 
and/or growth of cells can lead to the gap’s increased or decreased rate of ‘healing’. 
An example wound scratch analysis is shown in Figure 4.3. 
 
                                                 
2 The experiments for Section 4.2.2.2.2 were set up and conducted by Dr Antony Kam, a research assistant at the 
National Institute of Complementary Medicine’s Herbal Laboratory, Western Sydney University. The Hcy-Ado 
induced cell proliferation assay followed the methods in Kam et al (2015). The herbal extracts for the experiment 
were prepared as outlined in Section 4.1 and I assisted with the experimental procedure for DS-SQ sample testing.    
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Figure 4.3 Example of wound scratch analysis on control lymphatic endothelial cell 
line. The open wound area (%) is automatically calculated from Tscratch software. 
Modified from Gebäck et al. (2009). 
 
4.2.1.6.2 Experimental procedures 
A wound scratch assay was performed according to Gebäck’s protocol (Gebäck, 
2009; Liang et al., 2007). Briefly, 1 x 104 EAhy926 cells per well were seeded on a 
24-well plate and growth to confluence after 24–48 h incubation. Then the cell 
monolayer was scratched using a 1000 μL pipette tip, and rinsed gently with 
phosphate-buffered saline (PBS) to remove cell debris. Two cross-shaped gaps were 
scratched in each well, and these were instantly centre-imaged at 4 × magnification, 
using a Motic AE20 microscope and a Tucsen ISH500 digital camera with maximum 
contrast. The photo was viewed with ISCapture software, recorded as 0 h, and the 
cells were exposed to Hcy, Ado and/or drug treatments in serum-free medium. After 
24 h incubation, the wound at the same well was photographed again and recorded as 
24 h. The percentages of cell-free areas were then compared between 0 and 24 h, and 
the data was analysed using TScratch software (Gebäck, 2009; Liang et al., 2007). 
 
The possible involvement of the PI3K, eNOS, MEK and ERK pathways in the 
observed effects in these experiments were investigated using the relevant inhibitors, 
including wortmannin (a PI3K inhibitor, at 2 μM), L-NIO dihydrochloride (eNOS 
inhibitor, at 100 μM), U0126 (MEK inhibitor, 20 μM) and PD98059 (a specific 
inhibitor of ERK1/2, 2 μM). Each was co-incubated with the analyte, to examine 
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whether the analyte was affected by any of the uninhibitors. If so, the corresponding 
signal pathway was involved in the effect of this analyte, acting on the wound 
healing of EAhy 926 cells. 
 
4.2.1.7 Tube formation assay 
4.2.1.7.1 Principle 
Angiogenesis is the process of generating new blood vessels, derived as extensions 
from the existing vasculature. In vitro angiogenesis is usually conducted by tube 
formation assay (Folkman, 1995). It models the reorganisation stage of angiogenesis, 
including monitoring the actions of cell proliferation, migration and capillary-like 
tube formation. It is typically employed to determine the ability of various treatments 
to promote or inhibit in vitro angiogenesis. In this assay, a gelled basement matrix—
in which the natural substrate is coated on the plate before the assay starts—is 
followed by seeding the endothelial cells on the gel. Then the monolayer of the cells 
on the gel can form capillary-like structures (tubes) under incubation (Arnaoutova & 
Kleinman, 2010). The observed capillary-like structures requires the attachment of 
the endothelial cells to the membrane, cell proliferation, breaking through the 
basement membrane, migrating towards each other, aligning and eventually forming 
tubes. The tube formation activity is typically quantified by measuring the number of 
junctions, tube length or area of these capillary-like structures in two-dimensional 
microscope images of the culture dish. Image J with angiogenesis analyser is usually 
used for data analysis. An example of tube formation analysis on endothelial cells 
(HUVECs) is shown below (Figure 4.4). 
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Figure 4.4 Example of dynamical behaviour of endothelial cells (HUVECs) on tube 
formation after plating on a basement membrane substratum. The tube formation 
activity is observed from attaching to the membrane (1 h), migrating towards each 
other (2 h), forming capillary-like tubes (2–16 h) and apoptotic and tubes breaking 
apart (24 h). The image was obtained and modified from Arnaoutova & Kleinman. 
(2010). 
 
4.2.1.7.2 Experimental procedures 
Tube formation assay was performed according to Arnaoutova & Kleinman (2010). 
Briefly, 50 μL Cultrex BME per well was used to coat a 96-well flat-bottom plate. 
The plate was centrifuged at 250 g for 10 min to remove the bubble. Then the plate 
with the BME was incubated at 37 °C for at least 30 min, to gel. EAhy926 cells (1 x 
104) were then seeded in each well and incubated for 2 h. After incubation the cells 
were treated with Hcy, Ado and/or herb treatments in serum-free medium. After 20 h 
of incubation, the well was photographed using the inverted phase-contrast 
microscope. The total number of junctions (consisting of at least three branches) was 
quantified using a plug-in, Angiogenesis Analyzer in NIH Image J software 
(National Institutes of Mental Health, Bethesda, Maryland, USA). 
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5.1.3 Cell survival bioassays 
4.2.1.8 Cell culture 
The cell culture procedure was the same as for the angiogenesis bioassay. For details, 
see section 4.2.2.1. 
 
4.2.1.9 Cytotoxicity induced by Hcy-Ado-TNF3 
EAhy 926 cells were seeded on a 96-well cell culture plate for 24–48 hours until 
confluent. DS, SQ and DS-SQ extracts (10–150 µg/mL), consisting of different ratios 
of DS and SQ, were treated on EAhy 926 cells for 4 h, followed by Hcy (0.5 mM), 
Ado (0.5 mM) and TNF (0.5 ng/mL) for another 20 h before further analysis. 
 
4.2.1.10 Cytotoxicity induced by H2O2 
To investigate the protective effects of DS, SQ and DS-SQ extracts consisting of 
different ratios of DS and SQ on endothelial cell toxicity caused by hydrogen 
peroxide (H2O2), EAhy 926 cells were pre-treated with increasing concentrations of 
various herbal extracts (10–300 μg/mL) for 30 min, followed by H2O2 (0.5 mM) 
incubation for 20 h. The cell viability was measured by MTT assay (for the protocol 
for MTT assay see section 4.1.3.4 below). 
 
4.2.1.11 Cell viability determined by MTT reduction dye assay 
4.2.1.11.1 Principle 
The reduction of MTT colorimetric assay was used for measuring the viability of 
cells in a cellular model. MTT is a yellow tetrazole powder. When the MTT solution 
is subjected to the cells, it enters the living cells and passes into the mitochondria, 
which can reduce the NAD(P)H-dependent cellular oxidoreductase enzymes that 
                                                 
3 The model of the Hcy-Ado-TNF induced cell survival MTT assay for section 4.2.3.2 was conducted with the 
assistance and supervision of Dr Antony Kam, a research assistant at the National institute of Complementary 
Medicine’s Herbal Laboratory, Western Sydney University. The herbal extracts for the experiment were prepared 
as outlined in Section 4.1 and I assisted with the experimental procedure for DS-SQ sample testing. 
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only present in viable cells (Liu et al., 1997). It then turns to an insoluble dark 
purple-coloured formazan complex (Liu et al., 1997). Consequently, the density of 
the purple colour that reflects the amount of insoluble formazan formed in the viable 
cells only can be used as an indicator for cell viability. The insoluble formazan is 
normally solubilised with organic solvents, such as isopropanol and dimethyl 
sulfoxide (DMSO) and this colour measurement can be detected at wavelength at 
510–590 nm using a microplate reader. The cell viability of tested sample is 
calculated based on the equation as shown below: 
Cell viability % = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝑡𝑡𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡𝐴𝐴𝑑𝑑 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝑢𝑢𝑛𝑛𝑡𝑡𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡𝐴𝐴𝑑𝑑 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴 (𝐴𝐴𝐴𝐴𝑛𝑛𝑡𝑡𝐴𝐴𝐴𝐴𝑠𝑠)
× 100% 
 
4.2.1.11.2 Experimental procedures 
After the treatment period, MTT solution (final concentration 0.5 mg/mL in PBS) 
was added to the cells and incubated for 4 h at 37 °C. DMSO was then added to 
dissolve the insoluble formazan crystal. The absorbance was measured at 510 nm 
using a microplate reader (BMG Labtech Fluostar Optima, Mount Eliza, Victoria, 
Australia). The density of formazan formed in control (medium with vehicle) cells 
was taken as 100% of cell viability. 
 
4.2.1.12 Cell viability measurement by neutral red uptake assay 
4.2.1.12.1 Principle 
The neutral red assay system is a way of measuring viable cells via the uptake of the 
vital dye neutral red. Neutral red vital dye dissolved in a medium can penetrate the 
cell membrane and incorporate with the lysosomes in the viable cells (Chiba et al., 
1998). However, the dye cannot concentrate in the lysosomes in the non-viable cells 
(Zhang et al., 1990). Thus, the uptake of the dye is proportional to the concentration 
of the neutral red solution and the numbers of viable cells (Zhang et al., 1990). The 
reaction of increased neutral red uptake by viable cells with the time of incubation 
plateaued after 2 h (Repetto et al., 2008). The neutral red uptake can be extracted 
from lysosomes by a solubilisation solution (1% acetic acid in 50% ethanol) for 
quantitative measurement. The density of dissolved red dye solution can be measured 
spectrophotometrically at a wavelength of 540 nm, which directly reflects the cell 
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viability (Repetto et al., 2008). The calculation for the cell viability of tested sample 
is similar to that of MTT assay, shown below: 
Cell viability % = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝑡𝑡𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡𝐴𝐴𝑑𝑑 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴𝐴𝐴 𝐴𝐴𝑜𝑜 𝑢𝑢𝑛𝑛𝑡𝑡𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡𝐴𝐴𝑑𝑑 𝐴𝐴𝐴𝐴𝑠𝑠𝑠𝑠𝐴𝐴 (𝐴𝐴𝐴𝐴𝑛𝑛𝑡𝑡𝐴𝐴𝐴𝐴𝑠𝑠)
× 100% 
 
4.2.1.12.2 Experimental procedures 
Cell viability measurement by neutral red uptake assay was conducted based on the 
Nature Protocols (Repetto et al., 2008). After the treatment period, the supernatant in 
the plates were then incubated for 2 h with the medium containing neutral red 
solution (50 μg/mL). The cells were subsequently washed, the dye was dissolved in 
glacial acetic acid (1% v/v) in ethanol (49% v/v) and the absorbance was measured at 
540 nm using a microplate reader (BMG Labtech Fluostar Optima, Mount Eliza, 
Victoria, Australia). The density of the control (medium with vehicle) cells was 
taken as 100% of cell viability. 
 
4.2.1.13 Lactate dehydrogenase leakage measurement 
4.2.1.13.1 Principle 
Lactate dehydrogenase (LDH) is a cytosolic enzyme released from the cell 
membrane when injury or toxic material damages tissues or cells (Choksakulnimitr et 
al., 1995). Thus, LDH leakage measurement has been widely used to evaluate the 
presence of damage, toxicity or apoptosis of tissue and cells. Released LDH in 
culture supernatants is quite stable and can be quantitatively measured with a 30-
minute coupled enzymatic assay through a series of chemical reactions (Promega., 
2016). 
 
For the principle of the LDH measurement, the LDH released from the leaky cells 
reacts with lactate and forms pyruvate, and then results in the conversion of a 
tetrazolium salt (iodonitro-tetrazolium violet; INT) into a red formazan product 
(Promega., 2016). The amount of colour formed by formazan is proportional to the 
number of lysed cells (Promega., 2016). Absorbance for the optimal colour density 
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can be measured using a microplate reader under the wavelength of 540 nm. The 
main chemical reactions for detecting LDH are shown in Figure 4.5. 
 
Figure 4.5 Chemical reactions of LDH to red formazan product for absorbance 
measurement. The reaction is modified from in vitro Promega CytoTox 96® Non-
Radioactive Cytotoxicity Assay protocol (Promega, 2016) 
 
4.2.1.13.2 Experimental procedure 
After the treatment period, the supernatants from the cells were subjected to LDH 
measurement using a commercial kit (Promega, Australia), according to the 
manufacturer’s instructions. Briefly, the cells in the 96-well cell culture plate with 
supernatant after the treatment period were centrifuged at 250 X g for 4 min. Then, 
50µl of the supernatant was transferred from each tested well to a fresh 96-well flat-
bottom plate. Prepared CytoTox 96 substrate mix (50 µl) obtained from the kit was 
added to each well of the new 96-well plate, containing samples transferred from the 
original cytotoxicity assay plate. The plate was then covered with aluminium foil to 
avoid light and incubated for 30 min at room temperature. Finally, 50µl of stop 
solution (from the kit) was added to each well and the absorbance was monitored at 
490nm. 
 
4.2.1.14 Caspase-3 activity colorimetric assay 
4.2.1.14.1 Principle 
Caspase-3 is an essential indicator of cell apoptosis, a frequently activated death 
protease catalysing the specific cleavage of many key cellular proteins (Porter & 
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Jänicke, 1999; Jänicke et al., 1998). The measurement of caspase-3 protein has been 
widely applied for investigating the protecting/cytotoxic effects of various 
compounds in cellular models. The Caspase-3 colorimentric assay was applied in this 
study for the measurement of the amount of Caspase-3 in the apoptotic cells, and the 
principle and protocol are based on the kit purchased from R&D Systems (R&D, 
2016). In this study, Hcy, Ado and TNF combination was used to induce apoptosis 
on endothelial cells. After the cells were stimulated with this combination and 
underwent apoptosis, they were lysed to collect the intracellular contents. The 
amount of total Caspas-3 protein present in the cell lysate was then tested for 
protease activity by adding a caspase-specific peptide that is conjugated to the colour 
reporter molecule p nitroaniline (pNA) (R&D, 2016). The cleavage of the peptide by 
the caspase releases the chromophore pNA. The green colour density can be 
quantified spectrophotometrically at a wavelength of 405 (R&D, 2016). The level of 
caspase enzymatic activity in the cell lysate is directly proportional to the absorbance 
of the colour reaction (R&D, 2016). 
 
4.2.1.14.2 Experimental procedures 
A quantitative caspase-3 activity assay was conducted according to instructions of 
the R&D assay kit manufacturer (R&D systems, Australia), with minor 
modifications. EAhy 926 cells were seeded in six-well flat-bottom cell culture plates 
and incubated for 24–48 h until the cells were confluent. Then the cells were pre-
treated with increasing concentrations of herbal extracts (10–300 μg/mL) for 4 h, 
followed by Hcy (0.5 mM), Ado (0.5 mM) and TNF (0.5 ng/mL) incubation. After 
the cells underwent apoptosis for 4 h they were collected by centrifugation at 250 X 
g for 10 min. The supernatant was gently removed and discarded and the cell pellet 
was collected and lysed by the lysis buffer provided in the kit. After incubating the 
cell lysate on ice for 10 min, the protein was collected by centrifugation at 10,000 X 
g for 1 min. The total protein content was quantified by a Pierce BCA Protein Assay 
Kit (Thermo Fisher Scientific, Australia), and then the cell lysate was diluted to make 
the approximate total protein concentration at 1 mg/mL. Then, 50µl of the cell lysate 
was transferred to a fresh 96-well flat-bottom plate, and was mixed with 50 µL 
reaction buffer (1% DTT, v/v) and 5µL of Caspase-3 colorimetric substrate (DEVE-
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pNA). The plate was incubated at 37 °C overnight, and the absorbance was read on a 
microplate reader at a wavelength of 410 nm. 
 
4.2.1.15 Measurement of intracellular reactive oxygen species (ROS) 
production 
4.2.1.15.1 Principle 
Intracellular ROS is an important indicator in responding to cellular damage induced 
by oxidative stress, frequently used in cellular models for anti-oxidant or cell death 
assay. In the Cellular Reactive Oxygen Species Detection Assay Kit (ab113851), a 
cell permeant reagent 2’,7’–dichlorofluorescin diacetate (DCFDA) (a fluorogenic 
dye) is used to detect ROS within the cells through a series chemical reactions. After 
DCFDA is diffused into the cells, it is deacetylated by cellular esterases to a non-
fluorescent compound, which is later oxidised by ROS into 2’, 7’–
dichlorofluorescein (DCF). DCF is a highly fluorescent compound that can be 
detected by fluorescence spectroscopy with maximum excitation and emission 
spectra of 495 nm and 529 nm, respectively. The amount of ROS is proportional to 
the DCF that is measured. 
 
4.2.1.15.2 Experimental procedures 
The assay was conducted according to the instruction of the cellular ROS detection 
assay kit manufacturer (Abcam, Australia). EAhy 926 cells were seeded on a 96-well 
cell culture plate at a concentration of 2.5x105 cells/mL and allowed to be 
confluenced overnight. The medium was then removed and the cells were washed 
once with 1X assay buffer (from the kit). The cells were than stained with DCFDA 
(20 μM) at 100 μL per well. The plate was incubated with a staining solution for 45 
min at 37 °C in the dark. After the incubation, the DCFDA staining was removed and 
the plate was immediately read under a microplate reader to get the initial absorbance 
(A0). The cells were then washed again with PBS, and tested herbal extracts of DS, 
SQ, DS-SQ (1:9–9:1) with increasing concentrations (10–150 µg/mL) were added to 
the cells and treated for 1 h. Finally, the absorbance at the end point (A1) was 
measured in the presence of the treatments under the same microplate reader. The 
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wavelength was set up with excitation at 455 nm and emission 535 nm at fluoresce 
mode. The final absorbance was calculated as A1 normalised with its corresponsive 
A0 (A1/A0). 
 
4.3 Determination of synergistic behaviour  
5.1.4 Pharmacodynamics synergy determination 
CI and isobologram models are practical methods for evaluating the interactions of 
two agents on the same target. Computional software, such as CalcuSyn and 
CompuSyn, are designed to facilitate the data analysis for these two models. Thus, 
they are applied to analyse the interaction between DS and SQ on each of the anti-
inflammation, angiogenesis and anti-apoptosis bioassays. The principle and method 
procedure of the CI and isobologram models were described in sections 2.1.2.1 and 
2.1.2.2, respectively. 
 
For analysis, the concentration-response curves of DS, SQ and DS-SQ on the same 
bioassay were generated. The data were entered into the CompuSyn software 2.0 
(Biosoft, US). Through the software process, the CI-Fa (fraction affected level) curve, 
isobologram figure and the relevant statistic regarding the synergistic/antagonistic 
interactions were then generated automatically. Here, CI-Fa curve demonstrates the 
relationship between CI value and the effective level (e.g., suppressive effect on NO) 
on certain biological targets. Through this curve, the synergistic/antagonistic 
interaction at certain effective ranges can be interpreted (e.g., antagonistic interaction 
at 0–70% suppressive effect level, and synergistic interaction at above 70% 
suppressive effect level). Additionally, antagonistic/synergistic interaction can also 
be observed through isobologram figure. A flowchart for the methodology used for 
pharmacodynamic synergism determination is shown in Figure 4.6. 
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Figure 4.6 Methodology for pharmacodynamic synergy determination of DS-SQ on 
anti-inflammation, angiogenesis and cell survival. 
 
5.1.5  Pharmacokinetics synergy determination 
To determine the multi-component multi-target synergistic effect within DS-SQ, the 
bioactivity for 14 of the selected bioactive compounds were screened on each of the 
three bioassays. Thus, the potent compound on each of the biological targets can be 
obtained. The compounds in the DS-SQ extract was correlated to the bioactivity of 
the extract on each target, to investigate which compound contributes the most to the 
extract’s activity. A flowchart for the methodology used for pharmacokinetic 
synergism determination is shown in Figure 4.7. 
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Figure 4.7 Methodology for pharmacokinetic synergy determination of DS-SQ on 
anti-inflammation, angiogenesis and cell survival. 
 
5.1.6 Compound formula investigation  
Based on the bioactivity of the tested compounds from DS and SQ, the most potent 
compounds from each herb which also showed significant activities were selected (if 
applicable) for the compound formulation investigation. These two compounds were 
combined in various ratios (1:10, 1:9, 2:8….9:1, 10:1) and tested in the same 
aforementioned bioassays. Thus, the ratio of the compounds in the combination was 
not relevant to their original quantity in the DS-SQ extract. The experimental 
procedures for the compound formulation investigation in the three bioassays were 
identical to that of the extracts. After the testing, the pharmacodynamics synergistic 
behaviour of the compound formula was determined the same way as for the DS-SQ.  
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4.4 Statistical analysis 
All statistic comparisons were performed using GraphPad Version 5.02 (US). The 
significance was analysed by one-way ANOVA test. Data was expressed as a mean ± 
SEM. P<0.5 was considered to be statistically significant. 
 
4.5 Summary of bioassay and synergism methodologies  
Selected methods have been outlined for evaluating the pharmacodynamics and 
pharmacokinetics synergy in DS-SQ. These include anti-inflammatory, angiogenesis 
and anti-apoptosis assays. The synergistic effects were evaluated using CI and 
isobologram models.  
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Chapter 5: Results: Chemical Qualification and 
Quantification of a Herb Formula Containing DS and SQ 
 
 
Section 5.3 in this chapter was published largely as Zhou X, Razmovski-
Naumovski V, Chan K, A Multivariate analysis on the comparison of raw 
notoginseng (Sanqi) and its granule products by TLC and ultra-performance 
liquid chromatography (2015), Chinese Medicine, 10:13. doi: 10.1186/s13020-
015-0040-2.  
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5.2 Introduction 
Quality control is an essential step in the development of CHM products. The good 
quality of CHM ensures a consistent and reliable efficacy level and reduced toxicity. 
This chapter reports the chemical analysis results for DS, SQ and DS-SQ 
combinations. 
 
DS contains a vast number of chemical compounds, which can be classified 
according to their lipophilic or hydrophilic nature (Zhou et al., 2005). Phenolic acids 
are the main type of hydrophilic depsides, including DSS, SA and SB, whereas CT, 
TI, DT and TIIA present the greatest amount of lipophilic components. Hydrophilic 
compounds are effective in ameliorating acquisition and retrieval processes, neuron 
protection, reversing cognitive impairments, improve memory function, anti-
apoptosis, anti-inflammation and angiogenesis (Bonaccini et al., 2015). Tanshinones 
exert anti-apoptotic, anti-inflammatory, anti-oxidant, angiogenesis effects, dilate 
coronary arteries, increase coronary flow and protect the myocardium against 
ischaemia (Zhou et al., 2005; Bonaccini et al., 2015). 
 
The major active compounds in SQ are Panax Notoginseng saponins (PNS) of the 
protopanaxadiol and protopanaxatriol types, such as Rb1, Rb2, Rd, Re, Rg1, Rg2 and 
NR1 (Guan et al., 2007). PNS are also the main bioactives of the herb, contributing 
to pharmacological activities, including neuroprotective, anti-inflammatory, anti-
oxidant and anti-tumour effects (Rao & Gurfinkel, 2000; Ma et al., 1999). The 
structures of these active components from DS and SQ are shown in Figures 2.4 and 
2.5. 
 
Generally, the therapeutic effects of CHM formulae are integrative results of 
multiple bioactive compounds. Therefore, the quality control of DS-SQ combination 
is important and necessary in order to ensure bioactive compounds in the extract. 
One of the most common approaches for assessing the quality of herb products is 
confirming the minimum levels of major marker compound(s) using chromatography. 
TLC and HPLC are standard industry methods for the quality control of herbal 
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products (Liang et al., 2009; Fan et al., 2006b; Chen et al., 2008). TLC is included in 
most pharmacopoeias as the initial analytical tool for the quality and identification of 
a medicinal herb, and has been extensively used by industry due to its simplicity, low 
cost and versatility in analysing multiple samples simultaneously (Liang et al., 2004). 
UPLC is a newly developed Waters instrumentation with high power in separation 
and analysis speed over traditional HPLC (Liang et al., 2004; Yongyu et al., 2011; 
Kong et al., 2009b). An increasing number of publications have used UPLC in 
quality control of CHMs (Liang et al., 2004). 
 
Many analytical methods have been established for the quality control of crude drugs 
containing DS, SQ or its combinations. Methods of HPLC–UV or DAD (Wei et al., 
2007a; Chang et al., 2009), coulometric electrode array (Ma et al., 2007), 
nonaqueous capillary electrophoresis (Xia et al., 2008), capillary 
electrochromatography (Li et al., 2007) and LC-MS (Liu et al., 2007a) have been 
established to identify and quantify phenolic acids, diterpenes or both in DS, and 
saponins in SQ. However, all reported analytical methods dealt with the qualification 
or quantification of only one or two types of component from only one composition 
herb (DS or SQ), and there were few UPLC applications on quality assessment or the 
chemical fingerprint of DS-SQ combination preparations (Wei et al., 2007c). 
 
This chapter introduces the established TLC and UPLC methods used to analyse the 
single and combinational extracts of DS and SQ. Chemical compounds from DS 
(DSS, SA, SB, DT, CT, T1 and TIIA) and SQ (NR1, Rg1, Rb1, Rg2 and Rd) were 
simultaneously identified and quantified. The results for the chemical analysis are 
shown in this chapter.  
 
5.3 DS chemical analysis results 
5.3.1 TLC fingerprint 
A representative TLC fingerprint of DS6 extracts is shown in Figure 5.1. DSS was 
not detected under UV mode in both DSS standard (lane 1) and in DS6 sample (lane 
4). SA was observed in Lane 2 of its reference standard with double bands, as well as 
Chapter 5: Chemical analysis results 
125 | P a g e  
in DS6 lane. SB was successfully identified in the DS6 sample lane. Four tested 
tanshinones were all detected in their standard lane (from lanes 5 to 8). However, 
none were detected in sample DS6 (lane 4). 
        
1 2 3 4 5 6 7 8 
 
Figure 5.1 TLC fluorescence image of DS6 sample herb with the reference standards 
under UV mode (366 nm). Key: Lane 1–DSS; Lane 2–SA; Lane 3–SB; Lane 4–DS6; 
Lane 5–DT; Lane 6–CT; Lane 7–TI; Lane 8–TIIA. Six reference standards have been 
detected using this method, and two of the standards can be identified in the DS6 
sample herb.  
 
5.3.2 UPLC method validation 
The validation parameters, including linear regression equations, R2 value, LOQ, 
LOD, average intra and inter-day repeatability (RSD) for each standard are shown in 
Table 5.1. The R2 values were greater than 0.994 for all analytes, showing a good 
linearity for the experimental data for the analytical method. The LODs and LOQs of 
the seven marker compounds ranged from 0.001–0.019 mg/mL and 0.002–0.056 
mg/mL, respectively. Precision good instrumental and method precision was 
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obtained for UPLC. As shown in Table 5.1, the RSD for the intra and inter-day 
precision ranged from 1.334–4.596% and 3.271–6.293%, respectively. This suggests 
the good repeatability for the UPLC method and instrument for DS chemical analysis. 
 
Table 5.1 Regression data, detection/quantification limits and precision data for 
the seven compounds determined in DS by UPLC-PDA. 
Compound Regression equation R2 LOD 
(mg/mL) 
LOQ 
(mg/mL) 
Precision, 
RSD (%) 
Intra-day (n = 
3)  
Precision, RSD 
(%) 
Inter-day (n = 
3) 
DSS y = 3200900 x-30113 0.998 0.015 0.044 1.334 3.635 
SA y = 8561600x-16212 0.999 0.003 0.010 2.850 6.293 
SB y = 3465506x + 
79925 
0.994 0.009 0.026 1.738 3.515 
CT y = 11512000 x-
63831 
0.998 0.005 0.014 4.596 4.658 
DT y = 7861800x + 6550 0.999 0.019 0.056 3.579 5.811 
T1 y = 6067600 x-6694 0.998 0.001 0.002 3.211 5.112 
TIIA y = 1071000 x-27826 0.999 0.004 0.013 3.253 3.271 
 
n = 3; RSD (%) = 100 x SD/mean; y, peak area; x, the concentration of each reference compound 
(mg/mL); R, correlation coefficient of regression equations; LOD, limit of detection (3.33 x [SD of Y-
intercept/mean of slope]); LOQ, limit of quantification (10 x [SD of Y-intercept/mean of slope]). 
 
5.3.3 Identification and quantification of key chemical compounds 
Identity confirmation of the analyte was achieved by comparing the UV spectra of a 
reference standard peak to a sample peak at the same retention time. A characteristic 
absorbance maximum at 280 nm was displayed for each analyte. Similarities in 
absorbance between the sample and standard spectra for each reference standard are 
presented in Appendix 2. Typical UPLC-PDA profiles of DS mixed standards and 
DS6 are shown in Figure 5.2, as are the amounts of each marker compound in the 
samples. 
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Figure 5.2 Chromatograms of seven standards analysed by UPLC-PDA. (A) Mixed 
standards, (B) DS6. (1) DSS, (2) SB, (3) SA, (4) DT, (5) CT, (6) T1, and (7) TIIA. 
Seven standards were captured simultaneously in the mixed standards preparation 
and the DS6 sample.  
 
As shown in Table 5.2, the content of DSS, SA, SB, DT, CT, T1 and TIIA in six raw 
herbs (DS1-DS6) ranged from 0.04–2.82, 0.50–8.30, 12.35–34.34, 0.00–0.13, 0.03–
0.17, 0.03–1.74 and 0.11–2.17 mg/g per DW, respectively. SB was the most 
abundant compound among all tested compounds in six raw herbs, accounting for 
over 90% of the total seven components weight. In the Chinese pharmacopoeia, SB 
and TIIA were considered to be the two marker compounds for the quality control of 
DS raw herb samples (State Pharmacopoeia Committee, 2010). Our results showed 
that the contents of SB did not vary significantly among DS1, DS3, DS5 and DS6 
(P>0.05), but were significantly lower in DS2 and DS4 than in the rest of the tested 
samples (P = 0.013, analysed by t test). Non-parametric independent sample T-
testing revealed that the amount for TIIA and other tested compounds (DSS, SA, DT, 
CT and T1) was not significantly different among the raw herb samples (P-value was 
from 0.063 to 0.343). Therefore, four collected DS raw samples (DS1, DS3, DS5 and 
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DS6) were considered to be not significantly different from each other in terms of the 
number of major compounds. 
 
In the PPRC, SB and TIIA are recommended as the marker compounds for the 
quality assessment of DS (National Pharmacopoeia Committee, 2010). The amount 
of SB and TIIA should not be less than 3% and 0.2% of the total amount of starting 
material, respectively. From the UPLC calculations (Table 5.2), only DS6 met this 
minimum requirement, with the content of SB and TIIA at 3.43% and 0.22%, 
respectively. To ensure the pharmacological level in the following studies, DS6 
sample was selected for the preparation of DS-SQ combinations. 
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Table 5.2 Contents (mean ± standard deviation, mg/g and % in 1g of the starting material) of the seven compounds in DS sample 
analysed by UPLC-PDA (n = 3). 
Sample  DSS SA SB DT CT TI TIIA 
mg/g %  mg/g %  mg/g %  mg/g %  mg/g %  mg/g %  mg/g % 
DS1 2.82±0.16 0.28 1.35±0.00 0.02 22.71±0.00 2.27 ND ND 0.03±0.00 0.00 0.03±0.00 0.00 0.70±0.00 0.07 
DS2 0.72±0.36 0.072 0.51±0.00 0.00 12.35±0.00 1.24 0.10±0.07 0.01 0.16±0.04 0.02 0.51±0.05 0.05 0.50±0.00 0.05 
DS3 0.41±0.54 0.041 0.50±0.01 0.00 21.63±0.00 2.16 0.04±0.00 0.00 0.07±0.01 0.00 1.74±1.51 0.17 0.30±0.00 0.03 
DS4 0.35±0.52 0.035 3.98±0.00 0.40 13.17±0.00 1.31 0.03±0.00 0.00 0.10±0.01 0.01 0.10±0.00 0.01 0.11±0.00 0.01 
DS5 0.04±0.08 0.00 1.11±0.00 0.11 23.81±0.00 2.38 0.13±0.00 0.01 0.17±0.05 0.02 0.29±0.00 0.03 1.60±0.00 0.16 
DS6 0.19±0.13 0.02 8.30±0.00 0.83 34.34±0.00 3.43 0.08±0.07 0.00 0.09±0.00 0.00 0.09±0.00 0.00 2.17±0.00 0.22 
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5.4 SQ chemical analysis results 
5.4.1 Identification and quantification of major chemical 
compounds 
Representative TLC fingerprints of SQ4 extracts are shown in Figure 5.3. There was 
good separation and identification of Rg1, Rb1, Rd and Rg2 on SQ6 TLC fingerprint, 
except NR1 and Re. However, less resolving power for discerning the compounds 
NR1 and Re was observed in the extracts. 
       
1 2 3 4 5 6 7 
Figure 5.3 TLC fluorescence image of SQ4 with the reference standards under UV 
mode (366 nm). Key: Lane 1-Notoginseng NR1; Lane 2-Ginsenoside Re; Lane 3-
Ginsenoside Rg1; Lane 4-SQ6; Lane 5-Ginsenoside Rg2; Lane 6-Ginsenoside Rd; 
Lane 7-Ginsenoside Rb1. Six references standards have been detected using this 
method, and all of them can be identified in the SQ4 sample.  
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5.4.2 UPLC method validation 
5.4.2.1 Calibration, linearity, LOQ and LOD 
The calibration curve equation, correlation coefficients (R2) value, average 
percentage RSD, LOQ and LOD values, intra-day and inter-day repeatability (RSD) 
of each standard are shown in Table 5.3. Correlation coefficients were greater than 
0.993 for all the analytes, which provided good linearity for the experimental data for 
both analytical methods. The LOD of UPLC for the five marker compounds ranged 
from 3.31–16.20 µg/mL; LOQ was in the range of 9.95–48.80 µg/mL. As observed, 
LOD and LOQ of UPLC were low, indicating the high sensitivity achieved by the 
UPLC method. 
 
5.4.2.2 Precision (repeatability) 
Good instrumental and method precision was obtained for both UPLC methods. As 
shown in Table 5.3, percentage RSD for the intra-day and inter-day precision ranged 
from 0.739–3.579% and 0.236–4.591% for UPLC. 
 
Table 5.3 Regression data, detection/quantification limits and precision data for 
the five compounds determined in SQ by UPLC-PDA. 
Compounds Regression equation R2 LOD 
(ug/m
L) 
LOQ 
(ug/mL) 
Precision, RSD 
(%) 
Intra-day (n = 3) 
Precision, RSD 
(%) 
Inter-day (n = 3) 
NR1 y = 497892x + 1692a 0.994 3.77 11.30 1.95 4.59 
Rb1 y = 451285x - 
8794.1a 
0.997 4.26 41.70 1.67 0.55 
Rd y = 502877x + 
4048.3a 
0.994 3.31 9.95 0.74 1.98 
Rg1 y = 519908x - 
3073.3a 
0.993 16.20 48.80 3.58 2.82 
Rg2 y = 529865x + 
1901.5a 
0.998 5.97 17.90 2.18 0.26 
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Figure 5.4 Chromatograms of five ginsenosides analysed by UPLC-PDA in SQ SQ6. 
(A) mixed standard, (B) SQ6. (1) NR1, (2) Rg1, (3) Rb1, (4) Rb2, (5) Rg2 and (6) 
Rd. Six standards were captured simultaneously in the mixed standards preparation 
and the SQ6 sample. 
 
5.4.3 Quantification of major chemical constituents 
Typical UPLC-PDA profiles of SQ raw herb are shown in Figure 5.4. The amount of 
each marker compound in the samples is shown in Table 5.4. 
 
After many UPLC trials, Re and Rg1 could not be successfully separated, as noted in 
previous chromatography studies (Chan et al., 2007; Toh et al., 2010; Wan et al., 
2006a). According to Wan et al. (2007), the Rg1/Re ratio was 6.19±0.82 in 18 tested 
samples of SQ from different origins. Considering that the amount of Re is much 
smaller and this present study is a comparative study of samples, the total amount of 
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Rg1 and Re was calculated as Rg1. From Table 5.4, the low SD of the five standards 
in the raw herbs showed good quantification consistency. The content of NR1, Rg1, 
Rb1, Rg2, and Rd in six SQ raw herbs (R1-R6) were ranged from 4.26–9.15, 23.63–
39.68, 12.79–21.54, 1.83–3.59 and 4.02–7.08 mg/g per DW, respectively. Rg1 
showed the most abundant amount among all tested compounds in six raw herbs. 
Besides, non-parametric independent sample T-testing revealed that the amount for 
each of the five compounds was not significantly different within the raw herb 
samples (P>0.05). Therefore, all six SQ raw herb samples were not significantly 
different from each other in terms of the number of major components. 
 
In the PPRC, Rg1, Rb1 and NR1 are recommended for the quality assessment of the 
raw herb (National Pharmacopoeia Committee, 2010). The total ginsenoside content 
(NR1 + Rg1 + Rb1) in the root and rhizome of notoginseng (methanol extract) 
should not be less than 5%. From the UPLC data (Table 5.4), the raw herb samples 
(SQ1–SQ5) met the minimum requirement of PPRC, with total ginsenoside content 
ranging from 5% to 8.2%. Only sample SQ6 had a relatively low total ginsenoside 
content (4.4%). Thus, SQ4 was selected as a representative for SQ for the 
preparation of DS-SQ combinations. 
 
Table 5.4 Contents (mg/g, mean±SD, n = 3) of the five compounds in SQ 
samples (SQ1-SQ6) analysed by UPLC-PDA. 
Sample NR1 Rb1 Rd Rg1 Rg2 
mg/g %  mg/g %  mg/g %  mg/g %  mg/g %  
SQ1 6.06±0.97 0.61 17.82±1.38 1.78 4.02±0.23 0.40 38.70±1.51 3.87 1.83±0.12 0.18 
SQ2 5.48±1.16 0.55 19.21±2.37 1.92 7.08±1.54 0.71 25.38±2.34 2.54 3.39±0.77 0.34 
SQ3 6.05±0.92 0.61 17.78±0.78 1.78 6.82±0.12 0.68 33.87±0.93 3.39 2.56±0.03 0.26 
SQ4 9.15±0.23 0.91 21.54±0.23 2.15 6.95±0.33 0.70 39.68±1.40 3.97 2.30±0.11 0.23 
SQ5 6.20±0.55 0.62 12.79±0.38 1.28 6.00±0.41 0.60 35.71±0.73 3.57 2.38±0.25 0.24 
SQ6 4.26±0.05 0.43 16.48±0.77 1.65 6.90±0.67 0.69 23.63±0.39 2.36 3.59±0.06 0.36 
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5.5 Chemical analysis results for DS-SQ mixed extracts 
5.5.1 UPLC method validation 
UPLC validation results are presented in Table 5.5. The linear regression equations, 
coefficient of determination (R2), LOD, LOQ, RSD (%) for each standard are shown 
in Table 5.5. The R2 values were greater than 0.990 for all analytes, showing good 
linearity for the experimental data for both analytical methods. The LODs and LOQs 
of the six marker compounds ranged from 0.129–1.449 μg/mL and 0.387–4.351 
μg/mL, respectively. Precision good instrumental and method precision were 
obtained for both UPLCs. The RSD for the intra and inter-day precision ranged from 
1.317–13.624% and 2.614–18.812%, respectively. 
Chapter 5: Chemical analysis results 
Page | 135  
 
Table 5.5 Regression data, detection/quantification limits and precision data for the six compounds determined in DS-SQ combinations 
by UPLC-PDA. 
Compound Regression equation R2 LOD 
(μg/mL) 
LOQ 
(μg/mL) 
Precision, RSD 
(%) 
Intra-day (n = 3) 
Precision, RSD 
(%) 
Inter-day (n = 3) 
DSS y = 4211500x + 11143 0.999 0.129 0.387 1.317 8.456 
SA y = 13544000x + 60377 0.999 0.238 0.715 2.342 6.715 
SB y = 7142700x–42285 0.994 0.555 1.668 2.037 2.614 
Rb1 y = 1543100x–37793 0.990 0.405 1.217 13.624 18.812 
Rg1 y = 2082900x + 33204 0.991 0.379 1.139 3.083 13.609 
NR1 y = 1771100x + 21247 0.995 1.449 4.351 6.830 11.083 
 
n≥3; RSD (%) = 100 x SD/mean; y, peak area; x, the concentration of each reference compound (mg/mL); R, correlation coefficient of regression equations; LOD, limit of detection (3.33 x [SD of Y-intercept/mean of 
slope]); LOQ, limit of quantification (10 x [SD of Y-intercept/mean of slope]). 
a n = 3; b n = 4; RSD (%) = 100 x SD/mean; y, peak area; x, the concentration of each reference compound (mg/mL); R, correlation coefficient of regression equations; LOD, limit of detection (3.33 x [SD of Y-
intercept/mean of slope]); LOQ, limit of quantification (10 x [SD of Y-intercept/mean of slope]).
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5.5.2 Identification and quantification of major chemical 
compounds 
The established method has been successfully applied to the simultaneous 
determination of DSS, SB, NR1, Rg1, and Rb1 in DS-SQ combinations in various 
ratios. Based on the corresponding UV spectra of each reference standard peak to a 
sample peak at the same retention time, five reference standards were all detected in 
the DS-SQ combinations in various ratios, except for SA and tanshinone group. The 
UPLC chromatograms were shown in Figure 5.5. 
 
As presented in Table 5.6, the concentrations of the major components in DS-SQ 
extracts (9 ratios) were determined using the validated UPLC-PDA method. The 
DSS, SB, NR1, Rg1 and Rb1 content in DS extract were expressed as mg/g of dried 
extract (DE). Among all identified components, the amount of SB and Rg1 still 
overweigh the rest of the components, ranged from 2.43–18.44 and 3.31–13.33 mg/g 
from a ratio of DS-SQ 1:9 to 9:1. The comparison of the content of five bioactives 
among combinational extract in nine different ratios is shown in Figure 5.6. 
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Figure 5.5 Chromatograms of five standards analysed by UPLC-PDA. (A) DS6 observed at 280 nm wavelength, (B) SQ4 observed at 203nm 
wavelength, (C) DS-SQ combination (5:5) observed at 280 nm wavelength, and (D) DS-SQ combination (5:5) observed at 203 nm wavelength. 
(1) DSS, (2) SA, (3) SB, (4) NR1, (5) Rg1, (6) Rb1 and (7) Rd. (7)-(9) are unknown peaks. DSS, SB, NR1, Rg1 and Rb1 were routinely captured 
by UPLC in the DS-SQ mixtures regardless the original mixture ratio (1:9; 2:8; 3:7...7:3; 8:2; 9:1) of these two herbs.  
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Table 5.6 Contents (mg/g, mean±SD, n = 3) of the five compounds in DS-SQ 
combinations extract by UPLC-PDA. 
DS:SQ DSS  SB NR1 Rg1 Rb1 
1:9 ND 2.434±0.690 2.056±0.483 13.329±2.003 9.188±0.370 
2:8 0.144±0.015 4.752±0.070 1.359±0.164 8.913±0.478 7.165±0.290 
3:7 0.109±0.011 12.605±0.392 0.071±0.033 3.307±1.597 1.960±0.127 
4:6 0.117±0.025 9.399±0.235 1.103±0.067 8.832±2.314 4.710±0.750 
5:5 0.066±0.015 8.482±0.156 0.359±0.112 4.375±0.902 2.892±0.202 
6:4 0.473±0.072 15.209±0.318 0.384±0.311 5.842±2.229 3.299±0.265 
7:3 0.243±0.024 11.671±0.162 0.011±0.093 3.960±2.202 1.863±0.606 
8:2 0.281±0.034 16.733±0.268 0.117±0.180 3.280±1.716 1.614±0.441 
9:1 0.300±0.042 18.444±0.255 0.334±0.000 3.392±0.708 1.124±0.176 
 
 
Figure 5.6 Contents (mg/g, mean±SD, n = 3) of the five compounds in DS-SQ 
combination extract by UPLC-PDA. The quantity of the five compounds vary with 
the proportion of DS (%) in DS-SQ combinations.  
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5.6 Summary of chemical qualification and quantification 
results of a herb formula containing DS and SQ 
TLC methods have been established for the qualitative determination of DS and SQ 
extracts, respectively. A rapid UPLC-PDA method was developed and validated for 
the quality control of DS and SQ raw herb extracts. Seven chemical compounds 
including DSS, SA, SB, DT, CT, T1 and TIIA were simultaneously determined in six 
DS samples collected from different sources. The results revealed that the amount of 
the marker compouds was not significantly variable among all DS samples, except 
DS4 and DS6 which possessed significantly lower amount of SB (P<0.05). For SQ, 
UPLC was efficient for the simultaneous determination of the five maker compounds 
including NR1, Rg1, Rb1, Rg2 and Rd. This study has shown that the quality was not 
variable among six SQ samples collected from different sources. 
Furthermore, a simple and rapid UPLC-PDA method was established and partially 
validated for the quality control of DS-SQ extracts, which would be the key for 
following studies. Five checmial compounds, including DSS, SB, NR1, Rg1, and 
Rb1 were identified and quantified in DS-SQ preparations. Among all these 
identified compounds, SB and Rg1 possessed most of the mass. DSS, SB, NR1, Rg1 
and Rb1 were routinely captured by UPLC in the DS-SQ mixtures regardless the 
original mixture ratio (1:9; 2:8; 3:7...7:3; 8:2; 9:1) of these two herbs. However, 
other compounds in DS and SQ individual herb including SA, tanshinones, Rg2, Rb2 
and Rd were not captured in DS-SQ combination extract. No new compounds were 
detected in the combination. Knowing the fingerprint chemicals of DS, SQ and their 
combinations help to understand how the extracts work in the bioassays and which 
component has the highest biological effect as well as the determination of positive 
interaction, if any, between these two herbs.  
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Chapter 6: Results: Synergistic Effects of DS-SQ on 
Regulating Inflammatory Mediators in RAW 264.7 Cells 
 
This chapter has been accepted for publication largely as is in Zhou X, Razmovski-
Naumovski V, Chang D, Li CG, Kam A, Low M, Benoussan A & Chan K (2016). 
Synergistic effects of DS (Salvia Mitiorrhiza) and SQ (Panax notoginseng) formula 
in inhibiting inflammation mediators in RAW264.7 cells, Biomed Research 
International, 2016 (2016). Doi: 10.1155/2016/5758195. 
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6.1 Introduction 
Vascular disease is a subgroup of cardiovascular disease which is the leading cause 
of illness, disability and death worldwide. Hypertension, obesity, diabetes, high 
cholesterol levels, stress and elevated plasma homocysteine are all risk factors that 
could accelerate the formation of vascular pathological changes (Intengan & 
Schiffrin, 2001). The main trigger is the diminished generation of vasodilation 
factors, such as eNOS (Endemann & Schiffrin, 2004; Alp & Channon, 2004; 
Szmitko et al., 2003). The development of vascular disease is complex and involves 
the interplay of various factors and signalling pathways; the endothelial dysfunction 
is considered to be an early marker of the disease (Endemann & Schiffrin, 2004). 
Mounting evidence has suggested that pro-inflammatory responses induced by 
cytokines and chemokines play a pivotal role in endothelial impairment, leading to 
endothelial dysfunction, vascular inflammation and the development of many 
inflammatory vascular diseases. 
 
As vascular diseases involve complex vascular pathological changes, it has been 
noted that combinational therapy in CHM may address the complexity with 
synergistically enhanced pharmacological effects and multi-target actions (Jiang, 
2005). Previous literature has supported the single use of DS and SQ, as well as their 
bioactives, as anti-inflammatories. However, little is known about the interactions 
between the two herbs in combination, and the mechanisms underlying potential 
synergism of this herb-pair remains unclear. The study in this chapter investigates the 
combination effects of DS-SQ pair on lipopolysaccharide (LPS) stimulated pro-
inflammatory mediators including TNF, NO (induced by iNOS) and MCP-1, to 
elucidate their endothelial protection properties in RAW 264.7 macrophages cell 
model. This model has been frequently used for anti-inflammatory bioassays (Rhule 
et al, 2006). Possible synergistic interactions between the key bioactive components 
from each herb were analysed using CI and isolobologram models. 
 
This chapter reports the results of the combination activities of DS-SQ combinations 
(1:9, 2:8 …9:1) in inhibiting pro-inflammatory mediators in vitro. The key results 
suggest that DS-SQ 8:2 has synergistically enhanced activity in inhibiting LPS 
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induced NO, TNF and MCP-1 compared with single extracts on RAW264.7 cells. In 
addition, the lipophilic compounds are the key contributor to the anti-inflammatory 
activities of two herbal extracts with DT and Rd as the leading compounds. The 
formula of DT-Rd 7:3 significantly inhibited NO, TNF and MCP-1 at various 
concentration ranges. However, antagonistic interactions were largely observed.  
 
6.2 Results 
6.2.1 Lipopolysaccharide-induced NO (induced by iNOs) release in 
RAW 264.7 cells 
In the presence of LPS (50 ng/mL), a significant amount of nitrite production was 
detected and reached 215.56 ± 8.38 and 197.40 ± 3.36 μg/mL in sterile water and 
DMSO, respectively (Figure 6.1). A highly selective iNOS inhibitor, dihydrochloride 
(1400W), was used as a positive control and showed a strong nitrite suppression 
effect, with a half maximal inhibitory concentration (IC50) value at 5.53 µM. 
 
 
Figure 6.1 Nitrite production stimulated by LPS (12.5 to 400 ng/mL) on RAW 264.7 
cells in water and DMSO. 
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6.2.2 Cytotoxicity of DS, SQ and DS-SQ extracts on RAW 264.7 
cells detected by MTT assay 
To prove that the inhibitory effects of DS, SQ and DS-SQ on the inflammation 
mediators were not due to cytotoxicity, MTT assay was conducted to examine the 
safe concentration range for the extracts. In the MTT assay, the non-cytotoxic 
concentrations for DS, SQ and DS-SQ combinations were observed to be 0–2.5 
mg/mL, 0–2.5 mg/mL and 0–5 mg/mL, respectively (Figure 6.2). DS and SQ at 
5mg/mL showed cytotoxicity on RAW 264.7 cells. However, at the same 
concentration of 5 mg/mL, the DS-SQ combination did not show any cytotoxicty. 
The tested concentrations for DS, SQ and DS-SQ for the following bioassays were 
all within their safety concentrations (under 2.5 mg/mL). 
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Figure 6.2. Cell viability (% relative to control) verses concentrations (mg/mL) for DS, SQ and DS-SQ on RAW264.7 cells tested by MTT assay. 
A, DS. B, SQ. C, DS-SQ 9:1. D, DS-SQ 8:2. E, DS-SQ 7:3. F, DS-SQ 6:4. G, DS-SQ 5:5. H, DS-SQ 4:6. I, DS-SQ 3:7. J, DS-SQ 2:8. K, DS-SQ 
1:9. 
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6.2.3 Effects of DS, SQ and DS-SQ on the inhibition of inflammatory 
mediators stimulated by LPS in RAW 264.7 cells 
6.2.3.1 Effects of DS, SQ and DS-SQ in inhibiting nitrite release 
All tested single and combinational extracts of DS and SQ showed NO inhibitory 
effect in a dose-dependent manner. At 2.5 mg/mL, DS and SQ significantly inhibited 
the LPS-induced NO production in RAW 264.7 cells by 56.08 ± 1.00% and 59.58 ± 
2.42 %, respectively (P<0.05).  The IC50 values for DS and SQ in inhibiting NO were 
at 2.19 and 2.06 mg/mL, respectively (Table 6.1). All DS-SQ combinations showed 
NO inhibitory effects in a dose-dependent manner, with IC50 values ranging from 
0.34–2.98 mg/mL. It was noteworthy that the IC50 values for all DS-SQ 
combinations were lower than those of the single extracts, except DS-SQ 9:1. DS-SQ 
8:2 demonstrated the strongest NO inhibitory effect, with the lowest IC50 value of 
0.34 mg/mL, and at 2.5 mg/mL the NO generation was reduced by 77.29 ± 1.85% 
(P<0.001). 
 
Table 6.1. IC50 values of DS, SQ and DS-SQ in inhibiting NO, TNF and MCP-1 
expressions induced by LPS on RAW 264.7 cells.  
DS: SQ  IC50 (mg/mL) 
NO TNF MCP-1 
0:10 2.06 1.71 1.87 
1:9 1.10 0.72 0.86 
2:8 1.39 1.29 1.94 
3:7 1.27 0.84 1.68 
4:6 1.26 1.07 1.72 
5:5 1.59 1.22 1.34 
6:4 1.11 0.80 0.99 
7:3 1.40 0.61 0.69 
8:2 0.34* 0.85* 0.97* 
9:1 2.98 1.02 1.49 
10:0 2.19 1.43 1.39 
*It was observed that DS-SQ 8:2 constantly produced low IC50
 values in the suppression of LPS stimulated NO, TNF, and 
MCP-1 release on RAW 264.6 cells. 
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6.2.3.2 Effects of DS, SQ and DS-SQ in inhibiting TNF release 
In the presence of LPS (50 ng/mL), a significant amount of TNF production was 
detected and reached 870.08 ± 44.22 pg/mL in DMSO vehicle solution. The LPS-
induced TNF production in RAW 264.7 cells were suppressed by DS (0.01-2.5 
mg/mL), SQ (1.25-2.5 mg/mL) and DS-SQ (0.1 – 5.0 mg/mL) extracts in a dose-
dependent manner with no cytotoxicity (Table 6.1). DS and SQ inhibited TNF 
production by 66.38 ± 9.92% (p<0.001) and 70.93 ± 0.33% (p<0.001) respectively at 
2.5 mg/mL, with IC50 values of 1.43 and 1.71 mg/mL, respectively (Table 6.1). 
Similarly, all DS-SQ combinations showed TNF inhibitory effects in a dose-
dependent manner with IC50 values ranging from 0.61–1.29 mg/mL. These values 
were all lower than that of DS and SQ single extract, suggesting stronger inhibitory 
effects by the combination. The inhibitory effect generated by DS-SQ 6:4 to 8:2 
appeared to be relatively stronger than others (IC50 from 0.61–0.85 mg/mL), with 
DS-SQ 7:3 (0.1–5 mg/mL) having the most potent effect with the lowest IC50 value 
at 0.61 mg/mL. DS-SQ 8:2 (0.1–5 mg/mL) which produced the greatest NO 
inhibitory effect, also showed a notable effect on TNF, with the inhibition by 
66.57±2.93% at 2.5 mg/mL (IC50 at 0.85 mg/mL). 
 
6.2.3.3 Effects of DS, SQ and DS-SQ in inhibiting MCP-1 release 
In the presence of LPS (50 ng/mL), a significant amount of MCP-1 production was 
detected and reached 2435.38 ± 156.45 pg/mL in DMSO vehice solution. Individual 
DS (0.01–2.5 mg/mL) and SQ (1–2.5 mg/mL) extracts suppressed LPS-induced 
MCP-1 induced in a dose-dependent manner, with the IC50 value at 1.39 and 1.87 
mg/mL, respectively (Table 6.1). At a concentration of 2.5 mg/mL, DS and SQ 
inhibited MCP-1 by 87.53±1.14% and 71.37±3.42% (P<0.01), respectively. All DS-
SQ combinations (except DS-SQ 2:8) demonstrated a greater MCP-1 suppressive 
effect than DS and SQ extract alone, with IC50 values ranging from 0.69 to 1.94 
mg/mL. Relatively stronger effects were found in the DS-SQ combinations that have 
more DS (6:4 to 9:1), with DS-SQ 7:3 demonstrating the strongest effect (IC50 value 
at 0.69 mg/mL). DS-SQ 8:2 (0.1 -5 mg/mL) also exerted a potent effect in MCP-1 
assay and produced an 89.75±4.73% MCP-1 reduction at 2.5 mg/mL. 
 
Chapter 6: Anti-inflammatory results 
149 | P a g e  
6.2.3.4 Optimised ratio of DS-SQ combinations in NO, TNF and MCP-1 assays 
Based on the above results from the NO, TNF and MCP-1 assays (as shown in Table 
6.2), DS-SQ 8:2 consistently produced low IC50 values in the suppression of the three 
inflammatory mediators (NO, TNF and MCP 1) and therefore, was selected as the 
optimal ratio for anti-inflammatory activity.  
 
Table 6.2. Inhibitory level of NO, TNF and MCP-1 for DS, SQ and DS-SQ 8:2 
on LPS-induced RAW 264.7 cells at the concentration of 2.5 mg/mL (mean ± 
SEM %). 
Tested extracts Inhibitory level of LPS-induced pro-inflammatory mediators 
NO TNF MCP-1 
DS 56.08 ± 1.00 66.38±9.92 87.53±1.14 
SQ 59.58 ± 2.42 70.93±0.33 71.37±3.42 
DS-SQ 8:2 77.29 ± 1.85 66.57±2.93 89.75±4.73 
 
6.2.3.5 Synergy determination of DS-SQ (8:2) 
Based on the dose-effect curves of the DS, SQ and DS-SQ 8:2 established (Figures 
6.3, 6.4 and 6.5), CI values at a specific effect level (e.g. half maximal effective dose, 
ED50) were calculated using ‘CompuSyn’ software with classical isobologram 
equation. Isobologram curves (Figures 6.3D, 6.4D and 6.5D) and CI-Fa curves 
(Figures 6.3E, 6.4E and 6.5E) were generated, so that CI values at different effect 
levels can be easily compared. 
 
As shown in Figure 6.3D, DS-SQ 8:2 isobologram produced a synergistic effect in 
inhibiting NO generation indicating that lower concentrations were required of the 
combination to reach the same effect level compared with that of the single extract at 
ED50, ED75 and ED90. Moreover, this synergistic effect was confirmed by CI-Fa 
curve of DS-SQ 8:2, with a Fa value > 0.4 (40% of the NO inhibition). Thus, it was 
calculated that DS-SQ 8:2 exerted synergistic effects when its concentration was 
higher than 1.24 mg/mL (Figure 6.3E). 
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Similarly, as shown in Figure 6.4D, the isobologram showed a synergistic interaction 
between DS-SQ 8:2 in inhibiting TNF at 90% inhibitory effect level (ED90). The CI-
Fa curve in Figure 6.4E suggested that there was synergistic effect when Fa value 
was greater than 0.523 for DS-SQ (8:2). The corresponded synergistic concentration 
for DS-SQ (8:2) was calculated to be above 1.89 mg/mL. 
 
In Figure 6.5D, isobologram showed synergistic interactions in DS-SQ 8:2 in 
inhibiting MCP-1 at 75 and 90% inhibitory effect levels (ED75 and ED90). Further, 
CI-Fa curve revealed that a biphasic effect – a synergistic effect was produced when 
DS-SQ 8:2 concentration was greater than 2.17 mg/mL and wise versa indicating an 
antagonistic effect (Fa < 0.7) (Figure 6.5E). 
 
Therefore, synergistic effects of DS-SQ in inhibiting LPS-induced NO, TNF and 
MCP-1 release on RAW 264.7 cells were observed which were determined by CI and 
isobologram analysis. The optimal ratio of DS-SQ was determined to be 8:2 which 
showed a significantly lower IC50 values than other tested ratios. The minimum 
concentrations of DS-SQ 8:2 to exert synergistic effects in inhibiting LPS induced 
NO, TNF and MCP-1 release were 1.24, 1.89 and 2.17 mg/mL, respectively (Table 
6.3). 
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Figure 6.3 Inhibitory effects of DS, SQ and DS-SQ (8:2) on LPS-induced NO production are shown in A, B and C, respectively. D, 
isobologram curves of DS, SQ and DS-SQ. E, CI values were plotted as a function of fractional suppression of NO production (Fa) by 
‘Calcusync’ software. A dotted line is the reference line, where CI value equals 1; a solid line represents CI values at different Fa. Fa 
values correspond to % suppression. **P<0.01 and *** P<0.001 as compared to LPS stimulation only by one-way ANOVA. 
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Figure 6.4 Inhibitory effects of DS, SQ and DS-SQ (8:2) on TNF production (%) versus concentration (mg/mL) as shown in A, B, and 
C, respectively. D, isobologram curves for DS, SQ and DS-SQ 82 on TNF ELISA assay. E, CI values verses DS-SQ 82 TNF inhibition 
effect (Fa). 
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Figure 6.5 Inhibitory effects of DS, SQ and DS-SQ (8:2) on MCP-1 production (%) versus concentration (mg/mL) as shown in A, B and 
C, respectively. D, Isobologram curves for DS, SQ and DS-SQ 82 on MCP-1 ELISA assay. E, CI values verses DS-SQ 82 MCP-1 
inhibition effect (Fa).  
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Table 6.3. Dose range of DS-SQ (8:2) and DT-Rd (7:3) that showed synergistic effect (CI 
<1) analysed by CalcuSyn. 
Synergy concentration range  
Combination NO assay TNF ELISA assay MCP-1 ELISA assay 
DS-SQ (8:2)  >1.24 mg/mL > 1.89 mg/mL >2.17 mg/mL 
DT-Rd (7:3) >22.85 μg/mL > 2.22 μg/mL < 0.053 μg/mL 
Data was obtained from CalcuSyn 
 
6.2.4 Effects of chemical compounds from DS and SQ on inflammatory 
mediators in cultured RAW 264.7 cells 
6.2.4.1 Cytotoxicity of chemical compounds from DS and SQ 
The cytotoxicity of the selected chemical compounds from DS and SQ, including DSS, SA, 
SB, CT, TI, DT, TIIA, NR1, Rg1, Re, Rb1, Rb2, Rg2 and Rd was screened on MTT assay. As 
shown in Figures 6.6 and 6.7, the nontoxicity concentration range for CT and T1, DT, and 
TIIA were 0–31.25 µM, 0–15.63 µM and 0–15 µM, respectively. No cytotoxicity was 
observed for the chemical compounds from SQ, and the observed nontoxicity concentration 
range for NR1, Rg1, Re, Rb1, Rb2, Rg2, and Rd were 0.1–1000 µM, 10–1000 µM, 3.25–100 
µM, 25–200 µM, 12.50–400 µM, 1–200 µM and 0.1–100 µM, respectively. 
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Figure 6.6 Cell viability (% relative to control) verses concentrations (µM) for chemical 
compounds from DS on RAW264.7 cells tested by MTT assay. A, DSS. B, SA. C, SB. D, 
DT. E, CT. F, T1. G, TIIA. 
 
 
Figure 6.7 Cell viability (% relative to control) verses concentrations (µM) for chemical 
compounds from SQ on RAW264.7 cells tested by MTT assay. A, NR1. B, Rg1. C, Re. D, 
Rb1. E, Rb2. F, Rg2. G, Rd. 
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6.2.4.2 Effects of bioactive compounds of DS and SQ on NO production  
Most of the bioactive compounds tested demonstrated a dose-dependent inhibition of NO 
production. SB (1–1000µM) and Rg1 (1–800µM), the two most abundant compounds of DS 
and SQ respectively, producted a maximum reduction of NO generation by 72.16±5.8% and 
18.67 ±3.77%, respectively, with IC50 value for SB was 108.30 μM (Table 6.4). By contrast, 
the relatively lipid-soluble compounds group (DT, CT, T1, Rg2 and Rd) showed more potent 
NO inhibition activities (IC50 ranging from 4.64–116.80) compared to their water-soluble 
compound counterparts (NR1, Rg1, Rb1, DSS, SA and SB) as evidenced by significantly 
lower IC50 values (ranged from 26.02–144.10 μM) (P<0.5) (Table 5.4). DT (3.91–15.63 µM) 
and Rd (10–100 µM) were found to be key compounds responsible for NO inhibition 
(95.16±0.25% and 88.00±2.14% at the maximum, with IC50 values at 4.64 and 7.89 µM, 
respectively), and were comparable to that of the positive control dihydrochloride (IC50 = 5.53 
µM) (P>0.05). 
 
6.2.4.3 Effects of bioactive compounds of DS and SQ on TNF production  
Similar to the results in the NO assay, the relatively lipid-soluble compounds (CT, DT, TI, 
Rb2, Rg2, and Rd) caused a dose-dependent inhibition of LPS-induced TNF production with 
the IC50 ranging from 1.98 to 28.64 µM without cytotoxicity (Table 6.4). With the exception 
of Rb1, the inhibitory effects of the relatively water-soluble compounds (DSS, SA, SB, NR1, 
Rg1, Re) did not reach 50% even after the concentration was raised up to 1000 µM. CT (10–
31.25 µM) and Rd (0.1–200 μM) were found to be the most potent compounds in inhibiting 
TNF by 93.28±9.24% and 86.84±1.61% at the maximum, with IC50 at 1.98 and 9.79 μM, 
respectively. DT (20–31.25 μM) exerted a potent inhibitory effect (85.70±2.49% at the 
maximum). 
 
6.2.4.4 Effects of bioactive compounds of DS and SQ on MCP-1 production 
In the MCP-1 assay, only CT, DT and Rd caused inhibitory effect on MCP-1 generation, with 
IC50 values at 11.32, 13.97 and 36.00 μM, respectively. Other tested compounds did not show 
any significant MCP-1 inhibitory effect (P>0.05). Among the three bioactive compounds, DT 
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(20 µM) and Rd (100 µM) produced potent inhibitory effects (82.26±7.91% and 56.57±5.98%, 
respectively). 
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Table 6.4 IC50 value of the tested compounds from DS and SQ on NO, TNF and MCP-1 assay. 
 DS compounds IC50 (μM)  SQ 
compounds 
IC50 (µM) 
NO  TNF-α MCP-1 NO TNF-α MCP-1 
Relatively 
water-soluble 
components  
DSS 144.10 NA NA Relatively 
water-soluble 
components  
NR1 92.05 NA NA 
SA 90.23 NA NA Rg1 NA NA NA 
SB 108.30 NA NA Re 26.02 NA NA 
Relatively 
lipid-soluble 
components  
CT 116.80  1.98 11.32 Rb1 53.9 71.36 NA 
DT 4.64 24.25 13.97 Relatively 
lipid-soluble 
components  
Rb2 134.90 28.44 NA 
T1 5.45 7.627 NA Rg2 66.41 28.64 NA 
TIIA NA NA NA Rd 7.89 9.79 36.00 
NA: the inhibitory effect did not reach 50%. 
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6.2.4.5 Interactions between DT and Rd on NO, TNF and MCP-1 production 
DT from DS and Rd from SQ were found to be the most potent bioactive compounds 
in inhibiting LPS-induced NO, TNF and MCP-1 generation (Table 6.4), and thus 
were evaluated for their potential synergistic interactions.  
The IC50 values for the DT-Rd combinations in various ratios (w:w, 1:9, 2:8…8:2, 
9:1) ranged from 2.08 to 36.65 µg/mL (Table 6.5). DT-Rd combinations with the 
ratio of 1:9 to 5:5 showed significantly higher IC50 values (12.47–36.65 µg/mL) in 
inhibiting NO than other combinations (IC50 values from 1.28 to 7.36 µg/mL) 
(P<0.05). The NO inhibitory effect for DT-Rd combinations became stronger when 
the DT proportion increased, with DT-Rd ratios from 7:3 to 9:1 showing comparable 
IC50 values as DT on its own.  
 
A similar trend was found for TNF inhibition; the combinations with a higher 
proportion of DT (7:3 to 9:1) produced a greater inhibitory effects (IC50 values 
ranging from 2.01 to 9.10 µg/mL) than those with a lower DT ratio (IC50 values 
ranging from 9.41 to 35.56 µg/mL). Among them, DT-Rd 7:3 showed the greatest 
inhibitiory effect, with an IC50 value of 2.01 μg/mL, which was significantly lower 
than that of DT and Rd on their own. 
 
In the MCP-1 assay, all DT-Rd combinations showed significantly higher IC50 values 
(12.21–92.15 µg/mL) than that of DT (IC50 = 3.89 µg/mL) on its own. In spite of this, 
DT-Rd 7:3 exhibited significantly lower IC50 (12.21 µg/mL) than Rd on its own 
(IC50=34.10 μg/mL), suggesting a greatest inhibitory effect among all DT-Rd 
combinations. 
 
6.2.4.6 Optimised ratio of DT-Rd combinations on NO, TNF and MCP-1 
production 
As shown in Figures 6.8D and E, both isobologram and CI-Fa curve suggested that 
an antagonistic effect was largely observed for DT-Rd (7:3) combination in 
inhibiting NO (CI values was at 1.79 when Fa equals to 0.5). Similar to TNF 
bioassay, an antagonistic effect was largely observed, with a synergistic effect 
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predicted when the concentration of DT-Rd (7:3) was higher than 103.92 μg/mL (Fa > 
0.744) (Figures 6.9D and E). For the inhibition of MCP-1, slight synergistic effect 
was shown when Fa was lower than 0.584 (Figure 6.10D and E). The interaction 
tended to be additive as Fa increased to 0.6. Antagonism was observed and predicted 
to be stronger when Fa was higher than 0.6 (the concentration for DT-Rd was 
calculated to be higher than 12.65 μg/mL). 
 
Table 6.5 IC50 value of DT-Rd combination using NO, TNF-α and MCP-1 
ELISA assay. 
DT-Rd ratio  IC50 value (µg/mL) 
NO TNF-α MCP-1 
0:10 7.47 12.06 34.10 
1:9 33.72 31.20 48.50 
2:8 36.65 35.56 56.35 
3:7 26.66 33.46 92.15 
4:6 25.46 25.67 29.03 
5:5 12.47 9.41 34.47 
6:4 7.36 31.03 47.13 
7:3 2.08* 2.01* 12.21* 
8:2 2.53 2.46 16.06 
9:1 1.28 9.10 14.52 
10:0 1.29 87.14 3.89 
*It was observed that DT-Rd 7:3 constantly produced low IC50
 values in the suppression of LPS stimulated NO, TNF, and 
MCP-1 release on RAW 264.6 cells. 
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Figure 6.8 Inhibitory effects of DT, Rd and DT-Rd (7:3) on NO production (%) versus concentration (µg/mL) as shown in A, B, and C, 
respectively. D, Isobologram curves for DT, Rd and DT-Rd (7:3) on NO. E, CI values verses NO inhibition effect (Fa) by ‘Calcusync’ software. 
(Dotted line is the reference line, where CI value equals 1; solid line represents CI values at different Fa). 
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Figure 6.9 Inhibitory effects of DT, Rd and DT-Rd (7:3) on TNF production (%) versus concentration (µg/mL) as shown in A, B, and C, 
respectively. D, Isobologram curves for DT, Rd and DT-Rd (7:3) on TNF. E, CI values verses TNF inhibition effect (Fa) by ‘Calcusync’ 
software. (Dotted line is the reference line, where CI value equals 1; solid line represents CI values at different Fa). 
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Figure 6.10 Inhibitory effects of DT, Rd and DT-Rd (7:3) on MCP-1 production (%) versus concentration (µg/mL) as shown in A, B, and C, 
respectively. D, Isobologram curves for DT, Rd and DT-Rd (7:3) on MCP-1. E, CI values verses MCP-1 inhibition effect (Fa) by ‘Calcusync’ 
software. (Dotted line is the reference line, where CI value equals 1; solid line represents CI values at different Fa). 
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6.3 Summary of synergistic effects of DS-SQ on anti-
inflammation  
This study evaluated the combination effects of DS-SQ in nine different ratios on 
anti-inflammatory activities, suggesting that DS-SQ 8:2 has synergistically enhanced 
activity in inhibiting LPS induced NO, TNF and MCP-1 compared with single 
extracts on RAW264.7 cells analysed by CI and isobologram models (CI <1 at 1.24-
2.5, 1.89-5 and 2.17-5 mg/mL, respectievly). This finding that the herb pair 
combination is more effective than the individual herb supported pharmacopoeial 
descriptions of the traditional use of DS-SQ. Meanwhile, chemical compounds 
identified from two herbs were screened on NO, TNF and MCP-1 assays, which 
revealed that the lipophilic compounds generally showed stronger effect than 
hydrophilic compounds. The lipophilic compounds may be the key contributor to the 
anti-inflammatory activities of two herbal extracts. DT and Rd, two lipophilic 
compounds derived from DS and SQ, respectively, were found to be the most potent 
compounds in inhibiting NO, TNF and MCP-1. Thus, a compound formula of DT-Rd 
7:3 was formed and tested on the same bioassays, and our results showed that it 
significantly inhibited NO, TNF and MCP-1 at various concentration ranges. 
However, antagonistic interactions were largely observed for this combination in 
inhibiting NO and TNF (CI>1 at 1-32 and 2-67 μg/mL, respectively). For the 
inhibition of MCP-1, the effect was tend to be additive for DT-Rd 7:3 (CI was close 
to 1 at 1-32 μg/mL). This study provided a scientific-based insight into the 
synergistic actions in DS-SQ combination in protecting endothelial function through 
anti-inflammatory activity. 
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Chapter 7: Results: Synergistic Effects of DS and SQ on 
Angiogenesis in EAhy 926 Cells 
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7.1 Introduction 
Angiogenesis is defined as the formation of new vessels from existing vasculature 
(Potente et al., 2011). It is an essential physiological process for maintaining tissue 
homeostasis, facilitating nutrient transportation and promoting tissue growth and 
repair (Potente et al., 2011). In pathological disease progression, such as cancer, 
diabetic retinopathies, age-related macular degeneration and atherosclerosis, 
excessive and damaging angiogenesis occurs. However, in diseases such as 
ischaemic vascular disease, insufficient or improper angiogenesis can lead to 
complicated conditions such as mycardial infarction (MI) and ischaemic stroke, 
which are associated with inadequate blood supply (Potente et al., 2011). Therefore, 
therapeutic angiogenesis has been developed as a novel approach for facilitating 
blood vessel repair and improving the outcome of ischaemic CCVD. It stimulates the 
endothelium to improve perfusion, deliver survival factors to sites of tissue repair, 
mobilise regenerative stem cell populations, and ultimately restore form and function 
to the tissue (The Angiogensis Foudation, 2016). It has already been shown that the 
stimulation of angiogenesis using angiogenesis peptides has produced encouraging 
clinical results in treating coronary artery disease (Lay et al., 2003; Fan et al., 2006a). 
 
Increasing evidence has suggested the importance of Hcy as a new and important risk 
factor for vascular diseases, which has been shown to impair angiogenesis coupled 
with Ado. The anti-angiogenic effects of Hcy and Ado was associated with 
MEK/ERK pathways (Zhang et al., 2011b; Kam et al., 2015). Additionally, it has 
been well studied that the PI3K pathway plays an essential role in numerous cellular 
functions, including proliferation, adhesion, migration and the formation of blood 
vessels (Karar & Maity, 2011). 
 
An herbal combination of DS-SQ is widely used in Asian countries for promoting 
blood circulation and wound healing. Pharmacological studies have validated the 
angiogenic activities of these herbs as a single extract. However, studies on the 
combinational effects on angiogenesis remain lacking. Whether there are any 
synergistic interactions acting on angiogenesis is still unknown. Therefore, this 
chapter reports the results of the combinational activity of DS-SQ on promoting 
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endothelial angiogenesis against the damage from Hcy and Ado via promoting cell 
growth, cell migration (wound healing) and promoting tube formation. Further, their 
synergistic interactions were analysed by CI and isobologram model. The actions of 
their chemical compounds on angiogenesis were demonstrated. Finally, the possible 
associated signalling pathway for DS-SQ on angiogenesis was investigated to further 
elucidate their mechanism at molecular level. 
 
This chapter reported the results of the synergistic interactions of DS-SQ in 
promoting impaired endothelial cell growth, scratch wound closure and tube 
formation induced by Hcy and Ado. In addition, the actions of DS-SQ were 
associated with the activation of MEK, ERK and PI3K signalling pathways. SA and 
NR1 were the key bioactives contributing to the cell proliferation actions of DS-SQ. 
 
7.2 Results4 
7.2.1 Effects of Hcy and Ado on endothelial cell growth 
Hcy promoted a small increment in cell growth at 0.5 mM (Figure 7.1A), whereas 
Ado (up to 0.5 mM) showed no significant influences on cell growth (Figure 7.1B). 
However, the growth was significantly attenuated in a concentration-dependent 
manner when treated with both Hcy and Ado (0.1–0.5 mM) (Figure 7.1C). Further, 
the inhibition in EAhy926 cell growth caused by Hcy and Ado was dependent on 
incubation time (Figure 7.1D). Hcy and Ado both at 0.5 mM with incubation time at 
72 hours can cause around 60% cell growth inhibition, which is why the 72 hours 
time point was chosen for Hcy and Ado impaired cell proliferation model in this 
study. 
 
                                                 
4 The establishment of the Hcy-Ado impaired cell proliferation model as shown in Figure 7.1 is 
published in Kam, A., Razmovski-Naumovski, V., Zhou, X., Truong, J., Chan, K. (2015). Nucleoside 
transport inhibition by dipyridamole prevents angiogenesis impairment by homocysteine and 
adenosine. Journal of Pharmacy & Pharmaceutical Sciences, 18 (5):871–81.  
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Figure. 7.1 Effects of Hcy and Ado on endothelial cell growth as determined by 
crystal violet staining, following treatments with (A) Hcy, (B) Ado, and (C) Hcy plus 
Ado in EAhy926 cells for 96 hours. (D) Time-dependent effects of Hcy (0.5 mM) 
plus Ado (0.5 mM) on the growth of EAhy926 cells. Cell growth was expressed as 
fold change relative to control. All results were expressed as mean ± SEM from three 
separate experiments in triplicate. *P < 0.05 compared to control. 
 
7.2.2 Effects of DS, SQ and DS-SQ on Hcy-mediated angiogenesis in 
EAhy 926 cells 
7.2.2.1 Effects of DS, SQ and DS-SQ on cell growth 
As shown in Figures 7.2A and B, SQ significantly improved cell growth at 
concentrations greater than 200 μg/mL (P<0.05). However, DS did not show any 
significant improvements (P>0.05). DS-SQ combinations at all ratios, except at 9:1, 
showed significant improvements on impaired cell growth in a concentration-
dependent manner (Figure 7.3). DS-SQ ratios from 1:9 to 4:6 significantly promoted 
cell growth at concentrations 100–300 μg/mL, while ratios from 5:5 to 2:8 showed 
significant improvements at concentrations from 200–300 μg/mL. Among all these 
combinations, DS-SQ extracts at 1:9, 2:8 and 3:7 ratios demonstrated prominent 
protective effects when used at a dose range greater than 100 μg/mL (P<0.05). When 
the activity of extracts at the same dosage level was compared (see Figure 7.4), DS-
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SQ at the ratio from 2:8 to 3:7 (when DS occupies a smaller proportion in the 
combination) exhibited stronger cell proliferation activity than with other ratios at all 
concentration levels. Therefore, DS-SQ combinations at 2:8 and 3:7 ratios showed 
the strongest cell growth activity against the damage from Hcy and Ado at all dosage 
levels tested. 
 
Figure 7.2 Cell growth (relative to control) concentration curves for DS (A), SQ (B), 
DS-SQ 2:8 (C) and DS-SQ 3:7 (D) aqueous extract on cell proliferation assay. # 
P<0.05 compared with blank control (no Hcy or Ado); * P<0.5 compared with Hcy 
and Ado stimulation. The statistic is analysed by one-way ANOVA analysis on 
GraphPad Prism 5. 
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Figure 7.3 Cell growth (relative to control), concentration curves for DS-SQ combination at nine ratios from 1:9 (A), 2:8 (B)… to 9:1 (I) on cell 
proliferation assay. # P<0.05 compared with blank control (no Hcy or Ado); * P<0.5 compared with Hcy and Ado stimulation. The statistic is 
analysed by one-way ANOVA analysis on GraphPad Prism 5. 
Chapter 7: Angiogenesis results  
171 | P a g e  
 
 
 
Figure 7.4. Cell growth activity comparison among different ratios of DS-SQ 
combinations at the same concentration levels: 100 (A), 150 (B), 200 (C) and 300 
μg/mL (D). 
 
7.2.2.2 Effects of DS, SQ and DS-SQ on wound healing 
As demonstrated in Figures 7.5A and 5F, treatment with Hcy and Ado significantly 
inhibited the scratch wound closure in 24 h (P<0.05). However, DS, SQ, DS-SQ 2:8 
and DS-SQ 3:7 significantly restored the impaired wound healing activity in a 
concentration-dependent manner against Hcy and Ado (Figure 7.5F). The effects 
from DS and SQ were significant (P<0.05) when concentration was up to 300 µg/mL. 
However, lower concentration was required for DS-SQ 3:7 and DS-SQ 2:8 to the 
significance (P<0.05) at 200 µg/mL and 100 µg/mL, respectively. 
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Figure 7.5 DS, SQ, and DS-SQ on EAhy 926 endothelial cell wound scratch 
assay.The photos of EAhy926 cells after wounding at 0 h and 24 h with various 
treatments were taken and segmented automatically by TScratch, with identical 
settings for bright-field acquired. The percentage of the open wound area for each 
sample generated by TScratch was recorded, and the percentage of open wound area 
was calculated by: the percentage of open area at 24 h/the percentage of open area at 
0 h* 100%. (A) EAhy 926 cells with medium only (without any treatment) after 
wounding 0 h (top-left) and 24 h after wounding (bottom-left), and the cells treated 
with Hcy and Ado after wounding at 0h (top-right) and 24 h (bottom-right). (B) 
EAhy 926 cells treated with DS at the dosage from 50 to 300 µg/mL (from left to 
right) after wounding at 0 h (top) and 24 h (bottom). (C) EAhy 926 cells treated with 
SQ at the dosage from 50 to 300 µg/mL (from left to right) after wounding at 0 h 
(top) and 24 h (bottom). (D) EAhy 926 cells treated with DS-SQ 2:8 at the dosage 
from 50 to 300 µg/mL (from left to right) after wounding at 0 h (top) and 24 h 
(bottom). (E) EAhy 926 cells treated with DS-SQ 3:7 at the dosage from 50 to 300 
µg/mL (from left to right) after wounding at 0 h (top) and 24 h (bottom). (F) Statistic 
analysis for DS, SQ and DS-SQ 2:8 and 3:7 on wound healing activities in EAhy 926 
cells induced by Hcy and Ado. All results were expressed as mean ± S.E.M. from 
over three separate experiments. # P<0.05 compared with blank. * P<0.05 compared 
to Hcy plus Ado treated group. ** P<0.01 compared to Hcy plus Ado treated group. 
*** P<0.001 compared to Hcy plus Ado treated group. 
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7.2.2.3 Effects of DS-SQ on tube formation 
When EAhy 926 cells were cultured on Matri-gel, many tube-like structures were 
observed after 24 h incubation, as shown in Figure 7.6A. Hcy and Ado significantly 
reduced the tube-like structures and junctions of cells compared to the control 
(p<0.05), indicating the inhibition of tube formation (Figures 7.6A and B). When the 
EAhy926 cells were treated simultaneously with 50 to 300 µg/mL DS, no significant 
improvement was observed (P>0.05). As the tube formation photo of DS at 300 
µg/mL showed blurry precipitants and the data could not be analysed by Image J 
angiogenesis software, it was not included in the quantification of junctions in Figure 
7.6B. Similarly, SQ did not show any significant effect compared to the Hcy and 
Ado group. However, DS-SQ 2:8 and 3:7 at 200 and 300 µg/mL significantly 
restored tube formation impaired by Hcy and Ado (Figures 7.6A, 6B). 
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Figure 7.6 Effects of DS, SQ, DS-SQ 2:8 and DS-SQ 3:7 on angiogenic activities in 
EAhy 926 cells induced by Hcy and Ado. Angiogenic activities were analysed in 
EAhy 926 cells exposed to Hcy, Ado and herb samples for 20 h in serum-free 
medium. (A) Photo view of blank, Hcy + Ado and various herb treatment on tube 
formation in EAhy 926 cells.  
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Figure 7.6 Effects of DS, SQ, DS-SQ 2:8 and DS-SQ 3:7 on angiogenic activities in 
EAhy 926 cells induced by Hcy and Ado. Angiogenic activities were analysed in 
EAhy 926 cells exposed to Hcy, Ado and herb samples for 20 h in serum-free 
medium. (B) Statistical analysis of number of junction per field for each sample, 
generated by angiogenesis analyser, Image J. All results were expressed as mean ± 
SD from over three independent experiments. # P<0.5 Hcy + Ado stimulation 
compared with blank control. * P<0.5 compared with Hcy + Ado stimulation. *** 
P<0.001 compared with Hcy + Ado stimulation. 
 
7.2.2.4 Synergic effects of DS-SQ on cell proliferation, wound healing and 
tube formation 
As shown in the concentration-effect curves of cell proliferation activity of DS, SQ, 
DS-SQ (2:8) and DS-SQ (3:7) (Figures 7.7A and D), stronger effects of 2:8 and 3:7 
were constantly observed, compared to DS and SQ at all tested concentrations. CI 
model revealed that the effects in the combination of 2:8 and 3:7 were synergistically 
enhanced at all effect levels (at all tested concentrations) (Figure 7.7B and E). To 
confirm the synergistic interaction observed, isobologram analysis was performed. 
As shown in Figures 7.7C and 7.7F, synergism was shown for DS-SQ 2:8 and 3:7, 
when Fa was at 0.5, 0.7 and 0.8, where the dots represented the dose for 
combinations were located within the inner area of the dose-axes of the individual 
extract. 
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For wound healing activity, the concentration-effect curves for DS, SQ, DS-SQ (2:8) 
and DS-SQ (3:7) analysed by CalcuSyn (as shown in Figures 7.8A and D), stronger 
effects of 2:8 and 3:7 were constantly observed, compared to DS and SQ at all tested 
concentrations. A general synergistic effect was also observed for 2:8 and 3:7 when 
the wound healing effect level (Fa) was higher than 38% and 41%, respectively 
(Figure 7.8B and E). There was synergistic enhanced activity for wound healing in 
2:8 and 3:7 when the concentrations for the combination were greater than 50 and 
100 µg/mL, respectively. 
 
For the combinational activity of DS-SQ 2:8 and 3:7 on tube formation assay, the 
effects (tube junction number relative to control) of 2:8 and 3:7 were constantly 
higher than the single extract at all tested concentrations (Figure 7.9A and D). 
Moreover, CI model revealed that the combinational effects of 2:8 and 3:7 were 
synergistically enhanced at all effect levels (at all tested concentrations) (Figure 7.9B 
and E). To confirm the synergistic interaction observed, isobologram analysis was 
performed. As shown in Figures 7.9C and F, synergism was shown for DS-SQ 2:8 
and 3:7 when Fa was at 0.5, 0.75 and 0.9, where the dots represented the dose for 
combinations located within the inner area of the dose-axes of the individual extract. 
Therefore, the results demonstrated that the combinational effects were DS-SQ at 2:8 
and 3:7, and were synergistically enhanced when acting on promoting in vitro 
anagiogensis against Hcy and Ado on EAhy 926 cells analysed by CI and 
isobologram. 
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Figure 7.7 Synergism analysis of DS-SQ 2:8 and 3:7 on restoring cell proliferation against Hcy and Ado in EAhy 926 cells. (A) Concentration-
effect curves of cell proliferation activity of DS, SQ and DS-SQ (2:8). (B)CI values were plotted as a function of cell proliferation activity (Fa) 
by ‘Calcusyn’ software. Solid line is the reference line, where CI value equals 1. The curve with spots represents CI values at different Fa. (C), 
isobolograms of DS-SQ 2:8 at different effect levels (50%, 70% and 80%). (D), Dose-effect curves of cell proliferation activity of DS, SQ and 
DS-SQ (3:7). (E), CI values were plotted as a function of cell proliferation (Fa) by ‘Calcusync’ software. Solid line is the reference line, where 
CI value equals 1. The curve with spots represents CI values at different Fa. (F), isobolograms of DS-SQ 3:7 at different effect levels (50%, 70% 
and 80%). 
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Figure 7.8. Synergism analysis of DS-SQ 2:8 and 3:7 on restoring cell wound scratch against Hcy and Ado in EAhy 926 cells. (A), 
Concentration-effect curves of cell wound healing activity of DS, SQ and DS-SQ (2:8). (B), Log (CI) values were plotted as a function of cell 
wound healing activity (Fa) by ‘Calcusyn’ software. Solid line is the reference line, where Log (CI) value equals 0 (CI = 1). The curve with spots 
represents CI values at different Fa. (C), Isobolograms of DS-SQ 2:8 at different effect levels (50%, 75% and 90%). (D), Concentration-effect 
curves of cell wound healing activity of DS, SQ and DS-SQ (3:7). (E), Log (CI) values were plotted as a function of cell wound healing (Fa) by 
‘Calcusync’ software. Solid line is the reference line, where LogCI value equals to 0 (CI = 1). The curve with spots represents CI values at 
different Fa. (F), isobolograms of DS-SQ 3:7 at different effect levels (50%, 75% and 90%). 
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Figure 7.9 Synergism analysis of DS-SQ 2:8 and 3:7 on restoring endothelial tube formation against Hcy and Ado in EAhy 926 cells. (A) 
Concentration-effect curves of tube formation activity of DS, SQ and DS-SQ (2:8). (B), CI values were plotted as a function of tube formation 
activity (Fa) by ‘Calcusyn’ software. Solid line is the reference line, where CI = 1. The curve with spots represents CI values at different Fa. (C), 
isobolograms of DS-SQ 2:8 at different effect levels (50%, 75% and 90%). (D), Concentration-effect curves of tube formation activity of DS, SQ 
and DS-SQ (3:7). (E), CI values were plotted as a function of tube formation (Fa) by ‘Calcusync’ software. Solid line is the reference line, where 
CI value equals 1. The curve with spots represents CI values at different Fa. (F), isobolograms of DS-SQ 3:7 at different effect levels (50%, 75% 
and 90%). 
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7.2.2.5 Mechanistic pathways for DS-SQ on Hcy-mediated angiogenesis in 
EAhy 926 cells 
To investigate the combinational effects of DS-SQ on promoting in vitro 
angiogenesis against Hcy and Ado via PI3K, eNOS, ERK/MEK pathways, the 
inhibitor of each pathway was subjected to the wound scratch assay and the results 
were analysed. First, wortmannin (a PI3K inhibitor), L-NIO dihydrochloride (eNOS 
inhibitor), PD98059 (a specific inhibitor of ERK1/2) or U0126 (MEK inhibitor) 
alone did not show any significant impairment or promotion on wound healing in 
EAhy 926 cells. However, the co-incubation of wortmannin, U0126 and PD98059 
significantly reversed the wound healing activity of the DS-SQ 2:8 (Figures 7.10A, C 
and D). Only L-NIO dihydrochloride did not affect the wound closure activity of DS-
SQ 2:8 (Figure 7.10B). Thus, it is assumed that the angiogenic activity of DS-SQ 2:8 
against Hcy and Ado was associated with PI3K and ERK/MEK signalling pathway. 
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Figure 7.10 Possible associated signalling pathway of DS-SQ 2:8 in EAhy926 cells 
treated with Hcy and Ado inhibited cell growth. Effects of (A) wortmannin, (B) L-
NIO dihydrochloride, (C) U0126 and (D) PD 98059 on EAhy926 cell growth 
affected by Hcy and Ado. EAhy926 cells were exposed to Hcy, Ado, DS-SQ 2:8 
and/or each inhibitor for 24 h in serum-free medium after wound scratch. The open 
wound area before and after the treatment was analysed by Tscratch software. The 
percentage of open wound area was calculated by: the percentage of open area at 24 
h/the percentage of open area at 0 h * 100%. All results were expressed as mean ± 
S.E.M. from three separate experiments in triplicate. # P < 0.05 compared to control. 
* P < 0.05 compared to Hcy plus Ado treated group. ** P < 0.01 compared to Hcy 
and Ado treated group. 
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7.2.3 Angiogenic effects of chemical compounds from DS and SQ on 
Hcy-mediated angiogenesis on EAhy 926 cells 
Fourteen key bioactive compounds from DS and SQ — including DSS, SA, SB, CT, 
TI, DT, TIIA, NR1, Rg1, Re, Rb1, Rb2, Rd, and Rg2 — were screened for cell 
proliferation activity using crystal violet staining assay. Our results demonstrated that 
only SA and NR1 improved endothelial cell proliferation in a concentration-
dependent manner (Figures 7.11, 7.12 and 7.13), and the significance improvement 
was shown at above 100 μM and 300 μM, respectively (P<0.05). However, when SA 
and NR1 were further tested on wound scratch and tube formation assay, SA and 
NR1 did not show any significant effects at all on tested concentrations (P>0.05). 
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Figure 7.11. Cell growth (relative to control)-dose-response curves for SA (A) and NR1 (B) from DS and SQ, respectively. SA showed 
significant improvements since 100 μM, while NR1 extract significantly improved cell growth at dose of 300 μM. # Significant from 
blank control, *P<0.5 by one-way ANOVA analysis compared with Hcy-Ado stimulation only. 
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Figure 7.12. Cell growth (relative to control)-dose curves for DSS (A), SB (B), CT (C), DT (D), T1 (E) and TIIA (F) from DS on cell 
proliferation assay. None showed significant cell proliferation activity. 
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Figure 7.13. Cell growth (relative to control)-dose curves for Rg1 (A), Re (B), Rb1 (C), Rb2 (D), Rg2 (E), and Rd (F) from SQ on cell 
proliferation assay. None showed significant cell proliferation activity. 
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7.3 Summary of angiogenic effects of DS-SQ  
The results presented in this chapter demonstrate that DS-SQ at ratios of 2:8 and 3:7 showed 
significant effects in promoting impaired endothelial cell growth, scratch wound closure and 
tube formation induced by Hcy and Ado. CI and isobologram analysis suggested a synergistic 
interaction for DS-SQ 2:8 and 3:7 ratio at all tested concentrations (50–300 μg/mL). Further, 
the actions of DS-SQ were likely to involve the activation of MEK, ERK and PI3K signalling 
pathways. Studies from purified compounds indicated that SA and NR1 were involved in the 
cell proliferation actions of DS-SQ; other tested compounds showed no significant effect 
when used singularly. Thus, the overall results supported the traditional use of whole extract 
DS-SQ combination in treating Hcy-associated relevant vascular complications. 
 
The application of statistical analysis of combination effects on DS-SQ, using CI and 
isobologram model, provided an example for future studies of synergistic actions of complex 
herbal formulations. Further study may reveal important molecular mechanisms involved in 
the actions of DS-SQ and be used as a basis for developing relevant therapeutic applications. 
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Chapter 8: Results: Synergistic Effects of DS and SQ on 
Cell Survival from cellular toxicity and oxidative stress in 
EAhy 926 Cells 
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8.1 Introduction 
Endothelial dysfunction is an early marker of vascular dysfunction prior to the 
development of vascular structural changes and clinical symptoms, contributing to 
the progression of atherosclerotic plaques and leading to various types of vascular 
diseases (Bonetti et al., 2003; Kam et al., 2012; De Caterina, 2000). Additionally, 
improper function of endothelium resulted in uncontrolled cell death (excessive 
apoptosis), which is reported to be associated with atherosclerosis and thrombosis 
(Endemann & Schiffrin, 2004; Dimmeler et al., 1998; Tricot et al., 2000). 
Endothelial cell apoptosis has been detected in atherosclerotic plaques and provides 
an important step in the transition from a stable atherosclerotic plaque to a plaque 
with overlying thrombosis (Tricot et al., 2000). 
 
It has been repeatedly demonstrated that an elevated level of Hcy in blood 
(hyperhomocysteinaemia) is an independent risk factor for atherosclerotic vascular 
disease affecting the coronary, cerebral and peripheral arteries (Boushey et al., 1995; 
Hankey & Eikelboom, 1999; Fryer et al., 1993; Graham et al., 1997). Coupled with 
Ado it favours the accumulation of S-adenosylhomocysteine that leads to cellular 
DNA hypomethylation (James et al., 2002; Gopisetty et al., 2006), which in turn 
disregulates cell survival and results in cellular injury (Gopisetty et al., 2006). 
Previous literature has reported that TNF not only has a direct impact on endothelial 
dysfunction (down-regulating eNOS expression), but is also associated with 
endothelial cell apoptosis by modulating the interactions of cell apoptosis 
suppressors and inducers (Zhang et al., 2009a; Sprague & Khalil, 2009). Several in 
vitro studies reported that Hcy and TNF with Ado significantly impaired endothelial 
cell survival and induced cell apoptosis (Kam et al., 2012, 2014). 
 
ROS is another important biomarker for detecting endothelial cell death in 
endothelial dysfunction. It is known to induce endothelial cell death by modulating a 
series of intracellular signalling pathways (Thannickal & Fanburg, 2000; Kojda & 
Harrison, 1999). For example, it can direct quenching eNO and form peroxynitrite, 
which triggers endothelium dysfunction (Förstermann, 2010; Simon et al., 2000; 
Taniyama & Griendling, 2003). H2O2 is the major source of endogenous ROS 
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responsible for oxidative stress, and is mainly generated during hypoxia and IR 
injury (Ballinger et al., 2000). H2O2-induced endothelial apoptosis has been 
extensively used to induce cellular injury caused by oxidative stress in in vitro 
studies (Coyle et al., 2006). Thus, to efficiently manage and treat endothelial 
dysfunction, a combinational therapy that can act on multiple biological targets is a 
practical strategy. The herb-pair of DS-SQ have been widely used in CHM in Asian 
countries for the prevention and treatment of vascular diseases, including 
cerebrovascular diseases, coronary artery diseases and MI (Xu, 1996a). Although 
there have been numerous studies on the endothelial protective actions of DS and SQ 
as individual herbs, their combinational effects remain to be investigated. Thus, this 
chapter reported the results of the combinational effects of DS-SQ on protecting 
endothelial cells against the cytotoxicity induced by Hcy-Ado-TNF and oxidative 
stress (H2O2). The possible synergistic effects on these targets were also reported. 
Additionally, the actions of major chemical compounds from DS and SQ were 
investigated to elucidate the mechanistic actions of the extracts. 
This chapter reports the synergistic protective effects of DS-SQ on EAhy 926 cells 
against cytotoxicity induced by Hcy-Ado-TNF and H2O2 oxidative stress. 
Specifically, DS-SQ 6:4 showed the most prominent synergistic effects among all 
tested combinations. In addition, SA and Rb1 were found to be the most potent 
components to restore reduced cell viability. The combination of SA-Rb1 4:6 
showed synergistically enhanced effects in preventing Hcy-Ado-TNF cytotoxicity 
and H2O2-induced oxidative damage on EAhy 926 cells.  
 
8.2 Results 
8.2.1 Effects of Hcy-Ado-TNF on endothelial cell survival 
The cytotoxic effects of TNF associated with Hcy and Ado were demonstrated in a 
concentration-dependent manner in EAhy 926 Cells (Figure 8.1). As revealed in 
Chapter 7, Hcy (0.5 mM) and Ado (0.5 mM) significantly inhibited cell growth but 
did not affect the cell viability significantly (P>0.05). However, Hcy and Ado were 
co-incubated with TNF (0.1–10 ng/mL) in EAhy 926 cells, and a steadily decreased 
cell viability was observed. Significant cell viability reduction (by over 40%) was 
observed when the concentration of TNF was greater than 0.5 ng/mL (P<0.01). 
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Figure 8.1. Hcy-Ado-TNF exacerbated endothelial cell death. Cell viability, as 
determined by MTT dye reduction assay, following treatments with Hcy-Ado-TNF 
in EA.hy926 endothelial cells for 20 h. Cell viability was expressed as a percentage 
compared to blank control (no Hcy, Ado or TNF). All results were expressed as 
mean ± S.E.M. from three separate experiments. 
 
8.2.2 Effects of DS, SQ and DS-SQ on Hcy-Ado-TNF impaired cell 
survival in EAhy 926 cells 
8.2.2.1 Effects of DS, SQ and DS-SQ on Hcy-Ado-TNF impaired cell 
viability determined by MTT assay 
As Figure 8.2 illustrates, DS significantly improved cell viability at 150 µg/mL 
(P<0.05); however, SQ extract did not show any significant improvements up to 150 
µg/mL (P>0.05). Except for DS to SQ ratio at 9:1, herbal-pair extracts at all tested 
ratios significantly restored impaired cell viability in a concentration-dependent 
manner from 10–150 μg/mL (P<0.05; see Appendix 3). When the activity of 
combinational extracts at the same concentration level was compared, DS-SQ 
extracts at 6:4 ratios (150 µg/mL) showed the most prominent activity, with the 
highest cell viability (Appendix 3). 
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8.2.2.2 Effects of DS-SQ extracts on Hcy-Ado-TNF impaired cell viability 
determined by neutral red uptake assay 
Both DS and SQ extracts restored cell viability in a concentration-dependent manner 
against Hcy-Ado-TNF (see Figure 8.2). DS (100–300 µg/mL) and SQ (150–300 
µg/mL) significantly restored cell viability, respectively (P<0.05). Among all tested 
combinations, only DS-SQ 1:9, 5:5, 6:4 and 9:1 improved cell viability in a 
concentration-dependent manner from 10–200 μg/mL (Appendix 6). Further, DS-SQ 
at 1:9 and 6:4 (150–300 µg/mL) showed significant protective effects (P<0.05), 
similar to the results determined by MTT assay. 
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Figure 8.2. The protective effect of DS, SQ and DS-SQ (6:4) on EAhy 926 cells 
against cytotoxicity of Hcy-Ado-TNF, determined by MTT and neutral red assay, 
respectively. The synergism analysis of DS, SQ and DS-SQ 6:4 in protecting EAhy 
926 cells against Hcy-Ado-TNF-induced apoptosis determined by MTT. Cell 
viability, as determined by MTT and neutral red for DS (A), SQ (B) and DS-SQ 6:4 
(C) following treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell viability was 
expressed as a percentage compared to control. All results were expressed as mean ± 
SEM from three separate experiments in triplicate. * P< 0.05, ** P<0.01, *** P < 
0.001 in comparison with other combinations in the respective cell lines. D, Dose-Fa 
(% cell viability) curves of DS, SQ and DS-SQ 6:4 on Hcy-Ado-TNF-induced cell 
apoptosis determined by MTT assay. E, CI values were plotted as a function of 
fractional of cell viability (Fa) by ‘CompuSyn’ software. Dotted line is the reference 
line, where CI value equals 1; solid line represents CI values at different Fa. Fa 
values correspond to percentage cell viability relative to control. C, isobologram 
curves of DS, SQ and DS-SQ 6:4. F. isobologram curves for DS, SQ and DS-SQ 6:4 
on restoring impaired cell viability caused by Hcy-Ado-TNF. 
 
8.2.2.3 Optimised ratio of DS-SQ extracts on protecting EAhy 926 cells 
against Hcy-Ado-TNF-induced cytotoxicity 
By comparing the activities of DS-SQ combinations at all ratios on restoring 
impaired cell viability at the same concentration, it was observed that DS-SQ (6:4) 
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exhibited a stronger effect than other ratios (150–200 μg/mL) in both MTT and 
neutral red assay (see Appendices 5 and 7). Therefore, DS-SQ at 6:4 was selected as 
an optimal ratio of DS-SQ combinations for further analysis. 
 
8.2.2.4 Effects of DS, SQ and DS-SQ 6:4 on LDH leakage suppression in 
EAhy 926 cells 
EAhy 926 cells incubated with Hcy-Ado-TNF for 4 h caused a significant increase in 
LDH leakage, compared to the control group (P<0.01), which indicated significant 
cell damage. As Figure 8.3A demonstrates, all single and combinational extracts (6:4) 
attenuated the increased LDH leakage in a concentration-dependent manner from 10 
to 300 µg/mL. However, only DS-SQ 6:4 showed a significant inhibitory effect on 
LDH at the concentrations of 150 and 300 μg/mL (P<0.05 and P< 0.001, respectively) 
(Figure 8.3A). 
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Figure 8.3 Inhibitory effects of DS, SQ and DS-SQ 6:4 on elevated levels of LDH leakage in EAhy926 cells under cellular damage induced by 
Hcy-Ado-TNF. A. Inhibitory activity (% relative to control) of DS, SQ and DS-SQ 6:4 (10–300 µg/mL) in inhibiting increased LDH activity 
(relative to control). B. Concentration-effect curves of LDH inhibitory activity of DS, SQ and DS-SQ 6:4 generated by CompuSyn software. C. 
Log (CI) values were plotted as a function of suppression LDH leakage (Fa) by ‘CompuSyn’ software. Dotted line is the reference line, where 
Log (CI) value equals to 0; solid line represents CI values at different Fa. Fa values correspond to % LDH inhibitory effect relative to control. 
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8.2.2.5 Effects of DS, SQ and DS-SQ 6:4 on Caspase-3 total protein 
suppression in EAhy 926 cells 
EA.hy 926 cells incubated with Hcy-Ado-TNF for 4 h caused a significant increase 
in caspase-3 total protein expression compared to the control group (P<0.05). As 
shown in Figure 8.4A, the single extract of DS and SQ from 50 to 300 µg/mL 
showed no significant effect in attenuating the increased Caspase-3 total protein 
levels, compared to the Hcy-Ado-TNF group (P>0.05). However, a significant 
inhibitory effect was observed for DS-SQ 6:4 at a concentration of 300 μg/mL (P < 
0.001). 
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Figure 8.4 Inhibitory effects of DS, SQ and DS-SQ 6:4 on elevated levels of Caspase-3 total protein expression in EAhy926 cells under cellular 
damage induced by Hcy-Ado-TNF. A. The protein expression levels of caspase-3 were estimated by quantitative caspase colorimetric assay 
(R&D system, Australia). Results were shown as absorbance by microplate reader, with the means ± SD, n>3. * P<0.05 vs. Hcy-Ado-TNF group. 
Absorbance (410nm) versus concentrations (50–300 µg/mL) graph for DS, SQ and DS-SQ 6:4 in inhibiting increased caspase-3 protein 
expressions. ‘H+A+T’ represents Hcy-Ado-TNF stimulation only in group. B. Concentration-effect curves of Caspase-3 inhibitory activities of 
DS, SQ and DS-SQ 6:4 generated by CompuSyn software. C. CI values were plotted as a function of suppression of Caspase-3 proteins level (Fa) 
by CompuSyn software. The dotted line is the reference line, where CI value equals 1; solid line represents CI values at different Fa. Fa values 
correspond to % Caspase-3 inhibitory effect relative to control. All data are presented as means ± SEM, n > 3. * P< 0.05 vs. H+A+T group; *** 
P<0.001 vs. H+A+T group. 
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8.2.3 Effects of DS, SQ and DS-SQ 6:4 on cell survival against H2O2 
in EAhy 926 cells 
8.2.3.1 Cytotoxicity induced by H2O2 on EAhy 926 cells 
As shown in Figure 8.5, H2O2 (0.1–10 mM) concentration-dependently reduced cell 
viability. As 0.5 mM H2O2 caused a significant cell injury (P<0.001), this 
concentration was selected for the H2O2 induced cell injury model. 
 
 
Figure 8.5 Endothelial cell death induced by H2O2 (0.1–10 mM). (A) Cell viability, 
as determined by MTT dye reduction assay in EAhy926 endothelial cells for 20 h. 
Cell viability was expressed as a percentage compared to H2O2 treatment only. (B) 
Representative cell morphology in medium only (control) and treated with H2O2 
(0.5 mM). All results were expressed as mean ± SEM from three separate 
experiments. *** P<0.001 vs H2O2 treatment only. 
 
8.2.3.2 Effects of DS, SQ and DS-SQ on H2O2 - induced endothelial cell 
injury 
The cell viability with pre-treatment of DS, SQ and DS-SQ 6:4 followed by H2O2 
(0.5 mM) was shown in Figure 8.6. There were no significant protective effects from 
DS on restoring impaired cell viability against H2O2 (P>0.05). SQ (50–150 μg/mL) 
showed concentration-dependent effects and significantly restored the impaired cell 
viability induced by H2O2 (P<0.05). DS-SQ 6:4 (150 µg/mL) significantly restored 
cell viability against H2O2 (0.5 mM) (P<0.01). 
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Figure 8.6. Protective effect of DS, SQ and DS-SQ 6:4 on EAhy926 cells against 
H2O2 induced cell injury by restoring reduced cell viability. Cell viability was 
assayed by the MTT method (n = 4) in EAhy926 cells for 20 h. Cell viability was 
expressed as a percentage compared to H2O2 stimulation only. All data were 
presented as means ± SEM. Cell viability (% relative to control) versus increased 
concentrations of (A) DS, (B) SQ and (C) DS-SQ 6:4 (10–300 µg/mL) against H2O2 
induced cell damage. #P<0.05 vs control. * P<0.05 vs H2O2 treatment only. ** 
P<0.01 vs H2O2 treatment only. *** P<0.001 vs H2O2 treatment only. D. CI values 
were plotted as a function of restored cell viability (Fa) by ‘CompuSyn’ software. 
Dotted line is the reference line, where CI value equals 1; solid line represents CI 
values at different Fa. Fa values correspond to restored cell viability % relative to 
control. 
 
8.2.3.3 Effects of DS, SQ and DS-SQ on H2O2 induced ROS generation in 
EAhy 926 cells 
As shown in Figure 8.7, EAhy 926 cells incubated with H2O2 resulted in a significant 
increase of ROS production compared to the control group (P<0.01). Pre-treatment 
with DS (10–150 µg/mL) concentration-dependently attenuated the ROS generation 
by H2O2, with significance at 50–150 µg/mL. However, SQ extract showed no 
significant effect in inhibiting ROS from 10–150 µg/mL. DS-SQ 6:4 showed 
significant activity in decreasing the ROS generation at 50, 100 and 150 ug/mL 
compared to the H2O2 group (P < 0.001). Garlic acid was used as a posistive control 
in this assay, as its prominent anti-oxidant activity showed significant ROS 
inhibitory effect at 10 µg/mL. A one-way Annova test suggested that the inhibitory 
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effect of DS and DS-SQ 6:4 at 150 µg/mL were comparable with the effect of garlic 
acid (10 µg/mL)(P>0.05). 
Chapter 8: Cell survival results 
Page | 200  
 
 
Figure 8.7. Protective effects of DS, SQ and DS-SQ 6:4 against H2O2-induced endothelial cell injury by attenuating excessively 
expressed ROS production. (A) Inhibitory effect of DS, SQ and DS-SQ 6:4 on ROS production induced by H2O2 in EAhy926 cells. The 
ROS expression level was estimated by cellular ROS detection assay kit manufacturer (Abcam, Australia). TBPH (from kit) was used as 
positive control and gallic acid (10 µg/mL) was used as a positive control in the assay. Results were shown as absorbance by microplate 
reader, with the means ± SD, n>3. *** P<0.001 compared with H2O2 group. (B) Log (CI) values were plotted as a function of 
suppression fractional of ROS level (Fa) by ‘CompuSyn’ software. Dotted line is the reference line, where Log (CI) value equals to 0; 
solid line represents Log (CI) values at different Fa. Fa values correspond to percentage ROS inhibitory effect relative to control. 
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8.2.4 Synergic cytoprotective effects of DS-SQ 6:4 on cell survival 
against Hcy-Ado-TNF and H2O2 
8.2.4.1 Synergistic effect of DS-SQ 6:4 on cell survival against Hcy-Ado-TNF 
The results demonstrated the synergistic cytoprotective effects in DS-SQ 6:4 (10–
150 μg/mL) on MTT assay (Figure 8.2E). Isobologram analysis also showed 
synergism for the cytoprotective effects of DS-SQ 6:4 extract (Figure 8.2F). For 
LDH assays, synergistic effects were observed when the suppressive effect of DS-SQ 
6:4 was greater than 38% (Fa >0.38), as shown in Figures 8.3B and C. The 
synergistic effect was becoming stronger until the LDH inhibitory level reached 94%, 
and then it tended to be additive when the effect was predicted to be higher than 95%. 
A synergistic effect of DS-SQ 6:4 was largely observed in inhibiting Caspase-3 total 
protein production. The synergistic effect already became apparent at 10% effect 
level (Fa = 0.1) and continued to increase at higher effect levels (Figure 8.3 F). 
 
8.2.4.2 Synergistic effect of DS-SQ 6:4 on cell survival against H2O2 
Synergistic effect was largely observed for DS-SQ 6:4 in restoring impaired cell 
viability after the cells were exposed to H2O2, with CI values of 0.072 at ED50 
(Figure 8.6D). A synergistic effect was also observed for DS-SQ 6:4 in inhibiting 
ROS production induced by H2O2 (Figures 8.7 C and D), when the Fa level (ROS 
inhibitory effect) was lower than 0.2 (20% inhibition) and the concentration range for 
DS-SQ 6:4 was calculated to be smaller than 80.511 μg/mL. Whereas, the 
antagonistic effect was observed when the concentration of DS-SQ 6:4 was above 
80.511 μg/mL. The CI values were calculated to be 1.39 and 2.31 at ED50 and ED90, 
respectively. 
 
8.2.5 Effects of chemical compounds from DS and SQ on cell 
survival against Hcy-Ado-TNF and H2O2 in EAhy 926 cells 
8.2.5.1 Effects of chemical compounds on Hcy-Ado-TNF impaired cell 
viability determined by MTT assay 
Fourteen chemical compounds from DS and SQ were tested for their cytoprotective 
effects against the cellular damage induced by Hcy-Ado-TNF, using MTT assay. 
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Among all compounds from DS, only DSS and SA showed improvement of cell 
viability in a dose-dependent manner (Appendix 8). SA significantly restored the cell 
viability at the concentration greater than 100 µM (P<0.05). Whereas SB showed no 
significant protective effects (P>0.05). Among all tested compounds in SQ 
(Appendix 9), only Rb1 showed significant improvement at 150 µM (P<0.05). 
Therefore, SA and Rb1 were found to be the most active compounds in protecting 
EAhy 926 cells from Hcy-Ado-TNF from DS and SQ, respectively. 
 
8.2.5.2 Effects of SA-Rb1 on Hcy-Ado-TNF impaired cell viability 
determined by MTT assay 
Since SA and Rb1 showed prominent protective effects among all selected marker 
compounds, they were further studied by combining the specified ratios (1:9, 
2:8…8:2, 9:1) and tested using MTT assays. The results suggested that SA-Rb1 4:6 
demonstrated significant effects when the tested concentration was greater than 10 
µM (P<0.05, Figure 8.8). Therefore, this ratio of SA-Rb1 combination was further 
tested in LDH assay. 
 
8.2.5.3 Effects of SA-Rb1 on LDH suppression against Hcy-Ado-TNF 
As shown in Figure 8.9A, SA, Rb1 and SA-Rb1 4:6 attenuated the increased LDH 
leakage induced by Hcy-Ado-TNF in a concentration-dependent manner. SA, Rb1 
and SA-Rb1 (4:6) reduced the LDH leakage at all tested concentrations, except Rb1 
at 50 µM (P<0.05).  
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Figure 8.8 The protective effect of SA, Rb1 and SA-Rb1 4:6 on EAhy 926 cells against cytotoxicity induced by Hcy-Ado-TNF determined by 
MTT assay. Cell viability, as determined by MTT for SA (A), Rb1 (B) and SA-Rb1 4:6 (C) following treatments with Hcy-Ado-TNF in EAhy 
926 cells. Cell viability was expressed as a percentage compared to control. All results were expressed as mean ± S.E.M. from three separate 
experiments in triplicate. * P< 0.05, ** P<0.01, *** P < 0.001 in comparison to other combinations in the respective cell lines. (D) 
Concentration-effect curves of SA, Rb1 and SA-Rb1 4:6 (10–150 µM) on restored cell viability generated by CompuSyn software. € CI values 
were plotted as a function of fractional of restored cell viability (Fa) by CompuSyn software. Dotted line is the reference line, where CI value 
equals 1; solid line represents CI values at different Fa. Fa values correspond to % cell viability relative to control. 
Chapter 8: Cell survival results 
Page | 204  
 
 
Figure 8.9 Effects of SA, Rb1 and SA-Rb1 4:6 in inhibiting LDH leakage on EA.hy926 cells against cellular damage induced by Hcy-Ado-TNF. 
(A) Inhibitory activity (% relative to control) of SA, Rb1 and SA-Rb1 4:6 (50–150 µM) in inhibiting increased LDH activity (relative to control). 
All data are presented as means ± SEM, n > 3. * P< 0.05 vs. stim group; *** P<0.001 vs. stim group; ‘stim’ represents Hcy-Ado-TNF 
stimulation. (B) Concentration-effect curves of LDH inhibitory effects of SA, Rb1 and SA-Rb1 4:6 generated by CompuSyn software. (C) CI 
values were plotted as a function of suppression fractional of LDH leakage (Fa) by ‘CompuSyn’ software. Dotted line is the reference line, where 
CI value equals 1; solid line represents CI values at different Fa. Fa values correspond to % LDH inhibitory effect relative to control. 
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8.2.5.4 Effect of SA-Rb1 4:6 on H2O2 impaired cell viability determined by 
MTT assay 
The cell viability with pre-incubation of SA, Rb1, and SA-Rb1 (4:6) with different 
concentrations (1–300 μM) followed by H2O2 (0.5 mM) cell injury was shown in 
Figure 8.10A. Both SA (300 µM) and Rb1 (100–300 µM) showed significant effects 
for restoring the impaired cell viability of H2O2-treated EAhy 926 cells (P<0.05). 
Additionally, a prominent effect was observed for SA-Rb1 4:6 (1–150 μM), with 
significant improvement of cell viability when the concentration was greater than 10 
μM (P<0.001). 
 
8.2.5.5 Effect of SA-Rb1 4:6 on H2O2 induced ROS production 
As shown in Figure 8.11, pre-treatment with SA, Rb1 and SA-Rb1 4:6 (50–150 µM) 
significantly attenuated the increased ROS level induced by H2O2. Both SA and SA-
Rb1 significantly inhibited ROS production from 50–150 μM (P<0.001), whereas 
Rb1 showed no significant inhibitory effect for ROS production (P>0.05). 
Additionally, garlic acid (10 μg/mL) was used as a positive control in this assay, 
which inhibited ROS significantly. The non-parametric test suggested that the 
inhibitory effect of SA and SA-Rb1 4:6 from 50–150 μM was comparable to that of 
garlic acid (P>0.05). 
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Figure 8.10 Protective effect of SA, Rb1 and SA-Rb1 4:6 on EAhy926 cells against H2O2 induced cell injury by restoring reduced cell 
viability. (A) Cell viability (% relative to control) verses increased concentrations of SA, Rb1 and SA-Rb1 4:6 (1–150 µM) against 
H2O2 induced cell damage. (B) Concentration-effect curves of restored cell viability against H2O2 treatment with increased 
concentrated SA, Rb1 and SA-Rb1 4:6 (1–150 μM) were generated by CompuSyn software. (C) CI values were plotted as a function of 
restored cell viability (Fa) by ‘CompuSyn’ software. Dotted line is the reference line, where CI value equals 1; solid line represents CI 
values at different Fa. Fa values correspond to restored cell viability % relative to control. 
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Figure 8.11 Protective effect of SA, Rb1 and SA-Rb1 4:6 on EAhy926 cells against H2O2 induced cell injury by inhibiting excessive 
intracellular ROS production. (A) Inhibitory effect of SA, Rb1 and SA-Rb1 4:6 on ROS production induced by H2O2 in EAhy926 cells. 
The ROS expression level was estimated by cellular ROS detection assay kit manufacturer (Abcam, Australia). TBPH (from kit) was 
used as positive control in the assay. Results were shown as absorbance by microplate reader, with the means ± SD, n>3. (B) 
Concentration-effect curves of ROS inhibitory effects of SA, Rb1 and SA-Rb1 4:6 generated by CompuSyn software. (C) Log (CI) 
values were plotted as a function of suppression fractional of ROS (Fa) by ‘CompuSyn’ software. Dotted line is the reference line, 
where Log (CI) value equals 0; solid line represents CI values at different Fa. Fa values correspond to % ROS inhibitory effect relative 
to control. 
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8.2.5.6 Synergistic effects of SA-Rb1 4:6 on cell survival against Hcy-Ado-
TNF and H2O2 
Synergistic effects were generally observed for SA-Rb1 4:6 ratio at all tested 
concentrations (1–150 μg/mL) for restoring impaired cell viability on MTT assay 
(Figure 8.8). The synergistic interaction was tended to be weaker when the 
concentration of SA-Rb1 was higher than 150 μg/mL. The interaction was predicted 
to be antagonistic, when the concentration was higher than 465.51 μM. For inhibiting 
LDH leakage, a strong synergistic effect was generally shown at all tested 
concentration range (50–150 μM) for SA-Rb1 4:6 (Figure 8.9). Similarly, a 
synergistic effect for SA-Rb1 4:6 was observed against H2O2-induced cell damage 
with concentration under 35.14 μM. At the above concentrations, it became 
antagonistic as the protective effect of SA alone was stronger than the combination 
(Figure 8.10). For inhibitory effect of SA-Rb1 4:6 on ROS production, a synergistic 
effect was only observed to be below 50 μM. It was predicated to be antagonistic at 
concentrations greater than 100 μM (Figure 8.11). 
 
8.3 Summary 
The protective effects of single and combination extracts (nine different ratios) of DS 
and SQ on EAhy 926 cells against cytotoxicity induced by Hcy-Ado-TNF were 
evaluated by restoring impaired cell viability, inhibiting LDH and Caspase-3 protein 
expression. The results demonstrated that DS-SQ extracts alone at all tested ratios 
(excluding 9:1) were superior to DS and SQ extracts in restoring impaired cell 
viability from 10 to 150 μg/mL. Specifically, DS-SQ 6:4 showed the most prominent 
protective effects among all tested combinations. CI analysis revealed synergistically 
enhanced cytoprotective in DS-SQ 6:4 against Hcy-Ado-TNF. This synergistic 
interaction was confirmed to inhibit LDH leakage and Caspase-3 protein expression. 
Further, DS-SQ 6:4 continued to exert synergistically enhanced cytoprotective effect 
on EAhy 926 cells from oxidative damage (caused by H2O2) by restoring the cell 
viability and inhibiting excessive ROS production. 
 
The protective effects of fourteen key chemical compounds in DS and SQ were 
screened in the same assays on impaired EAhy 926 cells induced by Hcy-Ado-TNF 
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combination. Among the tested compounds, SA and Rb1 were found to be the most 
potent components to restore reduced cell viability. Also, SA-Rb1 4:6 showed 
synergistically enhanced effects in preventing cytotoxicity effects caused by Hcy-
Ado-TNF by CI analysis. This simplified combination was further tested on H2O2-
induced oxidative damage on EAhy 926 cells, and also demonstrated prominent 
effects. Therefore, we have established a simplified formulation of SA-Rb1 4:6, 
which represent the active components from DS and SQ and maintain the same level 
of therapeutic actions. 
 
These findings provided a theoretical basis for the purported synergistic efficiency of 
DS and SQ as multi-sourced botanical drugs for the treatment of vascular disease, 
through its protection on endothelial cells against major risk factors, Hcy, TNF and 
oxidative stress for endothelial cell survival. SA and Rb1 were found to be the active 
compounds that may contribute to the combination effect of DS and SQ on 
protecting endothelial cells. The simplified formulation of SA-Rb1 at the ratio of 4:6 
demonstrated prominent and synergistic protective activity on endothelial cells, 
which may provide further leads for future drug development. 
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This chapter provides the discussions of the results reported in Chapters 5 to 8 based 
on the specific aims given in chapter 2, which include the chemical analysis of single 
and combinational extracts of DS and SQ, pharmacodynamics and pharmacokinetics 
synergy of DS-SQ in anti-inflammatory, angiogenesis and anti-apoptosis, optimal 
ratios of DS-SQ and compounds formulation investigations. The interpretation, 
significance and limitation of the results are also provided.  
 
9.1 Discussions on qualitative and quantitative analyses 
9.1.1 Chemical analysis of DS and SQ 
It is well-recognised that quality control plays a fundamental role in the 
determination of the efficacy of medicinal herbal products. The complex nature, 
environmental issues and poor quality control processes are key factors that affect 
the quality of CHM and may lead to inconsistent therapeutic outcomes and safety 
issues. Therefore, quality control of the crude samples used for DS and SQ in this 
study was conducted prior to the investigation of their pharmacological actions. In 
the current regulation guidelines for CHM products, PPRC is a major reference for 
the methods and standards for quality control. Thus, the amount of marker 
compounds from DS and SQ after the chemical analysis was referred to PPRC 
requirements for quality examination. 
 
The chemical analysis for DS and SQ was conducted using TLC and UPLC, 
respectively. TLC technology was used for the identification of marker compounds 
in DS and SQ, by comparing the band (colour and position) of reference standards to 
the corresponding band in the sample extract. To optimise the TLC method, 
fluorescence mode (UV 366 nm) was used for the visualisation of the derivatised 
saponins that enhanced their detection, compared to the lower absorbance 
measurement at UV 254 nm. However, the noise level correspondingly increased 
(Fuzzati, 2004; Vanhaelen Fastre et al., 2000). From the TLC fingerprint of the DS 
extract (Figure 5.1), two marker compounds of SA and SB were successfully 
detected, which matched in the sample extract and confirming the identity of DS 
extract to some extent. DSS was not detected either in the standard band or in the 
sample extract. This may due to the limitation of this TLC method. As DSS is a polar 
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compound and the solvent system is not strong enough to separate it from the 
stationary phase, it was still located with the sample at the bottom of the plate. There 
were double bands in the SA standard lane as well as in the extract. The double 
bands of SA may be due to the degradation of the compound. 
 
To further examine the quality of the crude samples of DS, UPLC methods were 
successfully established and simultaneously determined seven chemical compounds 
in DS. SB was found to be the most abundant among all tested compounds in six raw 
herbs (over 90%), which was consistent with the literature (Zhao et al., 2008). The 
amount of the tested chemical compounds in DS samples did not vary significantly 
(P>0.05), except for SB, which was significantly lower in DS2 and DS4 than the 
other four samples. The variation of SB may be related to the different sources from 
which the DS crude samples were collected. Different origins with different climatic 
conditions and growth environments may affect the chemical composition of a plant. 
Although the chemical composition of the six DS samples did not vary substantially, 
the quality was found to be generally low, with only one sample meeting the quality 
standard in PPRC. This may be due to several reasons: 
1. The different extraction system used from PPRC. Methanol and 75% 
methanol solvents were used in PPRC for the extraction of TIIA and SB from 
DS, respectively (National Pharmacopoeia Committee, 2010). However, 
aqueous extract was used for the determination of TIIA and SB in this study. 
Different solvent systems were shown to affect the chemical composition of 
herbal extracts. As TIIA is a relatively non-polar compound, in which the 
extraction yield can be higher in the methanol than in water, this may explain 
the relatively low amount of TIIA in this study. 
2. Harvest time: previous studies have demonstrated that harvest time for a plant 
can significantly affect the chemical composition. For example, the amount 
of compounds in SQ varied by 30% between August and November (Dong et 
al., 2003). As the samples used for DS were collected from different areas 
and manufacturers, it is likely that various harvest seasons led to the 
fluctuating quality outcomes. 
3. Growth condition: as CHM is made from natural plants, growth conditions 
significantly affect quality. Shanxi, Sichuan, Hebei, Henan and Shandong 
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Provinces in China are traditional primary production areas for DS, and yield 
high quality. The majority of samples used in this study were collected from 
herbal retailers and grown mainly in Anhui and Guang Xi, which are not 
primary production bases. 
 
The chemical analysis results for SQ suggested a more consistent and higher sample 
quality compared that of DS. Good separation and identification of Rb1, Rd and Rg2 
were obtained from the established TLC and UPLC methods, except for Rg1 and Re. 
As in previous studies, Rg1 and Re shared similar chemical structures and therefore 
were quite difficult to separate in TLC and UPLC (see Figure 2.5). This also reflects 
the limitation of the method and technique used in this study. The chromatogram and 
quantification results for SQ were consistent with the literature. Rg1 was found to be 
the most abundant compound in six tested raw herbs. The amount of five tested 
chemical compounds did not vary significantly among six herbal samples (P>0.05), 
suggesting a consistent quality of SQ collected from different origins. In PPRC, the 
total amount of Rg1, Rb1 and NR1 was used for the quality standard of the SQ 
sample. The results showed that only one sample (SQ6) did not meet this standard, 
and this was originally from Jiang Su. The SQ plant is native to the southwest region 
of China, at high altitudes (1500–1800 metres) (Yang et al., 2008). Therefore, the SQ 
sample derived from Jiang Su may not be of high quality as it comes from the plains. 
All of these factors collectively highlighted the difficulty of quality standardisation 
for CHM. Moreover, it also emphasises the necessity of quality control before 
judging the efficacy of CHM. 
 
9.1.2 Chemical analysis of DS-SQ combinations 
The complex chemical nature of Chinese medicinal herbs poses a great challenge for 
quality control, especially for herbal formulae that contain multiple herbal 
ingredients. For traditional herbal formulae that were mixed and prepared together, 
the chemical components were found to be non-uniform and unpredictable. It has 
been repeatedly reported that the chemical compounds in the formula were not 
simply the sum of each ingredient, as new compounds were detected (Li et al., 2003; 
Zeng et al., 2004). In this study, DS-SQ combinations in nine different ratios (1:9, 
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2:8…9:1) were prepared and subjected to chemical analysis. UPLC methods were 
successfully established for the simultaneous determination of five compounds in 
DS-SQ. Due to the low extraction yield under aquous extraction, lipid-soluble 
compounds including tanshinones, Rg2 Rb2 and Rd were not detected in the DS-SQ 
extract. The chemical fingerprint and the amount of five hydrophilic compounds 
(DSS, SB, NR1, Rg1 and Rb1) were obtained from the UPLC analysis. By 
comparing the fingerprint of the single extract to the combinational extract at the 
same wavelength, it was observed that the chromatogram of DS (Figure 5.5A) 
looked similar to that in the combination at 280 nm wavelength (Figure 5.5C), with 
major peaks detected at similar retention times. However, the chromatogram of DS-
SQ at 203 nm (Figure 5.5D) showed many additional peaks from the SQ 
chromatogram in 203nm (Figure 5.5B). By comparing the UV spectra, it was found 
that the additional peaks that appeared in the combination were not new compounds, 
but were considered to be peaks in a combination that can be detected in 280 nm 
(peak 7 to 10). Peaks 8 and 9 were considered to be two phenolic acids from DS that 
interfered with the detection of NR1, according to the results of Wei YJ et al. (2007). 
This was due to the unstable baseline at 203 nm caused by gradient elution (Wei et 
al., 2007a). It was assumed that peaks 10 was also phenolic acids from DS, as it was 
detected in the 280 nm wavelength in the combination. Unfortunately, UPLC-PDA 
was unable to identify the unknown peaks without the reference standards, so a more 
advanced technique, such as LC-MS or NMR, would be required to investigate and 
confirm the unknown peaks appearing in the combination fingerprint. Rd was not 
detected in the combination at all ratios, which may due to the low yield in the 
combinational extraction. 
 
To the best of our knowledge, neither Rd has been previously reported, nor other 
lipid-soluble compound (tanshinones and Rg2) in DS-SQ extract. Although current 
evidence on whether new compounds were formed during co-decoction was 
controversial, studies agreed that the amount of chemical compounds was not 
directly proportional to the ratio of their herbal ingredients in the combination (Li et 
al., 2003; Zeng et al., 2004), in keeping with the results in this study (Figure 5.6). 
Although DS-SQ 9:1 and 1:9 possessed the highest amount of compounds from DS 
and SQ, respectively, these did not increase/decrease proportionally to the ratio in the 
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combination. For example, 30% of DS in the combination yield a higher amount of 
SB than in 40% DS, and the amount of Rg1 was higher in the 60% SQ in the 
combination than in the 70% SQ. The amount of Rg1 and Rb1 was in proportion to 
the SQ ratio in the combination, except 7:3 and 5:5, which was lower than expected. 
NR1 and DSS were observed to be constantly low, regardless of the proportion. It 
was discussed that the extraction procedure—including the solvent system, 
temperature and pH value—are key factors that would impact the chemical 
composition and the yield of the chemical compounds in the herbal formula, despite 
of the chemical nature of the herbal ingredients used in the formula (Li, 2014; Wang 
et al., 2012d). 
 
Unfortunately, there is no standard guideline at present that can be referred to for 
quality control of DS-SQ mixed preparation, reflecting the limitation of current 
quality control regulations worldwide. In the latest PPRC (2015), quality control for 
Chinese patent medicines has been updated in terms of patent products. However, 
quality standards for the herbal extract and traditional decoctions are still lacking. 
The lack of quality control methods for herbal formulae is one the major challenges 
and limitations to the current regulation guidelines. For the quality determination of 
an herbal formula that may have a very complicated chemical composition, 
determining a single or multiple marker compound is insufficient. By using DS-SQ 
as a case study, the chemical analysis results reflected the varied amount of abundant 
compound, ‘disappeared’ minor compounds and non-predictable amounts of the 
compounds in the mixture prepared in different ratios. Thus, the quality control of a 
formula required an overview of a full chemical profile and amount of multiple 
constituents. This issue requires further attention for the further development of 
herbal formulae. 
 
9.2 Bioactivity of DS and SQ on vascular disease 
Following the chemical analysis of DS, SQ and DS-SQ combinations, the samples 
that met the quality standard from PPRC were subjected to the bioassays to examine 
their bioactivity in anti-inflammatory, angiogenesis and anti-apoptosis.  
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9.2.1 Anti-inflammatory activity of DS and SQ 
Vascular disease represents complex pathophysiological mechanisms with 
endothelial dysfunction as an early hallmark. A series of pro-inflammation events 
modulated by iNOS, TNF and MCP-1 play a key role in vascular dysfunction. Thus, 
modification of these key inflammatory mediators has potent therapeutic 
implications. 
For the anti-inflammatory assay, murine macrophage RAW 264.7 cells were used. In 
the pathological development of vascular dysfunction, the initial steps are 
macrophage cells that engulf the pathogen which then are transformed to the foam 
cells. During this step, the macrophage cells release cytokines such as NO, TNF and 
interlukins which can recruit more of the neutrophils to help with the inflammatory 
events. On one side, it enhanced the phagocytosis which clears more pathogens, on 
the other hand, the released cytokines and free radicals can cause more damage to the 
adjacent endothelial cells. Thus, to reduce the amount of cytokines released from the 
macrophage cells are essential for the endothelial survival and functions.  
The anti-inflammatory effects of DS and SQ as single herb have been demonstrated 
in previous in vitro and in vivo studies, and were confirmed in the current study. Our 
results showed that DS significantly inhibited LPS-induced NO, TNF and MCP-1 
production in RAW 264.7 cells, which is consistent with the previous in vitro and in 
vivo findings. It has been suggested that the inhibitory effects of DS are associated 
with the attenuation of mRNA expressions of the inflammatory mediator (Kim et al., 
2005; Ravipati et al., 2012). Our study has demonstrated that the lipid-soluble 
components of DS (e.g., DT, T1 and CT) produced a greater inhibitory effect on NO 
production than their water-soluble counterparts (e.g., DSS, SA and SB). Specifically, 
DT was found to exert a comparable inhibitory effect on NO to that of 
dihydrochloride, a specific iNOS inhibitor, highlighting its anti-inflammatory 
potential as a single chemical entity. 
 
The anti-inflammatory activities of tanshinones reported in this study are compatible 
with the findings of previous studies. It was demonstrated that lipid-soluble extracts 
of DS were capable of inhibiting the LPS-induced gene and protein expression of 
iNOS, TNF, IL-1β and IL-6 in macrophages via blocking NF-kB activation (Li et al., 
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2012b; Jeon et al., 2008). It was also previously reported that CT down-regulated the 
expression of pro-inflammatory enzymes, including COX-2 and iNOS (Jeon et al., 
2008). Many in vitro studies suggested that TIIA was a key bioactive compound of 
DS, responsible for its anti-inflammatory activities through suppressing LPS-
stimulated NO, IL-1β, IL-6 and MCP-1 expressions (Fan et al., 2009; Ren et al., 
2010; Xu et al., 2011b). However, TIIA showed very low solubility in DMSO (less 
than 20 mM) and high cytotoxicity in our study, which started to impair the cell 
viability when the concentration was higher than 15 µM. No significant effects were 
detected for TIIA within its safe dosage. For hydrophilic compounds, it was not 
surprising that SB did not exert any significant anti-inflammatory activity as the most 
abundant compound in DS. Previous studies revealed that SB did not abrogate LPS-
induced inflammatory events on RAW264.7 and epithelial cells (Kim et al., 2005). 
However, its anti-inflammatory activity was shown in the microglia cells, which 
were beneficial for neuroprotection (Chen et al., 2001; Wang et al., 2010; Chen et al., 
2011b). Therefore, for targeting LPS-stimulated NO, TNF and MCP-1, the lipid-
soluble components (DT, TI and TIIA) played key roles in DS extracts. Our chemical 
analysis for DS suggested that the amount of lipid-soluble components in DS 
accounted for less than 3% of the total weight. Thus, the effects of DS extract were 
probably not solely a result of its lipid components; the remaining 97% fraction of 
the extract could also have such effects. The remaining part of the extract might have 
an additive or synergistic activity with the lipid-soluble fraction, to exert the overall 
efficacy for the extract. 
 
SQ also demonstrated significant inhibitory effects on NO, TNF and MCP-1, which 
was suggested to be associated with down-regulating the expression of COX-2 
mRNA and blockage of NF-κB via LXRα (Rhule et al., 2006). Ginsenosides from 
SQ were found to be the key components contributing to its anti-inflammatory 
effects via multiple mechanisms (Park & Cho, 2009). It has been suggested that Rb1 
and Rb2 blocked TNF production and attenuated NO and PGE2 via repression of 
NF-KB activation signals. Rg1 and Re appeared to inhibit NO and TNF production 
by acting on ERK and JNK pathways, and Rb2 was shown to target cAMP PDE 
(Park & Cho, 2009). Our results are in agreement with these findings. Rd was found 
to be a key ginesnoside compound responsible for the anti-inflammatory properties 
Chapter 9: Discussions 
218 | P a g e  
of SQ with the lowest IC50 values. The anti-inflammatory mechanism of Rd was 
related to interrupted iNOS and COX-2 expression (Park & Cho, 2009). 
 
9.2.2 Angiogenic activity of DS and SQ 
As previously stated, Hcy is an important risk factor for vascular disease. Hcy with 
Ado can impair the process of angiogenesis by inhibiting cell proliferation, cell 
migration and tube formation (Kam et al., 2015), and this impairment activity was 
confirmed on zebrafish angiogenesis models (Zhang et al., 2011b). In our study, cell 
proliferation, migration and tube formation stimulated with Hcy and Ado cellular 
models were established for examining the activity of DS, SQ and DS-SQ on Hcy-
mediated vascular disease via angiogenic activity. As expected, Hcy and Ado 
significantly impaired the cell growth, migration and tube formation activity of EAhy 
926 cells. DS has previously been shown to be active in promoting angiogenesis on 
endothelial cells, with phenolic acids the major contributor (Fan et al., 2006a). The 
mechanistic action of DS, as well as its major phenolic acid compound, SB, was via 
the up-regulation of the genes encoding MMP-2, VEGF, VEGF receptor 2 and Tie-1 
(Fan et al., 2006a). By contrast, the tanshinones group were potent in inhibiting 
angiogenesis, so the effects were widely studied on anti-tumour and anti-cancer 
treatments (Wang et al., 2005). When DS was tested on Hcy-stimulated angiogenesis 
models, our results showed that DS did not exert any significant angiogenic activity 
against Hcy and Ado-induced impairment, with only a slight wound healing effect at 
300 µg/mL. SB was also not capable of promoting angiogenesis against Hcy and 
Ado. Thus, it is presumed that the angiogenic activity of DS and SB was not via an 
Hcy-mediated pathway. 
 
The in vitro and in vivo angiogenic effect of SQ was shown to be largely derived 
from its saponin components (Hong et al., 2009). Similar to DS, the chemical 
compounds in SQ possessed apposing activities. Rg1 was shown to promote 
angiogenesis activity, whereas Rb1 exerted an inhibitory activity (Hong et al., 2009). 
The chemical analysis results suggested that the amount of Rg1 was approximately 
1.8 times Rb1 in SQ (Chapter 5). Thus, SQ was shown to promote angiogenesis 
activity due to the outweighed amount of Rg1. Our results demonstrated that SQ 
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promoted angiogenesis against Hcy and Ado via restoring cell proliferation and 
wound healing at 200–300 µg/mL and 300 µg/mL, respectively. However, NR1 but 
not Rg1 showed significant activity restoring impaired cell proliferation at 300 µM. 
Therefore, the angiogenic effect of Rg1 was assumed to not be related to the Hcy-
mediated pathway. Since SQ showed angiogenic activity to some extent, it was 
assumed that the other existing compounds together exerted additive effects for SQ 
on Hcy-mediated angiogenesis. 
 
9.2.3 Protective activity of DS and SQ on cell survival 
To target atherosclerotic-related vascular diseases, an Hcy-Ado-TNF induced 
endothelial cell apoptosis model was established. It was observed that when TNF 
was added in addition to Hcy and Ado, it significantly reduced endothelial cell 
viability, elevated LDH release and increased caspase-3 expression, indicating cell 
injury and increase in cell death or apoptosis. This is consistent with previous studies 
(Kam et al., 2012, 2014). It was suggested that elevations in Hcy and Ado favoured 
the accumulation of S-adenosylhomocysteine and potentiated cellular 
hypomethylation. This, in turn, sensitised TNF-induced cytolysis (Kam et al., 2014). 
DS was shown to possess a versatile protective effect on endothelial cells against 
various stimulants through many signalling pathways. Our results have demonstrated 
that DS exerted a significant protective effect on EAhy 926 cells against cytotoxicity 
from Hcy-Ado-TNF, via restoring cell viability and reducing LDH leakage. MTT 
assay suggested that DS significantly enhanced cell viability at 300 µg/mL, whereas 
it was 100 µg/mL in neutral red assay. This may be due to the higher sensitivity of 
neutral red to detecting the changes in cell viability. 
 
Although no statistical significance was detected, a decreased trend of Caspase-3 
protein content was observed for DS from 50 to 300 µg/mL. DS exerted a weak 
effect on restoring Hcy-Ado-TNF mediated cell apoptosis. Existing literature has 
suggested that the anti-apoptotic effect of DS may be associated with MAPK and 
NF-KB pathway. However, further studies need to be conducted to confirm this 
pathway on Hcy-Ado-TNF stimulated apoptosis model. Additionally, our results 
suggested that SA exerted prominent cytoprotective effects on Hcy-Ado-TNF via 
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restoring diminished cell viability and inhibiting LDH release at 100–150 µM and 
50–150 µM, respectively. SA was previously shown to possess anti-apoptotic 
activity against oxidative stress and stress tolerance via regulating Bax/Bcl 2 ratio. 
This is the first study to have demonstrated its protective effects on Hcy-Ado-TNF 
mediated cytotoxicity. However, the mechanistic pathway is yet to be determined. 
 
A significant protective activity of SQ was observed on Hcy-Ado-TNF mediated 
cytotoxicity model via restoring diminished cell viability and inhibiting LDH leakage 
at 150–200 µg/mL and 10–300 µg/mL, respectively. Similar to DS, the improvement 
of SQ on cell viability using MTT assay showed no statistical significance, whereas 
the significance was observed on neutral red assay within the same tested 
concentration range. This may indicate a higher sensitivity for neutral red to 
detecting the changes of cell viability. The effects of SQ on endothelial cell death 
have not been reported previously, although the protective effects were suggested on 
various other cell lines, such as neuron cells or myocardial cells. Additionally, Rd 
was the key contributor for the anti-apoptotic activity of SQ on neuron cells and 
artery smooth muscle cells (Ye et al., 2009). Our results demonstrated anti-apoptotic 
activity on endothelial cells against Hcy-Ado-TNF. Rb1 and Rb2 showed prominent 
effects, but not Rd. Rb1 significantly restored the impaired cell viability and reduced 
LDH leakage at 150 µM and 100–150 µM, respectively. This cytoprotective effect of 
Rb1 has not been reported previously. 
 
Oxidative stress - induced endothelial injury has been proven through substantial 
evidence, and an H2O2-induced cell injury model was frequently used to screen the 
protective effect of an agent against oxidative stress. Therefore, to study the 
protective effects of DS, SQ and DS-SQ combinations on endothelial cell injury, an 
H2O2-induced cell model has been established on EAhy 926 cells (Farber, 1994). The 
present findings confirmed the cytotoxicity of H2O2, which caused an approximate 40% 
reduction in cell viability and significantly elevated ROS production (P<0.05). Our 
results found that DS significantly suppressed elevated ROS production induced by 
H2O2; however, it did not significantly improve cell viability from 50 to 150 µg/mL. 
This may indicate that DS is capable of protecting cells against oxidative stress by 
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altering the ROS level, but is not strong enough to protect cells from induced cell 
death. In DS, SA continued to exert significant activity in improving cell viability as 
well as inhibiting ROS level at 100–150 and 50–150 µM (P<0.05). Previous studies 
have reported the prominent effect of SB on cell survival against oxidative stress, 
thus it is demonstrated that SA also exerted such effects on endothelial cells. 
 
The protective effect of SQ on cell survival against oxidative stress was also 
observed on cell viability and LDH assay. It significantly restored cell viability at 
50–150 µg/mL and showed a decreasing trend of ROS production. This corresponds 
to the existing literature, as several studies have shown the protective effects of SQ 
and saponins on the H2O2-induced apoptosis model. The mechanistic pathways were 
shown to be associated with regulating Bcl-2/Bax ratios. However, the dissimilarity 
was that previous studies reported Rd to be the key compound, while our study 
showed that Rb1 also exerted a prominent effect. Whether its mechanistic pathway 
was via Bcl-2/Bax is yet to be determined. 
 
The synergistic action of DS-SQ, as demonstrated in this study, does not necessarily 
predict the possible synergistic interactions among active compounds involved. Thus, 
the effects of forteen key bioactive compounds of DS and SQ were further 
investigated using the same assays. SA from DS demonstrated a potent cell 
proliferation activity, but the high absorbance of SA (representing a high cell number) 
at higher dosage may not be due to the effect of SA, but rather that the yellow colour 
interfered with the crystal staining, which may lead to a high absorbance reading. 
Therefore, the effect of SA was further tested on wound scratch and tube formation 
assay, which had no colour interference. Our results showed that SA did not 
significantly promote cell migration and tube formation. Thus, only NR1 was found 
to be active among all tested consistituents in promoting cell growth at a high 
concentration (300 μM). This is surprising, as both DS and SQ aqueous extracts can 
have concentration-dependent promoted cell regrowth. Several possibilities explain 
these results. First, most compounds investigated are not the active compounds in the 
extracts responsible for the actions of DS, SQ and DS-SQ. Second, the actions of DS, 
SQ and DS-SQ may be the result of combined actions of a number of constituents, 
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rather than a particular compound. Further studies are required to elucidate the exact 
mechanisms involved. 
 
9.3 Synergistic mechanisms of DS-SQ on vascular disease 
In addition to the individual effects of DS and SQ alone, our results further 
demonstrated the beneficial effects of the combination extracts on the 
aforementioned vascular events. The synergistic effect was explained via two aspects: 
enhanced activity on the same target and multi-target action. Based on the results of 
DS-SQ obtained from the aforementioned bioassays, discussions of their synergistic 
actions are summarised below. 
 
9.3.1 Synergistic mechanism via enhanced biological activity 
The results of Chapters 6, 7 and 8 collectively suggest that DS-SQ combination (8:2, 
2:8 and 6:4) produce a synergistically enhanced biological activity on vascular 
targets (CI<1). In the anti-inflammatory, angiogenic and anti-apoptotic bioassays, the 
synergistic effects for the combinations were reflected as the effect of a combination 
was greater than that the sum of the individual agents at the same concentration level. 
The underlying mechanism of observed pharmacokinetic synergy was associated 
with improved solubility, or physico-chemical effects improved solubility of 
constituents of an extract by one or several other components of the same extract 
(Wagner, 2011). 
 
From our chemical analysis results in Chapter 5, the amount of tested chemical 
compounds were not directly proportional to the ratio of their herbal ingredients in 
the combination; for example, 20% DS (DS-SQ 2:8) yielded the same level of Rg1 as 
40% DS in the combination. Previous studies also demonstrated that the chemical 
composition of DS-SQ combination was altered from the sum of the chemical 
constituents. New compounds were reported to form during the mixed preparation 
and a higher yield of chemical constituents from DS was observed. Therefore, the 
higher number and amount of chemical constituents in the combination may explain 
the synergistically enhanced biological activity. 
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It is noteworthy that the general trend of reaching synergism in three bioassays was 
similar: the higher the concentration used in combination, the greater the synergistic 
effect obtained (e.g., synergistic effect was observed for DS-SQ 8:2 to inhibit NO 
when the concentration was greater than 1.24 mg/mL). In CHM, fairly high doses of 
herbs were frequently used and documented in traditional texts. As documented in 
PPRC, to produce 1000g of Fufang DS Keli (granule), the dosage of DS and SQ are 
1350g and 423g, respectively. The clinical dosage for DS and SQ as single herbs are 
10–15g and 1–3g per day, respectively. However, the high concentration shown in the 
in vitro results does not directly reflect the high quantity for the raw material used in 
clinic. The actual dosage will vary depending on the form of the administration (e.g. 
decoction, powder, extract). Besides, the source of the raw material is important to note. 
It is evident that in vivo and human intervention studies will provide more solid 
evidence in this area. 
 
As detected by our results, we have demonstrated that it is possible to establish a 
platform to systematically study the synergistically enhanced biological targets for 
CHM combinations on various targets, using CI and isobologram. The synergistic 
effect in CHM combination can be observed and analysed at least on a cellular level. 
Additionally, the quantification data for synergistic effects provide early evidence to 
support the combinational use of CHM in a formulaic manner, following one of the 
TCM seven principles of Xiang Xu (synergy) and Jun-Chen-Zuo-Shi theory. 
 
9.3.2 Synergistic mechanism via multi-component and multi-target 
behaviour 
Unlike WM that uses mono-chemical substances, CHM applies multiple herbal 
ingredients that contain hundred chemical compounds. The chemical compounds 
exert weak and promiscuous interactions with each other and on biological targets. 
Thus, one of the biggest challenges in CHM is to elucidate the pharmacokinetics 
synergy of these interactions and their targets. 
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In this study, fourteen bioactive compounds from DS and SQ were screened on the 
three aforementioned biological assays. The results revealed that multi-components 
from DS-SQ have contributed to different targets relevant to vascular dysfunction. 
This has highlighted the pharmacokinetics synergism contributed from the various 
compounds in DS-SQ. As reported in Chapter 6, lipid-soluble components 
(tanshinons and Rd) were prominent in inhibiting the pro-inflammatory mediators of 
NO, TNF and MCP-1. For angiogenic activity, SA and NR1 were found to exert 
significant effects in promoting cell proliferation. SA and Rb1 were found to be 
effective in restoring impaired cell injury against Hcy-Ado-TNF and oxidative stress. 
Other tested compounds showed no significant effects in the current experimental 
condition, indicating that these compounds may be inactive on the cellular 
mechanisms studied. However, this also does not exclude the possibility that these 
compounds may become active in vivo due to metabolism or transformation 
(Huttunen et al., 2011). Another possibility is that other components of DS and/or 
SQ were involved in the actions of DS-SQ, as more than 100 single compounds have 
currently been isolated from DS and SQ. However, due to the limited time frame, 
further studies need to be conducted to confirm this. A systems biology approach can 
be applied to predict the key constituents for each of the targets, and the experimental 
data can be confirmed by fraction-bioassay. 
 
Since multi-target behaviors from various compounds in DS-SQ were observed, their 
molecular pathways were also investigated. This can help to further explain the 
mechanistic actions of this multi-target behaviour. In Chapter 7, the possible 
signalling pathways for DS-SQ on angiogenesis were studied. Although it remained 
only partially understood, a large body of evidence suggests that vascular endothelial 
growth factor-2 (VEGFR-2) is the most important of the VEGF receptors with regard 
to angiogenesis, with postreceptor signalling pathways that promote endothelial cell 
division, permeability and survival. Specifically, the downstream signalling effects 
of VEGFR-2 binding include integrin activation via the PI3K/Akt, and 
Raf/MEK/ERk signalling pathways (Adya et al., 2008; Chai et al., 2004; Chung et al., 
2008; Kubis et al., 2002). It is reported that the downstream effects of the binding, 
dimerisation and activation of the VEGF/VEGFR-2 complex include endothelial cell 
survival (through the PI3K/Akt pathway), migration (p38MAPK and PI3K/Akt 
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pathways) and proliferation (through the Raf/MEK/ERK pathway). Our findings 
suggested that the angiogenic activity of DS-SQ may be associated with the 
activation of the MEK/ERK signalling pathway, which can be disabled by Hcy and 
Ado (Zhang et al., 2011b). Additionally, the wound healing effect of DS-SQ was also 
affected by the PI3K inhibitor, suggesting the involvement of activating PI3K 
signalling pathway. 
 
Studies have further shown that endothelial-specific eNOS not only play an essential 
role in maintaining vascular health, but also that it is closely associated with vascular 
remodelling and angiogenesis. It is suggested that VEGF increases endothelial cell 
survival and angiogenesis by promoting Akt-dependent eNOS phosphorylation and 
NO production, which are involved in angiogenesis and endothelial cell survival. The 
eNOS/NO pathway has been shown to exert a permissive role for angiogenesis in 
adult organisms. Our results showed that eNOS inhibitor (L-NIO dihydrochloride) 
did not impair the wound closure effects of DS-SQ 2:8 (Figure 7.10B), indicating 
that eNOS pathway was not involved in the cell migration activity of DS-SQ 2:8. 
Previous studies showed that DS single extract (10 μg/mL) on murine SVR 
endothelial cell line was associated with the up-regulation of VEGF, VEGF-R2 and 
their receptor genes (Wenden et al., 2014). For SQ single extract, previous studies 
have demonstrated that the major components from SQ, PNS, also showed pro-
angiogenic effects through PI3K-Akt-eNOS signalling pathways (Hong et al., 2009). 
The present study has demonstrated that the signalling pathways of DS-SQ 2:8 was 
likely to be associated with several important angiogenic signalling pathways, 
including PI3K and MEK/ERK, highlighting the pharmacodynamic synergistic 
activity of the combination on angiogenesis. However, the involved protein and gene 
targets need to be examined to confirm our assumptions. The responsible chemical 
compound on each of the signal pathways would be elucidated via a systems biology 
model and Westernblot analysis. 
 
9.4 Optimal ratios of DS-SQ on vascular disease 
CHM prescription can be customised on a patient-by-patient basis by adjusting the 
dose of each ingredient with the progress of a patient’s symptom. The correct dosage 
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is the key to success in TCM. For example, patients with vascular diseases have 
different stages of clinical symptoms and may receive different compositions of 
herbal formulae. The adjusted ratio of herbal ingredients in a formula may be 
designed for different symptoms or therapeutic effects. This study revealed that the 
ratio of DS and SQ in the combination changed with the biological targets in order to 
reach the optimal effect. The optimal ratio of DS-SQ on anti-inflammation, 
angiogenesis and anti-apoptosis were 8:2, 2:8 and 6:4, respectively. These findings 
collectively indicated a ratio-dependent bioactivity of combination extracts. 
 
As documented in the official PPRC (Chinese Pharmacopoeia), the dosage of DS and 
SQ in Fufang DS tablet/dripping pill/granule are 450g and 141g, which represents a 
ratio around 3:1. This formula is indicated for angina pectoris in coronary heart 
disease (State Pharmacopoeia Committee, 2010). The classical ratio of these two 
herbs in the TCM textbooks are around 5:3 (Xu, 1996b). In addition, it is explained 
that DS should be used in higher proportions in the DS-SQ combination for the early 
stage of cardiovascular disease. Whereas, the proportion of SQ might be increased in 
severe stages, when tissue infarction is observed (Xu, 1996b). Our results in vitro 
correlate well with this claim. In the pathological development of vascular 
dysfunction, inflammation and apoptosis of the endothelial cells are largely involved 
in the early stages, and our results showed that a larger proportion of DS in DS-SQ 
rendered significant and synergic effects in anti-inflammation (8:2) and anti-
apoptosis (6:4). In addition, a study from Zeng et al. (2006) explained this synergy 
from a chemical analysis’s view. His study showed that the extraction yield of 
chemical compounds of DS increased in the co-decocted DS and SQ mixtures with 
the ratio of 5:3 yielding the highest amount of chemical compounds from DS (Zeng 
et al., 2004). This suggests that the amount of compounds in DS increased in the 
presence of a small proportion of SQ in the mixture. By considering the potent 
activity from the lipid-soluble components from DS on anti-inflammation, higher 
proportion of DS may be required to reach a greater effect. On the other hand, 
angiogenesis is a compensatory mechanism that is triggered after the endothelial 
damage which occurs at the later stage. Our results showed that SQ in a larger 
portion used in the combination gave significant and synergistic effects for 
angiogenesis which corresponds to the suggested proportion in the TCM textbook 
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(Xu, 1996b).” Our findings support this traditional rationale on the cellular level, 
however, further investigations in animal studies and clinical trials are needed to 
verify this theory. 
 
9.5 Compound combination 
There is the potential to use the chemical compound combination to replace the 
traditional CHM formulation in relevant applications due to easily controlled product 
quality, although further studies are needed to establish the efficacy and safety of 
such applications. The compounds combination was established to follow modern 
medicine and pharmaceutical drug development trends. However, antagonistic 
interactions were largely obtained. As reported in Chapter 6, DT and Rd 
demonstrated the strongest anti-inflammatory activity, and were selected and 
combined to form a compound formulation. Antagonistic effects were observed for 
SA-Rb1 combination on anti-apoptosis. This demonstrated that the combination of 
two isolated compounds may not necessarily engender a stronger effect; it may even 
produce an antagonistic interaction, as the two compounds may compete for the same 
cellular receptor/metabolic pathways. This is consistent with the idea that 
combinations of botanical extracts are more effective than isolated components in the 
mixture. The positive/negative interactions may depend on the complimentary nature 
of all the compounds in the extracts. In addition, the ratio of one extract to another, 
the mode of action and the necessity of common cellular resources are some 
examples of variables that may determine the efficacy of a mixture. This may be 
explained by the traditional TCM theory that the herb is always used as whole, and 
the belief in synergistic actions among components within and among the herbal 
extracts. This result may constitute scientific evidence supporting the prescription of 
a combination of herbs, instead of separate herb extraction mixtures. 
If there is no synergy between two compounds, they still can contribute to the 
activities of the extracts. The contribution of the compounds to the overall actions of 
the extract also depends on their individual activities and the quantity in the extract. 
Besides, even though there are no synergistic interactions between two selected 
compounds, they may exhibit synergistic behavious with other compounds 
coexisting in the extracts or there might be additive effects. It is worth mentioning 
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that the interactions of two compounds determined in this study were all in isolated 
form. In addition, their ratio was not correlated to the original composition in the 
extract. Thus, the interactions determined in the compounds formulation are no 
directly link with their activities in the extracts. Therefore, it is hard to draw the 
conclusion from our study that no additional synergistic interactions occur. As the 
compounds in the extracts co-exist with many other compounds they may still have 
weak and promiscuous interactions with each other. They may also still exert 
influence on the mixed extracts to some degree. Further studies need to be designed 
to investigate this area in depth. 
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10.1 Major findings and general conclusions  
In the last few decades, CHM has gained considerable attention in Western countries 
as a popular form of complementary medicine, and maintained popularity in Asian 
countries as a form of primary health care. As an ancient medical practice, CHM is a 
unique and complete medical system that is quite distinct from WM. Its diagnosis 
and prescription focuses on the holistic management on body’s natural responses 
(symptoms). It was developed from years of clinical practice. But, due to the lack of 
understanding of its practice and the uncertain standardisation of herbal medicines, 
its quality, safety and efficacy have been criticised. Synergy is the key mechanism 
for addressing the efficacy of CHM. Herbal formulae contain multiple ingredients 
and are frequently used for routine prescription in TCM clinics. Thus, the complex 
nature of CHM formulae, containing hundreds of chemical compounds, and their 
mode of action and positive/negative interactions, have carried signicant challenges 
for the efficacy evaluation of CHM. The synergy concept is behind traditional CHM 
Jun-Chen-Zuo-Shi theory, as investigated in Chapter 1. 
 
Synergy, can be understood from two angles: pharmcodynamic and pharmacokinetic 
synergy. Pharmacodynamic synergy refers to the mutual enhanced effect on the same 
target, whereas pharmacokinetic synergy suggests the interactions among multiple 
agents on different pathways or targets. To investigate the synergistic actions in a 
combinational therapy, different mathematic and computation models have been 
designed and applied. CI and isobologram models are frequently used to facilitate 
analysis of pharmacodynamics synergy. S2S mode/systems biology method 
approaches the synergistic interactions from a systematic perspective, and more 
suited for the study of pharmacokinetic synergy. Through a systematic review on the 
synergistic effects of CHM, it was found that current research is still in its infancy, 
and the synergistic interactions for a large number of the CHM formulae are yet to be 
investigated. 
 
The simplest form for a complex hebal formula is an herb-pair, comprised of two 
medicinal herbs that complement each other. One of the most popular Chinese 
medicinal herb pairs consists of Salvia Miltiorrhiza Radix et Rhizoma and 
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Notoginseng Radix et Rhizome (DS and SQ in Chinese), and was selected as a case 
study to evaluate their synergistic activities in CHM. DS-SQ has been one of the 
most frequently prescribed herb pairs in TCM clinics in China for the treatment of 
CVDs for at least 30 years (Wei et al., 2007a). However, basic research on its 
combinational benefits on vascular disease is still lacking, although numerous studies 
have shown their potent activity as single extracts. Moreover, the synergistic 
interaction between DS and SQ and the actions of their chemical consistituents have 
not been comprehensively studied; only a few studies suggest the multi-target 
potential of chemical substances on cardiovascular systems using systems biology. 
Therefore, this study were designed to systematically evaluate the synergistic actions 
of DS-SQ to understand its underlying mechanisms on the cellular level. The 
concentrations of the ingredients in a formula plays an essential role in the efficacy 
of the CHM formula, so the optimal ratio of DS-SQ was determined for vascular 
pharmacological targets. 
 
Vascular diseases are multi-faceted and involve many pathological targets. They are 
mainly triggered by endothelial dysfunction as an early marker. The specific 
biological targets for DS-SQ acting on vascular diseases that were investigated in 
this study were listed as follows (Chapter 2): 
1) pro-inflammatory mediators including iNO, TNF and MCP-1; 
2) angiogenesis via endothelial cell proliferation, migration and tube formation; 
3) Hcy-Ado-TNF and oxidative stress-induced cell injury; 
 
Before commencement of biological testing, chemical analysis of DS and SQ starting 
material was conducted, to ensure quality and efficacy for DS-SQ in the following 
studies. Key marker compounds were simultaneously determined though TLC 
fingerprint and UPLC analysis in DS (i.e., DSS, SA, SB, TI, DT, CT, TIIA) and SQ 
(NR1, Rg1, Rb1, Rg2, Rd) raw herb samples. The results revealed that the chemical 
composition of DS and SQ did not vary substantially among herb samples collected 
from different origins. The quality of the tested DS samples was generally low, with 
only one sample meeting the minimum quality standard against PPRC, whereas all 
SQ samples were found to be qualified based on PPRC standards. 
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The preparations of DS-SQ combination extracts used qualified crude sample of DS 
and SQ (against PPRC) and were mixed in nine different ratios (1:9, 2:8…9:1). A 
simple and rapid UPLC-PDA method was established and partially validated for the 
quality control of DS-SQ combination extracts. Five major compounds—including 
DSS, SB, NR1, Rg1 and Rb1—were constantly captured in the mixed extracts in 
different ratios, and they were identified and quantified in DS-SQ combination 
preparations. By comparing the fingerprint of the combination extract to that of the 
single extract under the same wavelength, no new chemical substances formed 
during mixed preparation. The amount of the tested chemical compounds was not 
directly proportional to the ratio of the herbal ingredients in the combination. 
 
Three bioassays were established; the results were presented in Chapters 6, 7 and 8, 
and demonstrated that the effects of DS, SQ and DS-SQ on vascular disease were 
through inhibiting inflammatory mediators, restoring angiogenic activity and 
protecting endothelial cells from cytotoxicity. The synergistically enhanced 
biological activities for DS-SQ were determined and quantified, and the tested 
chemical compounds were found to exert multi-target actions. 
 
10.1.1 Synergistic mechanism-enhanced pharmacological activity on 
vascular targets 
The study using CI and isobologram models suggested that the combination effect of 
DS-SQ at 8:2 was synergistically greater than DS and SQ used individually in 
inhibiting excessively expressed inflammation mediators NO, TNF and MCP-1 
stimulated by LPS on RAW 264.7 cells (Chapter 6). DS-SQ combination extracts at 
2:8 showed synergism in restoring inhibited endothelial cell growth, scratch wound 
closure and tube formation induced by Hcy-Ado on EAHy 926 cells (Chapter 7). For 
protecting EAHy 926 cells from Hcy-Ado-TNF and oxidative stress-induced cell 
injury, the effects of DS-SQ extracts at 6:4 were synergistically more prominent than 
its single extract counterpart (Chapter 8). The results collectively reflect the 
pharmacodynamic synergistic interaction among DS and SQ when acting on the 
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same target, and provide early evidence for the traditional combinational use of this 
herb-pair for mutual enhanced biological activity. 
 
10.1.2 Multi-component and multi-target mode of actions 
Fourteen key bioactive compounds from DS and SQ were screened on the same 
biological assays, as tested for the herbal extracts. It was revealed that different 
bioactives were acting on different biological targets. For inhibiting inflammatory 
mediators, the lipid-soluble components showed a stronger effect than water-soluble 
components. DT and Rd, two lipid-soluble components from DS and SQ, were found 
to be the most potent components in inhibiting NO, TNF and MCP-1 (Chapter 6). 
NR1 from SQ may be involved in the actions of DS-SQ for promoting Hcy-impaired 
angiogenesis, whereas other single compounds showed no significant effect (Chapter 
7). SA from DS was found to be active in both promoting angiogenesis and 
protecting endothelial cells from cytotoxicity (Chapters 6 and 7). Rb1 was found to 
be the most potent component from SQ to restore reduced cell viability induced by 
Hcy-Ado-TNF and oxidative stress, respectively (Chapter 8). The multi-component 
and multi-target action from the chemical constituents from DS and SQ are shown in 
Figure 10.1. 
 
 
Figure 10.1 Multi-components and multi-target therapeutic actions of DS-SQ herb-
pair on promoting vascular function 
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10.1.3 Optimal ratio for DS-SQ on different biological targets 
Nine different ratios (1:9, 2:8 … 9:1) of DS-SQ combinational extracts were 
prepared and subjected to biological testing. It was found that the ratio of DS and SQ 
in the combination has a direct impact on their pharmacological effects. Further, for 
acting on different therapeutic targets, different optimal ratios for DS-SQ were 
observed to reach the maximum effects. For anti-inflammation, DS-SQ at the ratio of 
8:2 showed the most potent activity in inhibiting NO stimulated by LPS on raw264.7 
cells, compared to that in all other tested ratios (Chapter 6). When the combinations 
were tested on the cell proliferation assay, the optimal ratio that demonstrated the 
maximum effects was 2:8. This ratio consistently showed potent effects in promoting 
cell migration and tube formation (Chapter 7). For restoring cell viability from 
cytotoxicity against homocysteine-adenosine-TNF, the ratio of 6:4 and 5:5 was found 
to be superior (Chapter 8). Therefore, we demonstrated the ratio-dependent activity 
of DS-SQ on various biological targets related to vascular system, and this may 
explain the importance for adjusting the ratio of herbal ingredients in a formula, in 
order to reach the optimised biological effects.  
 
10.1.4 Compound formulation 
Compound formulations (Rd-DT and SA-Rb1) mixing the most potent compound 
from DS and SQ were prepared and tested on anti-inflammatory and anti-apoptotic 
bioassays to see whether a compound formulation can be formed to represent the 
efficacy of DS-SQ combination and facilitate quality control. The results 
demonstrated that the compound formula exerted significant effects on anti-
inflammation and anti-apoptosis, with much lower dosage required than the extract 
combination. However, antagonistic effects were largely observed in the compound 
formulation, indicating that the effects of the compound formula were less significant 
than using the single compound itself. This result reflects the fact that the 
combination of two prominent compounds may not necessarily engender a stronger 
effect and support the rationale of using a whole extract in CHM without isolating 
any of the components. 
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10.1.5 Conclusion 
The DS-SQ exerted synergistic beneficial effects on vascular disease via both 
enhanced bioactivity on the same target and multi-components-multi-target manner. 
The biological effects of DS and SQ were synergistically enhanced in inhibiting pro-
inflammatory mediators against LPS, restoring Hcy attenuated-angiogenesis and 
protecting cell injury from Hcy-Ado-TNF and oxidative stress, in comparison to their 
individual extract counterpart. The multi-target action of DS-SQ was reflected, as 
different chemical compounds from each ingredient were found to be prominent in 
each target, with DT and Rd responsible for anti-inflammation, SA and NR1 acting 
on angiogenesis and SA and Rb1 the key components for anti-apoptosis. The optimal 
ratio for this combination also changes for different targets, with 8:2, 2:8 and 6:4 for 
DS-SQ exerting a relatively greater effect on anti-inflammation, angiogenesis and 
anti-apoptotic, respectively. Through the investigation in the DS-SQ case study, we 
have successfully established a platform to evaluate the synergistic mechanism in 
herb pairs. The issues revolved around the efficacy of CHM has been addressed with 
positive results, and thus provided early scientific evidence for the effectiveness of 
CHM. An overview of the major investigations of this study is shown in Figure 10.2. 
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Figure 10.2 Major investigations of this study. Five key bioactive compounds from 
DS and SQ including DT, SA, Rd, NR1 and Rb1 were found to be prominent acting 
on three biological targets of vascular diseases: anti-inflammation, angiogenesis and 
anti-apoptosis. This indicates the multi-component and multi-target actions from DS-
SQ. Moreover, DS-SQ 8:2, 2:8 and 6:4 were shown to have synergistic interaction on 
anti-inflammation, angiogenesis, and anti-apotosis, respectively. This reflects the 
mutual enhanced biological activity in DS-SQ with various ratios.  
 
10.2 Limitations and future work 
Due to constraints time, one sample from each herb was selected for the prepration of 
the combination extracts. The biological activities of DS-SQ were only demonstrated 
for this particular combination. As the chemical composition of DS-SQ may vary 
when using samples collected from other sources or at different times. They may 
lead to different therapeutic activity. The analysis of samples from various regions 
and combinations could provide a more complete picture, to ensure the reliability and 
repeatability of the pharmacological activity and synergistic actions of this herb-pair. 
However, we belive working with high quality tested samples (which has met the 
PPRC quality standard) provided reasonably indicative results.  
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Regarding the pharmacological activities of the current thesis, the experiments were 
limited to in vitro molecular assays. The cellular assays used in this study served as a 
preliminary screening method. Despite DS-SQ demonstrating anti-inflammatory, 
angiogenesis and anti-apoptotic activities in the current study, these results need to 
be re-examined in in vivo model and human intervention studies, especially for the 
multi-target actions. Moreover, the biological methods selected in this study were 
mostly preliminary in their field of testing. Three main biological targets for vascular 
dysfunction are chosen as in vitro models, but they are not necessary the most 
relevant activities or mechanisms in clinical usage of the two herbs. Other targets 
such as antiplatelet and autophagy activities are to be investigated. Besides, the 
signalling pathways of the pharmacological effects, target protein and gene 
expressions can be conducted in the future investigations.  
 
In this study, fourteen selected bioactives were screened on bioassays related to 
vascular therapeutic targets. Since there are many more chemical components in DS 
and SQ, the actions of a large number of other chemical components albeit less 
prominent or available are still largely unknown. A systems biology model might be 
able to predict the active components acting on vascular network systems. However, 
this model requires a large scale of available data of chemical compounds in DS and 
SQ, which is not practical to conduct at this stage. Bioassay-guided fraction is an 
alternate way to isolate individual potential active constituents on each therapeutic 
target. 
 
An herb-pair is the simplest form in the CHM prescription. In most cases, CHM 
prescription is an complex herbal formula consisting of between 2 and 30 herbs. Our 
study demonstrates the mechanistic action for an herb-pair. However, to fully 
understand the efficacy mystery for CHM formulae, the study on herb pairs is only 
the initial step. The pharmacological effect and interactions among herbal ingredients 
in well-constructed formulae still needs to be explored in future studies. 
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10.3 Significance of this study 
To our knowledge, this is the first study that has systematically demonstrated the 
combination effects of the herb-pair (DS-SQ), on key vascular disorders through 
three major perspectives: inhibiting pro-inflammation mediators, promoting 
angiogenesis and protecting endothelial cells. Moreover, this study provided insight 
into synergistic behaviours of CHM formulae. It applied statistical analysis of 
modern scientific models of CI and isobologram to analyse and quantify the 
synergistic behaviour in CHM formulation. Further, this study revealed the multi-
target actions of major bioactives from both DS and SQ in a molecular level. 
 
The results from this study support the hypothesis that it is possible to establish in 
vitro cellular models to test synergistic activities within a complex mixture of CHM 
formulation. Synergistic activity within CHM formulations can be detected and 
reflected through enhanced pharmacological effects and through activity on multi-
targets. This study addressed the challenges for investigating the efficacy mechanism 
of complex CHM formulation. More importantly, the research design for the 
synergistic mechanism and methodological approach used in this study provids a 
viable model for testing herb interaction (synergy/antagonism) that can be broadly 
applicable to other herb combinations, and potentially more complex CHM 
formulations. 
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Appendix 1: UPLC validation procedure 
 
Validation of an established UPLC method ensures its suitability for the intended purpose, 
such as its accuracy, repeatability and robustness. A full UPLC method validation is required 
for a new established method; the validation parameters consist of specificity, linearity range, 
precision, detection limit, quantitation limit and robustness (recovery) (Guideline, 2005). To 
use an already established UPLC method published previously literature, a partial validation 
may be needed. The AOAC International Guidelines for Single Laboratory Validation of 
Chemical Methods for Dietary Supplements and Botanicals’ definition of validation 
parameters and experimental procedures are listed below. 
 
Specificity/selectivity 
According to the AOAC guidelines (2005), specificity is ‘the ability to distinguish the analyte 
from other substances’. In the case of employing a suitable detector (such as PDA) in UPLC 
analysis, there are two ways of confirming the identity of analytes, by matching retention time 
and the UV-Vis spectra of sample peak to that of the reference standard peak. This is also 
conducted to confirm purity, as the observed chromatographic peak should only consist of a 
single component. 
 
Calibration 
According to the AOAC guidelines (2005), the identification and quantification of unknown 
concentrations of an analyte in the mixed substances depend on the comparison of a signal of 
the unknown analyte to that from a known concentration of the same or similar analyte 
(reference standard). Therefore, the availability of a reference standard with a range of 
concentrations and signal levels is required. In UPLC method validation, linear calibration 
curves are constructed using at least five different concentrations of each reference standard 
(Guideline, 2005). At least three replications of calibration standards are performed to check 
validity. The regression equation is calculated in the form of y = ax + b, where ‘x’ and ‘y’ are 
the values of different concentrations of reference standards (x) and peak areas (y) 
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respectively, and ‘a’ is the slope and ‘b’ represents the y-intercept. The residual sum of 
squares (R2) value obtained from the calibration curve is used to represent the linearity of the 
standard curve. The more R2 value close to 1, the better the linearity of the standard curve 
achieved. 
 
LOD/quantification 
The LOD is ‘the lowest amount of analyte in a sample which can be detected but not 
necessarily quantified as an exact value’ (page 5) (Guideline, 2005). The LOQ is defined as 
‘the lowest amount of analyte in a sample which can be quantitatively determined with 
suitable precision and accuracy’ (page 5) (Guideline, 2005). For UPLC analytical methods 
with baseline noise measured from the machine, LOD and LOQ can be determined as three 
times and 10 times the signal-to-noise ratios (minimum of n = 3), respectively (Chan et al., 
2004). Alternatively, LOD and LOQ can be calculated according to the equation below: 
LOD = 3.33× SD of y−intercept
mean of slope
 
LOQ = 10× SD of y−intercept
mean of slope
 
In the equations, SD of y, intercept and mean of slope are obtained from the regression 
equation of the calibration curve (Chan et al., 2004). 
 
Precision 
In the AOAC guidelines (2005), precision represents repeatability, which is described as ‘the 
degree of agreement of results when conditions are maintained as constant as possible with 
the same analyst, reagents, equipment, and instruments performed within a short period of 
time’ (page 10) (Guideline, 2005). Precision testing accounts for systematic error or random 
error and consists of repeatability and intermediate precision. The repeatability describes how 
well a measurement system can return the same measure (Guideline, 2005). The repeatability 
of the method is estimated by measuring the signal of each reference standard for at least 
three different concentrations (the selected concentration should be within the specified range 
of the analytical method) both intra-day (n≥3 within one day) and inter-day (n≥3 consecutive 
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days) (Chan et al., 2004). Precision is usually reported as the SD, RSD or confidence interval 
of the signal obtained for each tested concentration intra-day and inter-day (Chan et al., 2004). 
The lower the SD/RSD/confidence interval value is, the higher precision the method is 
demonstrated. 
 
Accuracy/recovery 
The accuracy of an analytical procedure is expressed as ‘closeness of the test result to the 
“true” or accepted value’ (page 8) (Guideline, 2005). In UPLC analytical method validation, 
the accuracy reflects how close the value measured by the method to the true value, and is 
calculated as recovery. Recovery studies are conducted by spiking the known amount of 
reference standard (usually at the 50, 100 and 200% levels) to the tested sample. Thus, the 
analyte peak height (or area) in the sample solution with added fortification solution will 
increase by approximately 50, 100 and 200%, to give fortification levels of 50, 100 and 200%. 
The quantity of each analyte added is subsequently obtained from the corresponding 
calibration curve. Thus, the recovery percentage can be calculated according to the equation 
below: 
Recovery (%) = 100 ×  Total amount measured−sample original amount without spiking
amount of spiked analyte 
 
The closer the recovery percentage value to 1, the lower the bias affecting the method, and 
thus the higher the trueness. A recovery value between 80% and 120% is usually acceptable 
(Chan et al., 2004). 
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Appendix 2: Comparison of the UV spectrum in standard solution 
and in the extract solution analysed by UPLC-UV 
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Comparison of the UV spectrum of DSS in the reference standard solution (A) and DS 
aqueous extract DS6 (B), SA in the reference standard solution (C) and DS6 (D), SB in the 
reference standard solution (E) and DS6 (F), CT in the reference standard solution (G) and 
DS6 (H), DT in the reference standard solution (I) and in DS6 (J), T1 in the reference 
standard solution (K) and in DS6 (L), TIIA in the reference standard solution (M) and in DS6 
(N). 
 
 
 
 
Appendix 3: Effects of DS, SQ and DS-SQ (1:9 to 9:1) on 
restoring cell viability against Hcy-Ado-TNF in EAhy 926 
cells determined by MTT assay 
 
 
 
 
 
 
 
 
 
 
Effects of DS, SQ and DS-SQ (1:9 to 9:1) on restoring cell viability against Hcy-
Ado-TNF in EAhy 926 cells determined by MTT assay. Cell viability, as determined 
by MTT for DS (A), SQ (B), DS-SQ 1:9 (C), DS-SQ 2:8 (D) … DS-SQ 9:1 (K) 
following treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell viability was 
expressed as a percentage compared to control. All results were expressed as mean ± 
S.E.M. from three separate experiments in triplicate. * P< 0.05, ** P<0.01, *** P < 
0.001 in comparison with other combinations in the respective cell lines. 
 
 
Appendix 4: Representative cell morphology of EAhy 926 cells treated with various treatments 
 
 
Representative cell morphology of EAhy 926 cells treated with DS (150 µg/mL), SQ (150 µg/mL), and DS-SQ 6:4 (150 µg/mL) followed by 
combined incubation of Hcy-Ado-TNF. 
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Appendix 5: Comparison of cell viability restoring among 
DS-SQ combinations at 150 µg/mL 
 
 
Cell viability versus DS, SQ and DS-SQ combinations at different ratios at the 
concentration of 150 μg/mL on MTT assay. 
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Appendix 6: Effects of DS, SQ and DS-SQ (1:9 to 9:1) on 
restoring cell viability against Hcy-Ado-TNF in EAhy 926 
determined by neutral red assay. 
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Effects of DS, SQ and DS-SQ (1:9 to 9:1) on restoring cell viability against Hcy-
Ado-TNF in EAhy 926 cells determined by neutral red assay. Cell viability, as 
determined by neutral red for DS (A), SQ (B), DS-SQ 1:9 (C), DS-SQ 2:8 (D) … 
DS-SQ 9:1 (K) following treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell 
viability was expressed as a percentage compared to control. ‘Stimulation’ here 
represents Hcy-Ado-TNF stimulation group. All results were expressed as a mean ± 
S.E.M. from three separate experiments in triplicate. * P< 0.05, ** P<0.01, *** P < 
0.001 in comparison with other combinations in the respective cell lines.
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Appendix 7. Comparison of cell viability restoring among 
DS-SQ combinations at 150 µg/mL 
 
Cell viability comparisons among DS, SQ and DS-SQ with different ratios at 150 
μg/mL determined by neutral red assay. 
  
Appendices 
283 | P a g e  
Appendix 8: Effects of bioactive compounds from DS on 
restoring cell viability against Hcy-Ado-TNF in EAhy 926 
cells determined by MTT assay. 
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Effects of bioactive compounds from DS on restoring cell viability against Hcy-Ado-
TNF in EAhy 926 cells determined by MTT assay. Cell viability, as determined by 
MTT for DSS (A), SA (B), SB (C), CT (D), T1 (E), DT (F) and TIIA (G) following 
treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell viability was expressed as a 
percentage compared to control. ‘Stim’ here represents Hcy-Ado-TNF stimulation 
group. All results were expressed as mean ± S.E.M. from three separate experiments 
in triplicate. * P< 0.05, ** P<0.01, *** P < 0.001 in comparison with other 
combinations in the respective cell lines. 
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Appendix 9: Effects of bioactive compounds from SQ on 
restoring cell viability against Hcy-Ado-TNF in EAhy 926 
cells determined by MTT assay. 
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Effects of bioactive compounds from SQ on restoring cell viability against Hcy-Ado-
TNF in EAhy 926 cells determined by MTT assay. Cell viability, as determined by 
MTT for NR1 (A), Rg1 (B), Re (C), Rb1 (D), Rb2 (E), Rg2 (F) and Rd (G) 
following treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell viability was 
expressed as a percentage compared to control. ‘Stim’ here represents Hcy-Ado-TNF 
stimulation group. All results were expressed as mean ± S.E.M. from three separate 
experiments in triplicate. * P< 0.05, ** P<0.01, *** P < 0.001 in comparison with 
other combinations in the respective cell lines. 
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Appendix 10: Effects of SA-Rb1 (1:9 to 9:1) on restoring 
cell viability against EA.hy 926 cells against Hcy- Ado-TNF 
in EAhy 926 cells determined by MTT. 
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Effects of SA-Rb1 (1:9 to 9:1) on restoring cell viability against Hcy- Ado-TNF in 
EA.hy 926 cells determined by MTT assay. Cell viability, as determined by MTT for 
SA-Rb1 1:9 (A), SA-Rb1 2:8 (B), SA-Rb1 3:7 (C) … SA-Rb1 9:1 (I) following 
treatments with Hcy-Ado-TNF in EAhy 926 cells. Cell viability was expressed as a 
percentage compared to control. ‘Stim’ here represents Hcy-Ado-TNF stimulation 
group. All results were expressed as mean ± S.E.M. from three separate experiments 
in triplicate. * P< 0.05, ** P<0.01, *** P < 0.001 in comparison with other 
combinations in the respective cell lines. 
 
